close

prescription drugs

Prescription drugs

Animal Prescription Drugs Market 2022-2030, by Top Key Players – Ourofino Saude Animal, Elanco Animal Health, Vetoquinol, Virbac, Dechra

The Animal Prescription Drugs Market report is a perfect basis for people who are looking for comprehensive study and analysis of the Animal Prescription Drugs Market. This report contains study and miscellaneous information which will help you to understand your niche and focus major market channels in the regional and global Animal Prescription Drugs Market. To understand the competition and take action based on your key strengths, market size, current and future years demand, supply chain information, business concerns, competitive analysis and prices as well as supplier information will be presented to you. The report also includes information about the major market players, Animal Prescription Drug applications, its type, trends and overall market share.

To put your business plan into action based on our detailed report, you will also receive comprehensive and accurate forecasts and projected figures for the future. This will provide an overview of the market and help design solutions to leverage key profitable elements and gain market clarity to develop strategic plans. The data present in the report comes from different publications in our archives as well as many reputable paid databases. Moreover, the data is collated with the help of dealers, raw material suppliers, and clients to ensure that the end result covers every detail regarding the Animal Prescription Drugs market making it a perfect tool for serious buyers of this study.

Animal Prescription Drugs Market: Competition Landscape

The Animal Prescription Drugs Market report includes insights into product launches, sustainability, and outlook from key vendors including: (Ourofino Saude Animal, Elanco Animal Health, Vetoquinol, Virbac, Dechra, MSD Animal Health, Boehringer Ingelheim, Zoetis, Ceva Sante Animale, Animalcare Group)

Click Link to Get Free Sample Copy of Report @ https://crediblemarkets.com/sample-request/animal-prescription-drugs-market-657793?utm_source=Amruta&utm_medium=SatPR

Animal Prescription Drugs Market: Segmentation

By types

oral-type
Smear type
Type of injection
Type of spray

By requests

Pet
Livestock

Animal Prescription Drugs Market: Regional Analysis

The whole regional segmentation has been studied based on recent and future trends, and the market is forecast through the forecast period. The countries covered in the regional analysis of the Global Prescription Animal Drugs Market report are US, Canada & Mexico North America, Germany, France, UK, Russia , Italy, Spain, Turkey, the Netherlands, Switzerland, Belgium and the rest of Europe. in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, the rest of the Middle East and Africa (MEA) as part of the Middle East and Africa (MEA), and Argentina, Brazil and the rest of the South America as part of South America.

Key benefits of the report:

  • This study presents the analytical description of the worldwide Animal Prescription Drugs industry together with the current trends and future estimations to determine the impending pockets of investment.
  • The report presents information related to key drivers, restraints, and opportunities, along with a detailed analysis of the global Animal Prescription Drugs market share.
  • Current market is quantitatively analyzed from 2021 to 2028 to highlight the growth scenario of the global Animal Prescription Drugs market.
  • Porter’s Five Forces analysis illustrates the power of buyers and suppliers in the marketplace.
  • The report provides a detailed analysis of the Global Animal Prescription Drugs Market based on the competitive intensity and how the competition will shape in the coming years.

Directly Buy This Market Research Report Now @ https://crediblemarkets.com/reports/purchase/animal-prescription-drugs-market-657793?license_type=single_user;utm_source=Amruta&utm_medium=SatPR

Main points covered in the table of contents:

Market overview: It includes six sections, research scope, key manufacturers covered, market fragments by type, Animal Prescription Drugs market shares by application, study objectives and years considered.

Market landscape:Here, opposition in the global Prescription Animal Drugs market is dissected, by value, revenue, transactions, and pie share by organization, market rate, fierce circumstances Most recent landscape and patterns, consolidation, development, obtaining and industry-wide portions of large organizations.

Manufacturer Profiles: Here, the driving players of the global Animal Prescription Drugs market are considered dependent on region of deals, key elements, net benefit, revenue, cost, and creation.

Market Status and Outlook by Region: In this segment, the report examines net benefit, transactions, revenue, creation, global industry share, CAGR and market size by region. Here, the global Animal Prescription Drugs Market is thoroughly examined based on regions and countries like North America, Europe, China, India, Japan, and MEA.

Application or end user: This segment of the exploration study demonstrates how extraordinary sections of end customers/applications are added to the global Animal Prescription Drugs market.

Market forecast: Production side : In this part of the report, the creators focused on the conjecture of creation and creation esteem, the gauge of the main manufacturers and the estimation of the creation and creation esteem by type .

Research results and conclusion: This is one of the last segments of the report where the findings of the investigators and the end of the exploratory study are given.

Answers to key questions in the report:

  • What will be the pace of market development of the Prescription Drugs for Animals market?
  • What are the key factors driving the global Animal Prescription Drugs market?
  • Who are the main manufacturers on the market?
  • What are the market openings, market risks and market outline?
  • What are sales volume, revenue, and price analysis of top manufacturers of Animal Prescription Drugs market?
  • Who are the distributors, traders and dealers of Animal Prescription Drugs market?
  • What are the Animal Prescription Drugs market opportunities and threats faced by the vendors in the global Animal Prescription Drugs Industries?
  • What are the deals, revenue, and value review by market types and uses?
  • What are the transactions, revenue and value review by business areas?

About Us

Credible Markets is a new era market research company with a firm grip on the pulse of global markets. Credible Markets has become a trusted source for business market research needs in a short period of time. We’ve partnered with leading market intelligence publishers and our report pool coverage spans all key industry verticals and thousands of micro-markets. The massive repository allows our clients to choose from recently released reports from a range of publishers who also provide in-depth analysis by region and country. Moreover, pre-booked research reports are among our best offers.

The collection of market intelligence reports is regularly updated to provide visitors with quick access to the latest market information. We provide round-the-clock support to help you reuse search parameters and benefit from a full range of reserved reports. After all, it’s about helping you make an informed, strategic decision on purchasing the right report that meets all your market research demands.

Contact us

Credible market analyzes
99 Wall Street 2124 New York, NY 10005
E-mail: [email protected]

read more
Prescription drugs

Most Commonly Misused Prescription Drugs in the United States

Cloth

Most Commonly Misused Prescription Drugs in the United States

The Substance Abuse and Mental Health Services Administration, or SAMHSA, reported that among people who abused prescription painkillers in 2020, nearly 65% ​​said their main reason for doing so was to relieve physical pain. The percentage of people reporting drug abuse as a reason for getting high was 11.3%.

Abuse is defined as patients who take prescription drugs in a manner other than that recommended by their doctor. It may be like taking someone else’s prescription or taking their own in larger or more frequent doses, or for a longer period of time.

Citing data from SAMHSA, Zinnia Health identified the most commonly used prescription medications in the United States, all of which are opioid pain relievers or opioid pain relievers. This class of drugs acts on the central nervous system by blocking pain signals to the brain. In addition to relieving pain, these drugs also intensely trigger the brain’s reward centers, releasing endorphins and creating positive feelings commonly referred to as euphoria. This is what makes prescription opioids – and all opioids, for that matter – so dangerously addictive.

Prolonged use of opioids may increase a patient’s tolerance to a particular drug. With higher tolerance, the drug becomes less effective and patients do not experience the same level of pain relief and feelings of euphoria, which often leads people to seek out stronger opioids. This could explain why such a large percentage of people reported misusing prescription opioids for pain relief. For example, someone who has abused and developed a tolerance to morphine may seek something stronger like oxycodone or hydromorphone, whose effects kick in faster and more intensely.

SAMHSA also found that nearly half of people who abused painkillers (47.2%) said they got the drugs from a friend or relative, either by stealing them, buying them, or getting them for free. . About 44% of people said they got prescriptions from a health care provider. Drug diversion—or the disruption of a prescription drug along its legal, intended journey from manufacturer to physician to patient—is a contributing factor to drug abuse. Diversion occurs, among other things, through doctor purchases, theft and tampering.

The United States is in its third wave of the opioid crisis, but it is important to note that this current wave is characterized by illicitly produced synthetic opioids. Overdose deaths from commonly prescribed opioids have declined in recent years. However, knowing the uses and risks associated with these drugs can save lives. Read on to learn about the most commonly used prescription drugs in the United States.



MedStock Photos // Shutterstock

#8. Morphine

– Abuse in the past year (former users): 8.9%
– Misuse in the past year (general population): 0.2%

Known by its brand names Avinza or Kadian, morphine is an opioid used to treat acute and chronic pain. Although morphine can be given intravenously, it is most often taken as tablets or capsules. Morphine is closely related to other painkillers like hydrocodone and oxycodone. The potency of other opioids is often determined or compared against the potency of morphine.



chatuphot // Shutterstock

#7. Tramadol

– Abuse in the past year (former users): 9.0%
– Misuse in the past year (general population): 0.5%

Tramadol, commonly referred to by its brand name Ultram, is a synthetic opioid used to treat moderate to severe pain, usually after surgery. The drug is commonly prescribed in the form of extended-release tablets to relieve severe chronic pain caused by conditions such as fibromyalgia. In 2019, approximately 5.5 million people were prescribed Tramadol, totaling almost 20 million prescriptions. It was the 35th most prescribed drug in the United States



Joe Mamer // Shutterstock

#6. Codeine

– Misuse in the past year (former users): 12.2%
– Misuse in the past year (general population): 0.9%

Codeine is an opioid used to treat mild to moderate pain and is most commonly prescribed as a cough suppressant. It can also be used to treat gastrointestinal issues like diarrhea. Because codeine is milder than other opioids, users with misuse intentions increase doses to achieve a higher high. Codeine abuse can lead to more intense opioid abuse.



Cloth

#5. Hydrocodone

– Misuse in the past year (former users): 12.6%
– Misuse in the past year (general population): 1.7%

Hydrocodone is the most frequently prescribed opioid in the United States In 2020, 4.7 million people misused hydrocodone products, making it the most commonly used type of prescription pain reliever this that year. Hydrocodone, also known by its brand name Vicodin, is given to patients with moderate to severe pain, usually after surgery or injury, or to relieve pain associated with medical conditions such as cancer. In combination with homatropine, hydrocodone can also be used as an antitussive. Unlike other opioids, hydrocodone is not often illicitly manufactured and the vast majority of diverted hydrocodone is pharmaceutical.



Cloth

#4. Oxycodone

– Abuse in past year (former users): 14.5%
– Misuse in the past year (general population): 1.1%

Oxycodone is an opioid prescribed to treat persistent severe pain. OxyContin and Percocet are two of the most recognizable brands, the former being a pure form of oxycodone and the latter a combination of oxycodone and aspirin. About 3.2 million people abused oxycodone products in 2020, making it the second most misused painkiller behind hydrocodone. Oxycodone abuse is prevalent across the spectrum of geographic, demographic, and socioeconomic conditions.



PureRadiancePhoto // Shutterstock

#3. Fentanyl

– Misuse in the past year (former users): 14.8%
– Misuse in the past year (general population): 0.1%

The pharmaceutical fentanyl, which this data refers to, can be up to 100 times more potent than morphine and is most commonly used to treat pain associated with advanced cancer. Legally produced fentanyl is usually given in the form of patches or lozenges. According to the Drug Enforcement Administration, misuse of these products may include ingesting the gel inside the patches or freezing the patches, cutting them into pieces, and placing them inside the cheek to absorb the contents. . Because a percentage of fentanyl remains in used patches even after three days of use, used patches are also targeted for misuse. Illegally manufactured, non-pharmaceutical fentanyl is at the heart of the third and current wave of the opioid epidemic in the United States.



Cloth

#2. Hydromorphone

– Misuse in the past year (former users): 16.6%
– Misuse in the past year (general population): 0.1%

Hydromorphone, commonly referred to by the brand names Dilaudid or Exalgo, is an opioid prescribed to treat severe pain in patients resistant to less potent opioids. It is about eight times stronger than morphine and the effects of a 1-2 mg dose can be felt in as little as 15 minutes. Hydromorphone carries a high risk of addiction and is only prescribed in certain medical circumstances, such as cancer pain management or cancer-related treatment. According to the Drug Enforcement Administration, hydromorphone was once the most commonly misused or misused drug, now supplanted by oxycodone and hydrocodone.



PureRadiancePhoto // Shutterstock

#1. Buprenorphine

– Abuse in the past year (former users): 26.5%
– Misuse in the past year (general population): 0.2%

Buprenorphine is an opioid used in the drug treatment of opioid use disorder, or OUD, specifically to reduce intense withdrawal symptoms that can lead to relapse. It works by stimulating the brain in the same way as heroin or methadone, but to a lesser degree, creating a limit to its effects. It can produce euphoria without the risk of suppressing breathing, which is the true cause of death in opioid overdose. Since prolonged use of opioids inhibits the brain’s ability to produce dopamine on its own, the right dosage of buprenorphine and a comprehensive treatment plan allow patients with OUD to feel “normal” or equilibrium.

This story originally appeared on Zinnia Health
and was produced and distributed in partnership with Stacker Studio.


read more
Prescription drugs

Global Prescription Drugs Market – Applications in various verticals will emerge in favor of market growth to increase sales revenue

Global Prescription Drugs Market Report Highlights Latest Market Advancements Amid COVID-19 Pandemic

Market research store has released the latest report on the Global Prescription Drugs Market. The report provides all the valuable data based on the fundamental fragmentation of the market into different sectors. In this research report, different vital elements including competitive landscape, geographical spread, market dynamics, market share, and other market growth attributes. The report on the prescription drug market also covers market breakdown and size through detailed study of regional and company profiles. The report entails all the information about the Global Prescription Drugs Market, breakdown, competitive players, applications, and more. decoded. The study also innately determines the market status, barrier analysis, sales breakdown, risks, growth drivers, and opportunities to guide through the in-depth market analysis.

Get Free Sample Report + All Related Charts & Graphs (with COVID 19 Impact Analysis): https://www.marketresearchstore.com/sample/prescription-drugs-market-813432

Prescription Drugs Market Size, Status and Forecast 2028

1 Market Overview
2 manufacturer profiles
3 Global Prescription Drugs Sales, Revenue, Market Share and Competition by Manufacturer
4 Global Prescription Drugs Market Analysis by Regions
5 Prescription Drugs in North America by Country
6 Europe Prescription Drugs by Countries
7 Asia-Pacific Prescription Drugs by Countries
8 South America Prescription Drugs by Countries
9 Middle East and Africa Prescription Drugs by Countries
10 Global Prescription Drugs Market Segment by Type
11 Global Prescription Drugs Market Segment by Application
12 Prescription Drugs Market Forecast
13 Sales channel, distributors, traders and resellers
14 Research findings and conclusion
15 Appendix

In addition, key market players mentioned in the report include Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG, Allergan PLC, AstraZeneca PLC, Johnson & Johnson, Eli Lilly and Company, Shire PLC, Novartis International AG, Novo . The company profile provides comprehensive market revenue, future development, industry policies, strategies, and demand analysis with the help of comprehensive market analysis. The study also details the market status, regional distribution, latest innovations, and government policies pertaining to the prescription drugs market. The regional segmentation United States, Canada, and Mexico into North America, Peru, Brazil, Argentina, and Rest of South America as part of South America, Germany, Italy, United Kingdom, France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia- The Pacific (APAC), South Africa, Saudi Arabia, United Arab Emirates, Kuwait, Israel, Egypt, the rest of the Middle East and Africa (MEA) offers the understanding, reach and application of this market. A valuable source of relevant data can be obtained from the report through the competitive and strategic analysis.

Read the full report @ https://www.marketresearchstore.com/market-insights/prescription-drugs-market-813432

The report also covers the details such as economic, environmental, social, technological, and political status of the Prescription Drugs market after observing and studying various factors. Regional profiling of market revenue, size and volume will provide insight into the growth rate of the market over the forecast period. The comprehensive summary of Prescription Drugs Market will provide readers with a clear overview of the investment potential in the market. The market research report provides a clear picture to fight competition in the market. All macroscopic and microscopic imprints of the market are well explained in the Prescription Drugs Market report.

Segmentation:

By product : Brand name drugs, Generic drug

By app : Hospital, Clinic, Other

Here are the questions answered by the market report:

What are the objectives of the report?

This market report shows the projected market size for the prescription drugs market by the end of the forecast period. The report also examines historical and current market sizes.

Based on various indicators, the charts present the year-on-year growth (%) and the compound annual growth rate (CAGR) for the given forecast period.

The report includes market overview, geographic scope, segmentation, and financial performance of key players.

The report examines the current state of the industry and potential growth opportunities in North America, Asia-Pacific, Europe, Latin America, Middle East and Africa.

The research report includes various factors contributing to the growth of the market.

The report analyzes the growth rate, market size and market valuation over the forecast period.

For an additional revised list of market players in 2021, request a sample report: https://www.marketresearchstore.com/sample/prescription-drugs-market-813432

What factors are taken into consideration while evaluating the major market players?

The report analyzes companies around the world in detail.

The report provides an overview of the major market vendors including key players.

The reports include information about each manufacturer, such as profiles, revenue, product prices, and other relevant information about the products produced.

This report includes a comparison of market competitors and a discussion of key player perspectives.

Market reports provide information on recent developments, mergers and acquisitions involving key players.

Get more information before buying@ https://www.marketresearchstore.com/inquiry/prescription-drugs-market-813432

What are the main conclusions of the report?

This report provides comprehensive information about the factors that are expected to influence market growth and market share in the future.

The report presents the current market status and future prospects for various geographical regions.

This report provides qualitative and quantitative insights into the competitive landscape of the market.

Combined with Porter’s five forces analysis, it serves as a SWOT analysis and competitive landscape analysis.

It provides an in-depth analysis of the market, highlighting its growth rates and growth opportunities.

read more
Prescription drugs

5 charged with attempted smuggling of prescription drugs into Michigan

GRAND RAPIDS, Mich. (WILX) – Five defendants have been charged with conspiring to smuggle prescription drugs into the United States, for distribution in the Western District of Michigan and elsewhere.

On Friday, US Attorney Andrew Birdge announced that five men had been charged in connection with the investigation. They have been identified as Joshua Ford of Troy, Michigan; James Funaro of Atlanta, Georgia; Jeremy Walenty of Tampa, Florida; Taylor McLaren of Colorado Springs, Colorado; and Brendon Gagne of Fountain, Colorado.

Related: Michigan Prescription Drug Task Force Recommendations Announced

Two of the defendants, Gagné and Funaro, are also charged with money laundering conspiracy. Funaro alone is charged with one count of money laundering.

According to court documents, the defendants operated two websites that sold prescription drugs and certain controlled substances. These sites were ExpressPCT.com and ExpressPEDS.ws.

The United States has shut down two websites suspected of illegally selling prescription drugs.(WILX)

Birge said in a statement that ExpressPEDS.ws also sells anabolic androgenic steroids.

The US government is now arguing that the drugs sold on these sites were largely, if not entirely, manufactured outside the United States and smuggled into the country to be sold to people in the United States. According to the indictment, the sites did not ask for prescriptions from customers even though the drugs being sold require a person to be under the supervision of a licensed practitioner.

Related: Michigan governor signs bills to cut prescription drug costs

ExpressPCT.com accepted Bitcoin as well as other forms of payment, including payments sent through digital payment networks such as Zelle and Cash App.

The indictment says that if customers chose to pay using alternative payment methods other than cryptocurrency, the co-conspirators directed payments through accounts linked to Funaro. It alleges that Funaro then converted proceeds from the scheme into cryptocurrency before it was transferred to accounts held by a group of co-conspirators.

Birge alleges that this group of co-conspirators included foreign nationals residing abroad.

Investigators say they have traced at least $12 million in revenue to the drug trafficking program. If convicted of conspiracy to smuggle drugs into the United States, the defendants face a legal maximum of five years in prison and a fine of up to $250,000. If Gagne and Funaro are convicted separately of the money laundering conspiracy charge, they face a legal maximum of twenty years in prison and a fine of up to $500,000 or double the value of the funds laundered. , whichever is greater.

Criminality: ‘I’ve been advocating for this day for a long time’ – Man who saved sister from heinous attack sees bipartisan public safety bills signed

Copyright 2022 WILX. All rights reserved.

Subscribe to our News newsletter 10 and get the latest local news and weather straight to your email every morning.

read more
Prescription drugs

Amazon Pharmacy will provide low-cost prescription drugs

Amazon Pharmacy provides lower cost prescription drugs in five states through a new partnership with Blue Cross Blue Shield.

The Verge reports that the retail giant’s pharmacy wing is offering a prescription drug discount card to Blue Cross Blue Shield customers in New Jersey, Nebraska, Alabama, Florida and Kansas. The partnership will allow customers to get discounts through a MedsYourWay card when using Amazon Pharmacy. Also, the cost of medications will still count towards insurance deductibles.

“They can be free to choose which is cheaper and not have to worry about what applies to their maximum disbursement or deductible, because both apply,” Nworah AyoguAmazon Pharmacy’s chief medical officer, said at a health technology conference this week.

While most prescription discount cards work in a pharmacy network, customers will be able to use the MedsYourWay card at Amazon pharmacies. MedsYourWay is offered by pharmacy benefit manager Prime Therapeutics, owned by more than a dozen BlueCross Blue Shield health plans.

Amazon Pharmacy debuted in 2020, two years after buying drug delivery startup Pillpack, offering discounted costs on common prescription drugs and drugs based on their manufacturing cost.

Others are getting into the prescription drug game, including Dallas Mavericks owner and Shark Tank investor Marc Cubanwhich launched its online pharmacy The Cost Plus Drug Co. in January.

“I want to be above the break-even point while maximizing the number of people who can afford their drugs,” Cuban told TechCrunch. “Shoot. I would be happy if we could earn a little, but bring down the prices of generics sold elsewhere considerably.”

According to BioSpace, prescription drugs have seen their prices increase by 3.3% in 2021 and 5.8% in 2020. This year, Pfizer, Purdue Pharma and Gilead have all increased the prices of drugs for HIV, cancer breast cancer, cardiovascular problems and opioids. .

read more
Prescription drugs

Free Prescription Drugs, Joining the National Power Grid, and the Future of Southfork Ranch

After my story reviewing pharmacy discount cards, I heard about “the first free pharmacy serving the general public in Texas”. The association is looking for a promotion. I gladly comply here.

On another subject, I have to tell you that between my last Atmos gas bill and the skyrocketing increase in home insurance, I’m at my wit’s end. I need to smell the salts.

Also, can anyone help solve the mystery of the future status of the legendary Southfork Ranch?

Let’s start this collection of great Watchdog shorts with the discount pharmacy.

Carlos Irula is the head pharmacist at St. Vincent de Paul Pharmacy. He tells me about free prescription drugs available primarily for chronic health conditions such as diabetes, hypertension, high cholesterol, and mental health.

To qualify, a person must have no health insurance, a household income at or below 300% of the federal poverty level ($83,250 in a four-person household), and be a Texas resident with a valid prescription. . You don’t need to go to the pharmacy because they deliver.

Find out if you or someone else you know may qualify by calling 469-232-9902 or visiting www.svdpdallas.org/pharmacy.

Increase in home insurance

I wondered why my home insurance had jumped 36% in one year. I made no complaints.

The culprit was the cost of replacing the house, which jumped $100,000 in one year, I was told. wow.

My initial guess was that it was the result of the February frost. Someone has to pay for all those broken water pipes in so many Texas homes. But Ben Gonzalez of the Texas Department of Insurance tells me my guess is wrong.

“Industry sources indicate that wood and other building materials are more expensive,” he said. He also cited labor shortages and natural disasters. “If it costs more to build a house, it will cost more to insure it,” he said.

Richard Johnson of the Texas Insurance Board told The Watchdog, “Your 35% increase seems like an outlier. …The national average is about 11.4%. We see closer to 7% to 10% in Texas. »

His advice for me? Shop!

Sale of Southfork Ranch?

I’ve been told that the future of Southfork Ranch, legendary home of the Ewing family of television, is in jeopardy.

I called there half a dozen times, but no one called me back. Finding out who shot JR was easier than finding out about this world famous tourist attraction from Parker.

Realtor Sarah Hamilton of 1845 Realty in Frisco checked it out for me. She learns that the ranch is under a sales contract. But the future of the tourist attraction is unknown.

Banking News

After I told you how several big banks were eliminating NSF fees and ending overdraft protection fees, another big one jumped into the pool. Citigroup has announced that it is ending all overdraft fees and insufficient funds fees.

The Center for Responsible Lending says Citi is the biggest bank to do so.

Join the grids

Isn’t it ridiculous that Texas leaders don’t want to join the two national power grids? I mean, come on, if Putin has taught us anything in the last few weeks, it’s that we need reinforcements.

I disagree with former Governor Rick Perry, who explained that “Texans would be without power for more than three days to keep the feds out of their business.”

But as University of Texas energy professor Michael E. Webber points out, Texas already deals with federal regulations when it exports natural gas, gasoline, liquefied natural gas and crude oil.

Why not electricity too? He estimates that by joining the large grids, Texas could sell $10 billion worth of excess energy each year. And in the event of a disaster, we could buy back some of it.

Note that Pat Wood, a former chairman of the Utilities (Public) Commission, told the Texas Tribune last month that Texas could join without losing control of its system. But for politicians, it sounds better to say we don’t want the federal government in our business.

Post office changes

I will never forget that 16 years ago I reported a story to my editor about the US Postal Service, but he didn’t believe it could be true.

The USPS had raised the price of a stamp by two cents and charged more for priority, express, and certified mail. Most people thought it was because the post office was failing. But in fact, that year, the post office had a surplus.

While attending a postal conference, I learned that the money was used to pre-fund future pension benefits for postal workers, not postal operations themselves. My boss didn’t believe it.

Now, all these years later, Congress has voted to end the practice of pre-funding retirees on postage.

A postal overhaul bill awaiting President Biden’s signature also locks down six-day-a-week delivery and — my favorite part — imposes special postage rates for local newspapers to promote local news, The Wall Street Journal reported.

AT&T Tip of the Day

Finally, I pass on this common-sense advice from Arlington’s Mark Schnyder:

“Whenever I have a billing issue with AT&T, at the very end of the call, when they ask if there’s anything else they can do for me, I say, ‘Hey, since this issue has was caused by AT&T and I had to spend x-amount of time dealing with it, how about a $25 loyalty credit?”

“I get it almost every time,” he says. “The thing is, they will if you ask. I’d like to think that if we all did this when AT&T had to correct its own mistakes, maybe the company would start to feel enough pain, it would make fewer mistakes. A guy can dream.

Become a citizen of Watchdog Nation.

Join Dave Lieber and learn how to be a super consumer.

Surveillance bulletin: Sign up for The Watchdog’s FREE weekly newsletter to keep up to date: click here.

Watch this free training video from Dave: https://youtu.be/uhUEUCNKGjc

Subscribe: PLEASE support The Watchdog’s brand of simple journalism designed to save you time, money and aggravation. Treat yourself to a digital subscription (and make it look good!) using the special Watchdog code: https://www.dallasnews.com/subscribe/watchdog-1

Watchdog home page: You can’t afford to miss The Watchdog’s two reports every week. Follow our latest reports always on The Watchdog home page which presents all the recent headings.

Facebook: Connect with The Watchdog on our Facebook group. Search for “Dallas News Watchdog Posse”.

The Dallas Morning News Watchdog column is the 2019 winner of the National Society of Newspaper Columnists’ top column writing award. The contest judge called his winning works “models of suspenseful storytelling and public service.”

Read his winning columns:

* Assist the widow of Officer JD Tippit, the Dallas police officer killed by Lee Harvey Oswald, to be buried next to her late husband

* Help a waitress injured by an unscrupulous used car dealer

read more
Prescription drugs

Reduce prescription drug costs

The cost of prescription drugs is too high in this country. We know Ohioans are concerned about the cost of living right now, and one of the worst inflations we see, year after year, is drug prices. And often the culprit is price hikes by big pharma.

That is why I introduced the Affordable Medicines Act. It would penalize drug companies that raise the price of their drugs without justification, and it would finally allow Medicare to negotiate lower drug prices for American seniors.

My entire career I’ve pushed for allowing Medicare to negotiate directly with drug companies for lower prices. Currently, the Secretary of Health and Human Services is prohibited from negotiating better prices for Americans on Medicare like VAs or private companies do.

It is not a mistake that the law protects the profits of big pharmaceutical companies, to the direct detriment of patients. The pharmaceutical companies were there when this law was drafted. And it’s something I’ve been fighting to fix ever since. And with the cost of living hitting American retirees on fixed incomes particularly hard, now is the time to do so.

We also know that some companies increase the price of drugs year after year, even though the drug costs the same to produce. Many of these companies do not create new drugs or invest in innovation – they simply buy the rights to existing drugs from other companies; dismiss workers; multiply prices by eight, nine or ten; and then expecting patients, hospitals and taxpayers to foot the bill.

If drug companies raise prices at twice the rate of inflation for no other reason than to increase their bottom line at the expense of sick Americans, then that’s a price hike, and they should pay the price.

AARP recently released a study showing that between 2019 and 2020, the price of more than 250 brand name prescription drugs widely used by older Americans rose more than twice as fast as overall inflation.

We have to control these prices.

We know high drug costs are a problem. We know how to fix it: we let Medicare negotiate, we penalize companies that price-gouging, and we cap out-of-pocket expenses.

The purpose of prescription drugs is to help Ohioans live longer, healthier lives, not to line the pockets of Big Pharma executives.

President Biden has made it clear in the State of the Union that this is a priority, and I will work to make it happen.

Brown-062609-18446-0008

Sherrod Brown is the senior US senator from Ohio.

read more
Prescription drugs

Rising cost of prescription drugs is a concern | News

WASHINGTON, DC – Although current prices have recently skyrocketed due to inflation and global issues, they pale in comparison to the rise in prescription drugs.

“For years, increases in prescription drug prices have eclipsed even the highest rates of inflation,” said Holly Holtzer, director of Ohio AARP.

“To give you an example, if consumer prices had risen as fast as drug prices over the past 15 years, gasoline would now cost $12.20 a gallon and milk $13 a gallon,” he said. she added.

Holtzer said last month that major drugmakers had hiked prices on 800 prescription drugs.

“They’ve imposed similar increases for decades with no effective way to stop them from raising prices for American seniors,” Holtzer said.

She said her organization frequently hears of older Americans in Ohio having to choose whether to pay for medicine or for food and heat.

In an attempt to alleviate the problem, U.S. Senator Sherrod Brown, D-Ohio, introduced the Affordable Medicines Act, which would penalize drug companies that raise the price of their drugs without justification and also end the restriction that prevents Medicare to negotiate lower prices. prizes for beneficiaries.

“It is no mistake that current law protects the profits of Big Pharma, to the direct detriment of patients, by prohibiting the government from negotiating better prices for the American people,” Brown said. “The pharmaceutical companies were in the room when this law was written.”

Holtzer said giving Medicare the ability to negotiate would lower prices.

Brown also supports other efforts to reduce the cost of health care for workers in Ohio by capping the cost of insulin at $35 per month, imposing penalties on drugmakers who raise prices at above inflation and capping out-of-pocket expenses for Medicare beneficiaries at $2,000 per month. year.

“The point of prescription drugs is to allow (people) to live longer, healthier lives, not to make a bunch of drug company executives in New Jersey and elsewhere much richer,” Brown said.

“Congress has promised for years to lower the price of prescription drugs,” Holtzer said. “For any member of Congress concerned about inflation, lowering drug prices should be high on the to-do list.”

On Wednesday, Ohio AARP presented members of Congress with a petition signed by 182,000 Ohioans calling on lawmakers to act on prescription drug prices.

read more
Generic drugs

Savings on Generic Drugs Continue to Grow, Says Canadian Pharmacy Intermediary SaveRxCanada.to

VANCOUVER, BC, March 3, 2022 /PRNewswire/ — SaveRxCanada.to, a Leading Canadian Pharma Intermediary Since 2002, Continues to See an Uptrend Among Americans buy generic drugs. Generic drugs contain the same active ingredients with the same strength and purity as their brand name counterparts, but at a fraction of the cost.

the Rx Select The SaveRxCanada program was one of the first programs of its kind launched in 2004 to provide access to generic drugs. By adding several international pharmacies to their network, patients were able to find many generic and branded drugs not available in Canada.

The RxSelect program offers free shipping and 5% in rewards points that can be redeemed on future orders.

In United States76 million patients consult at least one prescription drug in 2020.

the 2021 U.S. Generic and Biosimilar Drug Savings Report highlighted the increased cost savings on generic drugs. Some key research findings:

  • $338 billion: US healthcare system savings
  • 90%: Portion of U.S. prescriptions filled with generic drugs
  • $6.61: The average generic share
  • $7.9 billion: savings on biosimilars
  • $109.6 billion: Medicare savings

The savings of individual consumers and the health care system as a whole continue to grow, reaching $338 billion in 2020. Tens of millions of Americans trust their health to generics and biosimilars. These savings are the main component of an often overlooked success story in public health.

About SaveRxCanada.to

SaveRxCanada.to has been a reliable, affordable and reliable Canadian pharmaceutical intermediary for over 18 years.

The company is committed to providing affordable prescription drugs to patients around the world through its network of licensed Canadian pharmacies and international pharmacies.

Visit SaveRxCanada.to to learn more about the company.

Customer service

Toll free: 1-866-799-3435 – Use reference #100048
Monday Friday 9:00 a.m. to 5:00 p.m. (EST)

All orders required a valid prescription from a licensed physician or physician.

This press release was published via 24-7PressRelease.com. For more information, visit http://www.24-7pressrelease.com.

SOURCESaveRxCanada.com

read more
Prescription drugs

Letter to the Editor – About Prescription Drugs | Opinion

As a Registered Nurse with decades of professional experience, I have provided health care to hundreds of rural Iowas. From treating traumatic injuries to chronic disease care to helping patients manage medications, we healthcare providers gain valuable insight into the inner workings of one of the largest sectors of the economy. And sometimes that hands-on experience and training in healthcare can be incredibly frustrating.

The high cost of life-saving drugs and prescription drugs is at the top of my list of concerns. I’m not alone. 83% of Americans say the cost of prescription drugs is unreasonable, according to an October 2021 public opinion poll conducted by the nonpartisan health care organization Kaiser Family Foundation (KFF).

The KFF poll also shows strong, bipartisan public support – more than 80% in favor – for government actions that:

facilitate the marketing of generic drugs

limit the drug company’s ability to raise prices above inflation

limit out-of-pocket spending for people on Medicare

allow governments to negotiate with pharmaceutical companies for lower prices on Rx drugs covered by Medicare and private insurance

Federal action to implement these grassroots policy changes has been blocked primarily by Senate Republicans and filibuster rules that Democrats seem unwilling to change.

Fortunately, we have an opportunity here in Iowa this legislative session to make prescription drugs more affordable and accessible. House File 263 would cap the cost of insulin at $100 per month for state-regulated health care plans in Iowa. House File 262 would allow those who need insulin, Epi-Pens and inhalers to receive emergency prescriptions from their pharmacist if their doctor is unavailable for a prescription. Both bills would help tens of thousands of Iowans.

Both of these bills passed the Iowa House of Representatives last year 91-0 and 89-2. Unfortunately, the state senate took no action. Sen. Jeff Edler (R, State Center), who chairs the Senate Human Resources Committee, declined to schedule votes on these incredibly popular and important bills.

Senator Edler is certainly aware of his role in this process. For example, regular Iowans who rely on insulin to manage their diabetes have called and met with Senator Edler to implore him to allow a yes or no vote on these issues. Senator Edler needs to stop playing political games with people’s lives. After all, over 10% of adults in Iowa have diabetes, with diabetes rates over 20% for Iowans earning less than $25,000 a year.

If Senator Edler isn’t supporting Iowans with diabetes, who is he protecting? U.S. Senator Charles Grassley (R-IA), who was a key leader of Edler’s party for half a century, led an investigation into how drug companies measured insulin prices in 2019 when Grassley was Chairman of the Senate Finance Committee. The Grassley Committee report found that pharmaceutical companies Eli Lilly, Sanofi and Novo Nordisk have dramatically increased the prices of long- and short-acting insulins over the past decade, in some cases by more than 70% by only 5 years old.

It’s not a complicated question. To refuse to provide basic cost controls for life-saving prescription drugs is simply cruel and cynical policy. Pharmaceutical companies are among the most profitable companies in the world. Our political leaders, both in Washington DC and here at the Des Moines Statehouse, have allowed corporate power to block grassroots reform for too long. Now is the time to act, and it starts with Senator Edler scheduling a vote on House Items 262 and 263 before it’s too late during this year’s legislative session.

Barb Kalbach is a 4th generation family farmer, registered nurse, and board member of Iowa Citizens for Community Improvement. Barb can be reached at [email protected]

read more
Prescription drugs

REUTHER: Prescription Drugs: America’s Scam | Opinion

By DAVID REUTHER

The continued rise in prescription drug prices remains a long-term hardship for many American families. Overall, US residents spend significantly more on prescription drugs than residents of other comparable developed countries.

Soaring drug prices, coupled with an aging population in dire need, have led many congressional lawmakers and public groups to tackle the current pricing system with increasing urgency.

It is a harsh reality that many people have to choose between food, shelter and medicine. According to an AARP report, applying the drug price increase rate to everyday items would mean a gallon of milk would cost $13, a loaf of bread $4.21, and a gallon of gasoline $12.20.

When President Biden visited Culpeper on Feb. 10, Rep. Abigail Spanberger (D-Va.) introduced him to Shannon Davis and her 12-year-old son Joshua, who, like his father, has diabetes from type 1 and whose insulin is expensive. the family about $1,000 a month. It’s not an optional expense, it’s vital to preserve their lives.

People also read…

To shed some light on the problem, Rep. Spanberger, along with five bipartisan colleagues, introduced the Public Disclosure of Drug Rebates Act, which would require that rebates, rebates, and price concessions negotiated by intermediaries be made public on a website through the Department. health and social services. The bill originally passed the House unanimously in 2019 and now sits in the divided Senate, where it languishes in committee.

The Elijah Cummings Reduce Drug Costs Now Act of 2021 was also originally passed by the House in 2019; all Democrats voted for the measure and all but two Republicans voted against. The Republican-controlled Senate never picked it up. This would have allowed Medicare to negotiate drug prices like Veterans Affairs and Medicaid do with drug companies.

The Congressional Budget Office estimated the Cummings bill would save $345 billion in federal spending over seven years, and the Centers for Medicare & Medicaid Services found it could reduce out-of-pocket costs by $158 billion. dollars over a decade. It was reintroduced in 2021 and was later included in the President’s Build Back Better bill, which passed the House along party lines in November 2021. Facing unanimous Republican opposition, the bill died in the Senate.

The Build Back Better Act would have included a $2,000 annual cap on out-of-pocket expenses for people enrolled in Medicare Part D drug plans and a $35 co-pay cap on certain insulins. It also reportedly allowed Medicare to begin negotiating the price of certain prescription drugs. From 2025, 10 drugs in addition to insulin would have been traded, with this number increasing to 20 drugs in 2028 and beyond.

Out of control drug prices, so difficult for so many Americans, translate into out of control profits for pharmaceutical companies, a problem unheard of in most other developed countries.

In a democratic republic, the people choose representatives to act for them and for the good of the country. Today, there appears to be a major disconnect between citizens and Congress, as well as hyper-partisanship within and between the two chambers.

The BBB is just one indicator of this unsatisfactory inaction, and the drug companies will happily continue to make obscene profits. If we don’t demand that our representatives meet the challenges we face, nothing will happen.

David Reuther, a retired US foreign service officer, is a former chairman of the Culpeper Democratic committee.

read more
Prescription drugs

Making prescription drugs more affordable

The rising cost of prescription drugs is a growing concern, especially for those who depend on their medications to stay healthy. Spending on prescription drugs is only expected to risehttps://payorsolutions.cvshealth.com/updates/consultant-briefing-december-2021 with the specialty drug market expected to reach $373 billion in 2025. As more therapies come to market, they provide new options for patients who may previously have had no treatment available for their condition or who have not found the right medication for them – this has been true for conditions such as migraines and weight loss. However, new treatments on the market can also increase the overall cost of drugs, which increases the pressure on consumers. For example, autoimmune diseases were the main contributor to specialty growth, accounting for 54% of all specialty utilization trend.

Reduce the cost of prescription drugs

That’s why we’re committed to working with employers and health insurance plans to make prescription drugs more affordable. From ensuring appropriate use of treatment to negotiating with drug manufacturers for the lowest prices, we use every tool possible to increase member affordability – and our Trends Report in medicine proves that we can deliver. In fact, we delivered an overall drug trend of 2.4% for our customers.

Through our clinical-first approach, innovative new programs, and digital tools, we’ve kept out-of-pocket expenses low, consistently reduced member cost share, and passed millions in savings on to members. We’re proud of the work we do — and invite you to dig deeper into how CVS Health partners with employers and health plans to reduce costs and make prescription drugs more accessible and affordable for members.

read more
Prescription drugs

Sleeping Pills (Prescription Drugs) Market Share of APAC, Europe & Americas Application will grow at XX% CAGR to 2026





Abstract:

The latest Sleeping Pills (Prescription Drugs) Market research report offers an in-depth assessment of this business sphere and highlights the key driving factors, growth barriers and lucrative prospects influencing the earnings trajectory over the period 2021-2026.

Request a sample copy of this report @ https://www.getnewsalert.com/request-sample/28757

The Sleeping Pills (Prescription Drugs) industry is expected to register a CAGR of xx% over the forecast period. To arrive at such projections, the research relies on the history of the market increase as well as proven research mythologies.

The document also includes data pertaining to the regional scope of the industry and emphasizes the factors fueling segmental development. Additionally, it provides in-depth company profiles of key players to offer a comprehensive view of this vertical’s competitive dynamics.

Market overview:

Regional outlook:

  • Regionally, the Sleeping Pills (Prescription Drugs) market is classified into North America, Europe, Asia-Pacific, South America, Middle East & Africa, Southeast Asia.
  • The study examines economic indicators for key geographies along with their implications for the overall expansion of the industry.
  • The market share as well as the consumption growth rate of each of the listed regional segments are also presented.

Product Land Overview:

  • According to the report, product portfolio of Sleeping Pills (Prescription Drugs) Market is divided into Zolpidem Eszopiclone (Lunesta) Ramelteon (Rozerem) Ativan (Lorazepam) Adapin (Doxepin).
  • The document shows the consumer market share of each product segment.
  • Information on prices, sales and revenue generated by each product category is specifically covered in the study.

Overview of scope:

  • Based on scope, the sleeping pills (prescription drugs) market is divided into hospital pharmacy and retail pharmacy.
  • The document includes forecasts of the consumption value and consumption share of each application category over the analysis period.
  • The market share captured by each application segment is also listed.

Review of the competitive landscape:

  • The competitive atmosphere of the Sleeping Pills (Prescription Drugs) market is defined by top performers such as Sanofi Abbott Laboratories Takeda Pharmaceutical Apotex Aurobindo Pharma Actellon Pharmaceuticals Allegiant Health Cayman Chemical Ambitropin Hayao.
  • The report presents basic company information and a summary of each company.
  • Statistical data relating to sales, price structure, revenue share and gross margins are also presented.
  • The research document identifies major manufacturing bases, distribution channels and operational areas of key players.
  • Updated information on new product launches, market concentration rate, potential entrants, mergers and acquisitions, and development trends are also offered in the research document.

Research objective:

  • Focuses on the key global Sleeping Pills (Prescription Drugs) Market manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans over the next few years.
  • Moreover, the business contributors, as business analysts of the whole value chain, have made extensive efforts to carry out this group action and the bulk of the work adds order to produce the actors keys with useful primary and secondary data regarding the global Sleeping Pills (Prescription Drugs) market
  • Analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
  • Establish a strategic profile of key players and analyze in depth their growth strategies.

Influence of the Sleeping Pills (Prescription Drugs) Market Report:

  • Comprehensive assessment of all opportunities and risks in the Sleeping Pills (Prescription Drugs) Market.
  • Recent innovations and major happenings in the Sleeping Pills (Prescription Drugs) Market.
  • A detailed study of business strategies for growth of the Sleeping Pills (Prescription Drugs) Market-leading players.
  • Revealing study on the growth area of ​​the Sleeping Pills (Prescription Drugs) Market for the forthcoming years.
  • In-depth understanding of Sleeping Pills (Prescription Drugs) market drivers, restraints, and major and minor markets.
  • Favorable impression amid vital technological and market latest trends striking the Sleeping Pills (Prescription Drugs) Market.

Main points covered in the table of contents:

  • Overview of the Sleeping Pills (Prescription Drugs) Market
  • Market competition by manufacturers
  • Production market share by regions
  • Consumption by regions
  • Global Sleeping Pills (Prescription Drugs) Production, Revenue, Price Trend by Type
  • Global Sleeping Pills (Prescription Drugs) Market Analysis by Applications
  • Sleeping Pills (Prescription Drugs) Business Profiles and Key Figures
  • Manufacturing Cost Analysis of Sleeping Pills (Prescription Drugs)
  • Marketing channel, distributors and customers
  • Market dynamics
  • Global Sleeping Pills (Prescription Drugs) Market Forecast
  • Research results and conclusion
  • Methodology and data source

Customization request on this report @ https://www.getnewsalert.com/request-for-customization/28757





read more
Prescription drugs

Prescription Drugs Market Global Production, Growth, Share, Demand and Application Forecast to 2027 – ZNews Africa

Prescription Drug Market Research Overview

Global Prescription Drugs Market exhibits comprehensive information which is a valuable source of insightful data for business strategists during the decade 2017-2027. Based on historical data, the Prescription Drugs market report provides key segments and their sub-segments, revenue and demand and supply data. Given the technological breakthroughs in the market, the prescription drug industry is likely to emerge as a laudable platform for emerging investors in the prescription drug market.

The results of recent scientific endeavors towards the development of new prescription drug products have been studied. Nonetheless, factors affecting major industry players to adopt synthetic sourcing of market products have also been studied in this statistical survey report. The findings provided in this report are of great value to major industry players. Every organization involved in the global production of the Prescription Drugs Market products has been mentioned in this report, to study the information on cost-effective manufacturing methods, competitive landscape and new application avenues.

This report contains an in-depth analysis of pre-pandemic and post-pandemic market scenarios. This report covers all recent developments and changes recorded during the COVID-19 outbreak.

Get a sample report: https://www.marketresearchupdate.com/sample/355929

Major Key Players in the Market:
F. Hoffmann-La Roche AG, Eli Lilly and Company, Pfizer, Inc, Novo Nordisk A/S, Amgen, Inc, Merck & Co., Inc, Sanofi, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Bristol- Myers Squibb Company, AbbVie, Inc, GlaxoSmithKline PLC, Allergan PLC, Bayer AG, Celgene Corporation, Novartis International AG, Boehringer Ingelheim GmbH, Gilead Sciences, Inc, Shire PLC

The types covered in this report are:
brand name drugs
General medicine

Based on the app:
Sold online
Hospital
Clinical
Other

With the current market norms being revealed, the Prescription Drugs market research report has also illustrated the latest strategic developments and patterns of the market players in an unbiased manner. The report serves as a presumptive business document that can help the buyers in the global market to plan their next courses towards the future position of the market.

Check Prescription Drugs Market Report @ https://www.marketresearchupdate.com/discount/355929

Regional Analysis of the Prescription Drugs Market

North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia and Italy)
Asia Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia, etc.)
The Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Why B2B companies around the world rely on us to grow and sustain revenue:

  • Get a clear understanding of the prescription drugs market, how it works, and the different stages of the value chain.
  • To understand the current market situation and future growth potential of the Prescription Drugs Market throughout the forecast period.
  • Develop marketing strategies, market entry, market expansion and other business plans by understanding the factors that influence market growth and buyer buying decisions.
  • Understand your competitors’ business structures, strategies and prospects and react accordingly.
  • Make more informed business decisions using relevant primary and secondary research sources.

This report provides:

  1. A detailed overview of the global prescription drugs market.
  2. Assessment of global industry trends, historical data from 2015, projections for the upcoming years and anticipation of compound annual growth rates (CAGR) by the end of the forecast period.
  3. Discoveries of new market insights and targeted marketing methodologies for Global Prescription Drugs
  4. Discussion on R&D and demand for new product launches and applications.
  5. Varied company profiles of major industry players.
  6. The composition of the market, in terms of dynamic molecule types and targets, highlighting the key industry resources and players.
  7. The growth of patient epidemiology and market revenue for the global market and among key players and market segments.
  8. Study the market in terms of generic and premium product revenues.
  9. Determine business opportunities in the market sales scenario by analyzing trends in licensing and co-development agreements.

Get the full report @ https://www.marketresearchupdate.com/industry-growth/prescription-drugs-report-2022-2027-355929

Ultimately, the Prescription Drugs Market report includes analysis of investments and development trends. Present and future opportunities of the fastest growing international industry segments are covered throughout this report. This report additionally presents the product specification, manufacturing method, product cost structure, and price structure.

Contact us:
[email protected]

read more
Prescription drugs

Anti-Obesity Prescription Drugs Market Key Vendors, Opportunities, In-Depth Analysis by Regional and Country Perspective

the Prescription Anti-Obesity Drugs Market The report covers the whole scenario of the global market including key players, their future campaigns, preferred vendors, market shares along with historical data and price analysis. It continues to offer key details on changing dynamics to generate market improving factors. Its objective is to rationalize the company’s costs. You can also find interest and expense points on current income here. The best thing about the Prescription Anti-Obesity Drugs market report is the provision of guidelines and strategies followed by leading market players. The investment opportunities in the market that are highlighted here will go a long way in moving the business forward. Knowing the current market situation is the most important thing discussed here to help major players survive in the deadly market.

This Prescription Obesity Drugs Market study outlines the economic catastrophe caused by the covid-19 outbreak, which has affected all sectors of the business. A major global economic loss has occurred due to various industrial closures and loss of income. A high degree of information is offered here to assess the market situation.

Get Sample Full PDF Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://reportsglobe.com/download-sample/?rid=109105

The authors of the report draw up an encyclopedic assessment of the most important regional markets and their evolution in recent years. Readers are provided with accurate facts and figures about the Prescription Anti-Obesity Drugs market and its important factors such as consumption, production, revenue growth, and CAGR. The report also shares gross margin, market share, attractiveness index, and value and volume growth for all segments studied by analysts. It highlights key developments, product portfolio, markets served and other areas depicting business growth of major companies profiled in the report.

The report has been prepared using the latest primary and secondary research methods and tools. Our analysts rely on government documents, white papers, press releases, reliable investor information, financial and quarterly reports, and public and private interviews to gather data and information about the market in which they operate.

Major Players Covered in Anti-Obesity Prescription Drugs Markets:

  • F Hoffmann La Roche SA
  • Alizyme
  • Arena Pharmaceuticals
  • Therapeutic Ordemanden
  • Boehringer Ingelheim
  • Novo Nordisk A/s
  • Lived
  • Glaxosmithkline

    Prescription Anti-Obesity Drugs Market Split By Type:

  • Orlistat
  • Phentermine and Topiramate
  • Bupropion and Naltrexone
  • Lorcaserin
  • Liraglutide

    Anti-Obesity Prescription Drugs Market Split By Application:

  • Pediatric
  • Adult

    The Prescription Anti-Obesity Drugs Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is rated based on CAGR, participation, and growth potential. In the regional analysis, the report highlights the potential region, which is expected to generate opportunities in the global Keyword Market in the coming years. This segment analysis is sure to prove to be a useful tool for readers, stakeholders, and market players to get a complete picture of the global Keyword Market and its growth potential in the coming years.

    Get | Discount on the purchase of this report @ https://reportsglobe.com/ask-for-discount/?rid=109105

    Scope of Anti-Obesity Prescription Drugs Market Report

    ATTRIBUTES

    The description

    ESTIMATED YEAR

    2022

    YEAR OF REFERENCE

    2021

    FORECAST YEAR

    2022 to 2028

    HISTORICAL YEAR

    2020

    SECTORS COVERED

    Types, applications, end users, and more.

    REPORT COVER

    Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends

    BY REGION

    North America, Europe, Asia-Pacific, Latin America, Middle East and Africa

    Geographic segment covered in the report:

    The Anti-Obesity Prescription Drugs report provides information about the market, which is divided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate for each region, country and sub-region over the estimated period.

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

    Aims and objectives of Anti-Obesity Prescription Drugs Market Research

    • Understanding the opportunities and advancements in Anti-Obesity Drugs determines the market strengths, along with the key regions and countries involved in the market growth.
    • Study the various segments of the Prescription Anti-Obesity Drugs market and the dynamics of the Prescription Anti-Obesity Drugs in the market.
    • Categorize the Anti-Obesity Prescription Drugs segments with increasing growth potential and assess the market for the futuristic segment.
    • To analyze the most important trends related to the various segments which help decipher and convince the Prescription Anti-Obesity Drugs market.
    • Check region-specific growth and development in the Prescription Anti-Obesity Drugs Market.
    • Understand the major stakeholders of the Prescription Anti-Obesity Drugs market and the competitive image value of the Prescription Anti-Obesity Drugs market leaders.
    • To study the key plans, initiatives, and strategies for the development of the Prescription Anti-Obesity Drugs Market.

    The study thoroughly examines the profiles of major market players and their key financial aspects. This comprehensive business analysis report is useful for all new and existing participants when designing their business strategies. This report covers KEYWORD production, revenue, market share and growth rate for each key company and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Anti-obesity prescription drug historical distribution data from 2016 to 2021 and forecast for 2022-2028.

    Ask questions about personalization at @ https://reportsglobe.com/need-customization/?rid=109105

    Some highlights from the table of contents:

    1 Presentation of the report

    2 Market Trends and Competitive Landscape

    3 Prescription Obesity Drugs Market Segmentation by Types

    4 Prescription Obesity Drugs Market Segmentation by End Users

    5 Market Analysis by Major Regions

    6 Core Products of Anti-Obesity Drugs Market by Major Countries

    7 North America Anti-Obesity Drugs Landscape Analysis

    8 Europe Obesity Drugs Landscape Analysis

    9 Asia-Pacific Obesity Drugs Landscape Analysis

    10 Latin America, Middle East and Africa Obesity Drugs Landscape Analysis

    11 Profile of Key Players

    How Reports Globe is different from other market research providers:

    The creation of Reports Globe has been underpinned by providing clients with a holistic view of market conditions and future possibilities/opportunities to derive maximum benefit from their business and assist in decision making. Our team of in-house analysts and consultants work tirelessly to understand your needs and provide the best possible solutions to meet your research needs.

    Our team at Reports Globe follows a rigorous data validation process, which allows us to publish publisher reports with minimal or no deviation. Reports Globe collects, separates and publishes over 500 reports each year covering products and services in many areas.

    Contact us:

    Mr. Mark Williams

    Account Manager

    WE: +1-970-672-0390

    E-mail: [email protected]

    Website: Reportsglobe.com

  • read more
    Prescription drugs

    Representative Glenn backs plan to reduce Michigan prescription drug costs


    Representative Annette Glenn, R-Midland, continued her work to reduce prescription drug costs in Michigan.

    Glenn voted in favor of House Bill 4348, which will help patients save on drug prices by reforming regulations and improving transparency related to Pharmacy Benefit Managers (PBMs). The legislation passed the House with overwhelming bipartisan support and advances to Governor Whitmer for his consideration.

    “Michigan families are grappling with the rising cost of prescription drugs,” Glenn said. “This is an important step to help bring prices under control so people can get the medicines they need for themselves, their children and their parents.”


    PBMs act as intermediaries between health plans, drug manufacturers and pharmacists. The PBM industry’s unregulated practices have contributed to the rising prices consumers pay for prescription drugs. House Bill 4348 would provide specific requirements for PBMs to improve transparency and combat unfair trade practices that unnecessarily increase drug prices.

    The reforms target additional fees charged retroactively to pharmacies, discriminatory purchase limits and price increases for certain pharmacies, and restrictions that prevent pharmacies from providing relevant medical information to patients or discussing and selling alternatives. less expensive.

    The measure is just one of the many ways Glenn is fighting to make health care more affordable. She co-sponsors House Bill 4346, which would reduce out-of-pocket expenses for many diabetics who need insulin. Insurance companies could charge no more than $50 for each 30-day supply.

    read more
    Prescription drugs

    D’Augusta – Ensuring Access to Prescription Medicines and Protecting Mainers

    In our community, I know many of us are concerned about the cost of health insurance and the availability of life-enhancing or life-saving drugs. This year alone, pharmaceutical companies have raised the wholesale and retail prices of 450 drugs. When it comes to drug availability, recent surveys have found doctors and physicians struggling with cumbersome prior authorization protocols that slow or restrict their ability to prescribe drugs to their patients.

    Anne Carney

    Fortunately, two of my colleagues — Sen. Heather Sanborn (D-Portland) and Rep. Amy Roeder (D-Bangor) — have introduced bills to help protect Mainers from an unfair practice that some insurance companies use and to ensure that patients can obtain their prescription drugs.

    Sanborn’s bill would protect Mainers from double billing. For those who don’t know, double billing occurs when a patient’s insurance company uses a “co-pay accumulator program” that – usually unknown to the patient – prevents manufacturer assistance coupons to co-pay to count for both the patient’s deductible and the maximum out-of-pocket expense. Unfortunately, the patient ends up paying more for the prescription drug, even though he needed financial assistance to pay for it in the first place. Patients can suffer financial hardship, especially when they need expensive drugs.

    For example, a patient can take a pre-exposure prophylaxis (PreP) to prevent HIV named Descovy, which retails for $2,165.79. The drugmaker, Gilead, has a co-pay (voucher) assistance program that helps patients pay for their medications. However, if the patient’s insurance company uses a copayment accumulation program, the patient’s discounted copayment does not count toward the patient’s annual out-of-pocket maximums. Eventually, the patient will end up paying their entire deductible. Sanborn’s bill, LD 1783, would prevent double billing, which would protect Mainers from financial hardship and ruin when they need expensive prescription drugs.

    My colleagues and I are working in other ways to ensure patients can access their prescription medications. Roeder’s bill, LD 1776, would allow pharmacists to dispense emergency supplies of medication to a patient when a prescription authorization is not available. As long as the pharmacist has a record of a previous prescription, he can dispense medication to the patient.

    The bill would require insurance companies to cover emergency drug supplies. The bill would also give patients with chronic conditions, such as asthma, diabetes or heart disease, the peace of mind of being able to access their medications in an emergency.

    On these issues, and more, my colleagues and I remain committed to helping Mainers live happy, healthy, and full lives. I know there is still a lot of work to be done to make health care affordable for everyone, but I also know that these two bills will ease the financial strain caused by high health care costs and uncertain access to medicines. on prescription.

    If you have questions about healthcare and medications, please contact Consumers for Affordable Healthcare. Its consumer help line is 1-800-965-7476. If you ever need further assistance or would like to share your comments and thoughts with me, please contact me.

    Anne Carney represents Senate District 29: Cape Elizabeth, South Portland and part of Scarborough. She can be reached at [email protected] or 207-287-1515.

    ” Previous

    read more
    Prescription drugs

    Hundreds of prescription drug pills, including pregabalin, seized by police

    A huge amount of prescription drugs have been removed from the streets of Manchester.

    Hundreds of tablets were found by police on Harris Street in the downtown Strangeways area.

    The seizure off Bury New Road in Cheetham Hill included boxes marked with pregabalin – a prescription drug used to treat nerve pain and anxiety.

    It has been linked to a growing number of deaths in England and Wales – and the Manchester Evening News previously reported that tablets were widely sold on city streets, with the area around Bury New Road and Strangeways on the outskirts of Manchester city center being a hotspot.

    There are concerns that pregabalin is increasingly being used among the homeless and drug addicts in the inner city.

    Police said the seizure was part of a dedicated operation – codenamed ‘Cranium’ – to tackle the street sale of prescription drugs only in north Manchester.

    Greater Manchester Police shared an image which they said showed only part of the drugs found.

    Boxes labeled flucloxacillin, an antibiotic, and zopiclone, a type of sleeping pill, were also revealed, along with blister packs of nitrazepam.



    The seizure took place in Bury New Road

    No arrests were referenced by force.

    In a Facebook post, GMP Manchester North said: “While proactively patrolling this weekend a large amount of controlled drugs were found on Harris Street in the Strangeways area of ​​Manchester.

    “Officers from the local Neighborhood Team carry out regular patrols as part of Operation Cranium – a dedicated investigation into the illicit supply of prescription drugs only in areas of North Manchester.

    “The photo is just a few of these found tablets.

    “If you are the owner of these, please contact us, we could have a chat.”

    Last year pregabalin was linked to 344 deaths in England and Wales – 60 in the North West alone.

    No other details were revealed.

    Sign up for MEN’s email newsletters to get the latest on sports, news, current affairs and more by following this link

    read more
    Prescription drugs

    Prescription Animal Drugs Market Size and Forecast by 2029 – Sox Sphere

    New Jersey, United States,-The latest report published by Market Research Intellect presents an in-depth analysis of the global animal prescription drug market. This research report assesses ever-changing market dynamics that are expected to affect the trajectory of the overall market. Analysts have studied historical market performance and compared it to current market trends, charting the trajectory. For a detailed discussion of the global animal prescription drugs market, analysts have segmented the market on the basis of applications, products, and end users. The research reports have been collated using primary as well as secondary research methodologies to provide readers with a precise understanding of the ongoing development of the Animal Prescription Drugs market.

    Analysts used Porter’s Five Forces Analysis, Study Worm Analysis, and Pestle Analysis to determine the path major vendors should follow in the coming years. The research report also includes the assessment of these vendors’ financial prospects, Pet Prescription Drugs market growth strategy and expansion plan during the forecast period. All information presented in the Global Animal Prescription Drugs Market research report has been certified by market experts.

    Get | Download Sample Copy with TOC, Charts and List of Figures @ https://www.marketresearchintellect.com/download-sample/?rid=228630

    The report includes a detailed segmentation study of the global Animal Prescription Drugs market, in which all the segments are analyzed in terms of market growth, share, growth rate and other important factors. It also provides the attractiveness index of the segment, allowing players to inform about the profitable revenue pockets of the global Animal Prescription Drugs Market. A broad assessment of the segments provided in the report enables investments, strategy, and teams to focus on the right areas of the global Animal Prescription Drugs Market.

    Major Players Covered in Animal Prescription Drugs Market:

    • Elanco Animal Health
    • Ceva Animal Health
    • MSD Animal Health
    • Zoetis
    • Virbac
    • Dechra
    • Vetoquinol
    • animal group
    • Ourofino Sauce Animal
    • Boehringer Ingelheim

    Animal Prescription Drugs Market Split By Type:

    • oral-type
    • Smear type
    • Type of injection
    • Type of spray

    Animal Prescription Drugs Market Split By Application:

    • Pet
    • Livestock

    The Animal Prescription Drugs Market report has been segregated into distinct categories such as product type, application, end-user, and region. Each segment is valued based on CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is expected to generate opportunities in the Global Animal Prescription Drugs Market in the coming years. This segmental analysis will surely prove to be a helpful tool for readers, stakeholders, and market players to get a complete picture of the global Animal Prescription Drugs market and its growth potential in the coming years. .

    Get | Discount on the purchase of this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=228630

    Scope of the Animal Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Base year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in USD Million and CAGR from 2021 to 2027
    Segments Covered Types, applications, end users, and more.
    Report cover Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free report customization (equivalent to up to 8 analyst business days) with purchase. Added or changed country, region and segment scope.
    Pricing and purchase options Take advantage of personalized purchasing options to meet your exact research needs. Explore purchase options

    Regional Analysis of the Animal Prescription Drugs Market can be represented as follows:

    Each regional Veterinary Drugs industry is carefully researched to understand its current and future growth scenarios. This helps players strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

    Based on geography, the global animal prescription drug market has been segmented as follows:

      • North America includes the United States, Canada and Mexico
      • Europe includes Germany, France, UK, Italy, Spain
      • South America includes Colombia, Argentina, Nigeria and Chile
      • Asia Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

    For more information or query or customization before buying, visit @ https://www.marketresearchintellect.com/product/global-animal-prescription-drugs-market-size-and-forecast/

    About Us: Market Research Intellect

    Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations, in addition to the goal of providing customized and in-depth research studies. range of industries including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. etc Our research studies help our clients to make decisions based on higher data, to admit deep forecasts, to grossly capitalize with opportunities and to optimize efficiency by activating as their belt in crime to adopt a mention precise and essential without compromise. customers, we have provided expert behavior assertion research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    USA: +1 (650)-781-4080
    UK: +44 (753)-715-0008
    APAC: +61 (488)-85-9400
    US toll free: +1 (800)-782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Teenagers target prescription drugs and cash in armed robbery at Sycamore Walgreens: Police – Shaw Local

    read more
    Prescription drugs

    Biden aims to revive efforts to fight expensive prescription drugs

    President Joe Biden will address the high cost of prescription drugs at an event on Thursday, an issue for which there is some bipartisan support and which could help the White House make progress on its stalled national agenda.

    AP: Biden stresses drug prices as he tries to revive agenda

    President Joe Biden is trying to revive progress on his stalled national agenda by refocusing attention on one of his most popular proposals, limiting the cost of prescription drugs. Biden is traveling to Culpeper, Va., on Thursday, where White House press secretary Jen Psaki said the president would draw attention to the “unacceptable” cost of the drugs. (Megerian, 2/10)

    Fox Business: Biden Trip to Emphasize Lower Drug Prices as He Tries to Revive Agenda

    President Biden will travel to Culpeper, Va., on Thursday and is expected to draw attention to the “unacceptable” cost of drugs in the United States as part of his effort to realize one of his key program proposals: limiting the cost of prescription drugs. The trip is seen as a chance to get his stalled national agenda back on track. Biden’s trip will also be an opportunity for him to begin promoting his party’s candidates in the November midterm elections. He is expected to appear alongside Rep. Abigail Spanberger, D-Va., who faces losing her seat representing a central Virginia district. Prescription drugs will be the focus of Biden’s visit. (Martin, 2/10)

    And the White House pushes back on crack pipe ‘misinformation’ –

    The Hill: White House challenges reports on federal funds for crack pipes

    The Biden administration on Wednesday pushed back against what it called “misinformation,” saying a federal grant program intended to reduce harm to drug users does not include taxpayer funding for pipes that can be used. to smoke crack or methamphetamine. The Department of Health and Human Services (HHS) released a statement clarifying “no federal funding will be used directly or through subsequent reimbursement to recipients to put pipes into safe smoking kits.” (Samuel, 2/9)

    AP: No money for drug pipes: Feds quell social media storm

    Putting out a firestorm on social media, the Biden administration said Wednesday that a grant program to combat the harms of illicit drugs would not pay for safer pipes for smoking crack or meth. The White House has been put on the defensive as outrage from the political right, some of it racially charged, mounts online. “No federal funding will be used directly or through subsequent reimbursement to recipients to put pipes into safe smoking kits,” said Health and Human Services Secretary Xavier Becerra and drug policy adviser of White House Rahul Gupta in a joint statement. (Alonso-Zaldivar and Dupuy, 2/9)

    More details emerge after Biden science adviser resigns –

    Politico: Lander held on to vaccine maker’s stock for months

    As Biden’s top science adviser, Eric Lander, the head of the Office of Science and Technology Policy, publicly promoted Covid-19 vaccination efforts while having a significant financial investment in one of the vaccine makers, according to financial disclosures. Under the White House ethics accord Lander signed, he had 90 days to dispose of his shares after being confirmed by the Senate on May 28. While Lander lost most of those shares in June — including shares of BioNTech SE, the German biotech company and Pfizer’s Covid-19 vaccine partner — he waited until August 5 to sell the $500,000 to $1 million of remaining stock he held in that company. When Lander finally sold the stock 69 days after it was confirmed, it was the company’s second-highest price ever at $404.92 per share, after climbing more than $50 per share two days earlier. . (Thompson, 2/9)

    Stat: The fall of Eric Lander and the end of science’s ‘big ego’ era

    Eric Lander’s resignation as President Biden’s chief science adviser is not just a blow to a president’s plans to advance research, but a sign on the death march in a way to do science. It’s not quite “big science”, which leads nowhere. Call it “big ego”. In science, the “big ego” is not exactly a new phenomenon. But in recent decades it has grown with the emergence of researchers who can both handle the kind of gloveless debate that can mark academic discourse and mobilize vast resources to make certain kinds of scientific discoveries, like mapping genomes or understanding molecular changes in a cell. lead to cancer. (Herper, 2/9)

    This is part of the KHN Morning Briefing, a summary of health policy coverage by major news outlets. Sign up for an email subscription.

    read more
    Generic drugs

    U.S. Generic Drugs Market Report 2021: Small

    Dublin, 07 Feb. 2022 (GLOBE NEWSWIRE) — The “Generic Drug Market in the United States, by Type (Generic to Small Molecule vs. Biosimilars), by Application, by Mode of Drug Delivery, by Form, by Source, by Distribution The Report Channel, by Region, Competition, Forecast and Opportunities, 2026” has been added to from ResearchAndMarkets.com offer.

    The U.S. Generic Drugs Market was valued at USD 70.78 Billion in 2020 and is expected to grow at a CAGR of 9.43% during the forecast period and may reach the market value of USD 126.74 Billion by 2026 .

    Factors such as the cost-effective nature of generic drugs and growing demand from developing economies are majorly responsible for this futuristic growth estimate of the generic drugs market in the United States over the next five years. Generic drugs do not require extensive research and development as in the case of prescription drugs and patent drugs.

    Market players and research institutes are investing heavily in patented pharmaceuticals. Moreover, FDA approvals for generic drugs are not required as generic drugs contain the same composition as that of the previously patented drug and thus support the growth of the generic drug market in the United States over the next five years . The healthcare industry in the United States, in terms of generic drugs, has gone from an 80% growth in 2020 to a previous growth of 20% in 2015.

    The increase in generic drug exports to developing economies like Kenya, India, etc. also justifies the growth of the US generic drug market over the next five years.

    The US generic drugs market is segmented on the basis of type, drug delivery route, form, manufacturing source, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars. Small molecule generics are expected to register the largest market revenue shares and dominate the market segment over the next five years owing to their simpler and easier manufacturing processes.

    When producing small molecule generics, generic drug manufacturers are required to prove that the final product contains the same chemical compounds as the patented drug. With similar functions and pharmacokinetic properties, the generic small molecule is accepted. Additionally, the demand for cost-effective generic drugs is expected to further support the growth of the generic drug market in the United States over the next five years.

    Based on applications, the market can be fragmented into cardiovascular diseases, diabetes, neurology, oncology, infectious diseases, and others. Cardiovascular diseases are expected to dominate the market segment while recording the highest market revenue shares over the next five years owing to the increasing cases of cardiovascular diseases in the United States.

    Additionally, increased demand for treatment and extended medication protocols is driving the growth of cardiovascular disease sub-segment while sustaining the growth of the generic drug market in the United States over the next five years.

    The increase in pharmaceutical research and development for the oncology disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.

    Major market players in the United States leading the growth of the generic drugs market include:

    • Teva Pharmaceuticals USA, Inc.
    • Pfizer Inc.
    • Sandoz US
    • Endo Pharmaceuticals Inc.
    • Aurobindo Pharma USA, Inc.
    • Abbott Laboratories Inc.
    • Eli Lilly and company
    • Sun Pharma Inc.
    • Lupine Pharmaceuticals, Inc.
    • Zydus Pharmaceuticals USA Inc.

    Report Scope:

    Years considered for this report:

    • Historical years: 2016-2019
    • Reference year: 2020
    • Estimated year: 2021
    • Forecast period: 2022-2026

    Generic Drugs Market in the United States, by Type:

    • Generic Small Molecule
    • Biosimilars

    Generic Drugs Market in the United States, by Application:

    • Cardiovascular illnesses
    • Diabetes
    • Neurology
    • Oncology
    • Infectious diseases
    • Others

    Generic Drugs Market in the United States, by Mode of Drug Delivery:

    • Oral
    • Parenteral
    • Topical
    • Others

    Generic Drugs Market in the United States, by Form:

    • Tablet
    • Capsule
    • Injection
    • Others

    Generic drugs in the United States, by source:

    • In-house manufacturing
    • Contract manufacturing organizations

    Generic Drugs Market in the United States, by Distribution Channels:

    • Retail pharmacies
    • Online pharmacies
    • Hospital pharmacies
    • Others

    For more information on this report visit https://www.researchandmarkets.com/r/3b41r9

    • Generic drugs market in the United States

    
            
    read more
    Prescription drugs

    A man has been investigated for supplying counterfeit prescription drugs after a raid on Jarrow’s property

    Video released by Northumbria Police showed officers breaking down the front door to enter the property where they found a supply of painkillers including pregablin, temazepam and oxycodone, all of which failed been prescribed to the occupier.

    Read more

    Read more

    Homeless man racks up £11,000 legal debt after damaging police stations for…

    While searching the rooms, officers also found a quantity of cannabis which was also seized.

    Register to our daily newsletter

    The newsletter mute the noise

    Officers carried out the search after a warrant was issued following concerns raised by the local community.

    The warrant was executed at the property on Wednesday morning (February 2) after police learned that suspected illicit substances were being supplied from the property.

    A man in his 40s has since been questioned on bail in connection with the findings.

    Chief Inspector Neil Hall, of Northumbria Police, praised the public who provided information about the alleged drug supply linked to the address.

    Some of the counterfeit prescription drugs seized following a raid on a house in Jarrow.

    He said: ‘These illicit prescription drugs could have caused serious harm if they got into the hands of someone for whom they were not prescribed.

    “We are therefore delighted to have been able to seize various medicines from this address – and this was only possible thanks to the public coming forward and raising their concerns.

    “Their information, along with our own intelligence on the drug supply in the area, enabled us to deploy officers and execute a morning warrant – with excellent results.

    Officers raided a property in Jarrow over concerns that illicit substances were being supplied from the property.

    “I hope this warrant shows the merits of the public who come forward and speak to us. Your information can help us to take action and get a clearer picture of the identity of potential perpetrators – and to ensure that we protect some of the most vulnerable in our communities.

    The man, who voluntarily surrendered to the police station for questioning, is still under investigation.

    Anyone with information about crime in their area is asked to report it via the ‘Tell us something’ page on the Northumbria Police website or by calling 101.

    People can also submit information anonymously via Crimestoppers, an independent charity, by calling 0800 555 111.

    A message from the editor:

    Support your Gazette and subscribe today.

    Enjoy unlimited access to all our news and sports, see fewer ads, enjoy faster loading times, test your brain with daily puzzles and access to exclusive newsletters.

    Your support for our journalism means we can continue to tell the stories of South Tyneside for generations to come. Click here to subscribe – and click here to get the latest Gazette news and sport delivered to your inbox via our email newsletters.

    read more
    Generic drugs

    Generic Drug Markets Over $125 Billion in the United States, Competition, Forecast and Opportunities, 2026

    DUBLIN, February 2, 2022 /PRNewswire/ — The “Generic Drugs Market in the United States, by Type (Small Molecule Generics vs. Biosimilars), by Application, by Mode of Drug Delivery, by Form, by Source, by Distribution Channel, by Region, Competition, Forecast and Opportunity, 2026” report has been added to from ResearchAndMarkets.com offer.

    Research and Markets Logo

    The generic drug market in the United States has been assessed $70.78 billion in 2020 and is expected to grow at a CAGR of 9.43% over the forecast period and could reach the market value of $126.74 billion by 2026.

    Factors such as the cost-effective nature of generic drugs and growing demand from developing economies are majorly responsible for this futuristic growth estimate of the generic drugs market in the United States over the next five years. Generic drugs do not require extensive research and development as in the case of prescription drugs and patent drugs.

    Market players and research institutes are investing heavily in patented pharmaceuticals. Moreover, FDA approvals for generic drugs are not required as generic drugs contain the same composition as that of the previously patented drug and thus support the growth of the generic drug market in the United States over the next five years . United States The healthcare industry, in terms of generic drugs, has gone from 80% growth in 2020 to a previous growth of 20% in 2015.

    Increased generic drug exports to developing economies such as Kenya, Indiaetc also justifies the growth of the generic drugs market in the United States over the next five years.

    The US generic drugs market is segmented on the basis of type, drug delivery route, form, manufacturing source, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars. Small molecule generics are expected to register the largest market revenue shares and dominate the market segment over the next five years owing to their simpler and easier manufacturing processes.

    When producing small molecule generics, generic drug manufacturers are required to prove that the final product contains the same chemical compounds as the patented drug. With similar functions and pharmacokinetic properties, the generic small molecule is accepted. Additionally, the demand for cost-effective generic drugs is expected to further support the growth of the generic drug market in the United States over the next five years.

    Based on applications, the market can be fragmented into cardiovascular diseases, diabetes, neurology, oncology, infectious diseases, and others. Cardiovascular diseases are expected to dominate the market segment while recording the highest market revenue shares over the next five years owing to the increase in the cases of cardiovascular diseases in United States.

    Additionally, increased demand for treatment and extended medication protocols is driving the growth of cardiovascular disease sub-segment while sustaining the growth of the generic drug market in the United States over the next five years.

    The increase in pharmaceutical research and development for the oncology disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.

    The main market players in United States that are driving the growth of the generic drugs market include:

    • Teva Pharmaceuticals United StatesInc.

    • Pfizer Inc.

    • Sandoz US

    • Endo Pharmaceuticals Inc.

    • Aurobindo Pharmacy United StatesInc.

    • Abbott Laboratories Inc.

    • Eli Lilly and company

    • Sun Pharma Inc.

    • Lupine Pharmaceuticals, Inc.

    • Zydus Pharmaceuticals United States Inc.

    Report Scope:

    Years considered for this report:

    Generic Drugs Market in the United States, by Type:

    • Generic Small Molecule

    • Biosimilars

    Generic Drugs Market in the United States, by Application:

    • Cardiovascular illnesses

    • Diabetes

    • Neurology

    • Oncology

    • Infectious diseases

    • Others

    Generic Drugs Market in the United States, by Mode of Drug Delivery:

    • Oral

    • Parenteral

    • Topical

    • Others

    Generic Drugs Market in the United States, by Form:

    • Tablet

    • Capsule

    • Injection

    • Others

    Generic drugs in the United States, by source:

    Generic Drugs Market in the United States, by Distribution Channels:

    • Retail pharmacies

    • Online pharmacies

    • Hospital pharmacies

    • Others

    For more information about this report visit https://www.researchandmarkets.com/r/k9pvax

    Media Contact:

    Research and Markets
    Laura Woodsenior
    [email protected]

    For EST office hours, call +1-917-300-0470
    For USA/CAN call toll free +1-800-526-8630
    For GMT office hours call +353-1-416-8900

    US Fax: 646-607-1904
    Fax (outside the US): +353-1-481-1716

    Quote

    Quote

    View original content: https://www.prnewswire.com/news-releases/united-states-125-billion-generic-drugs-markets-competition-forecasts-and-opportunities-2026-301473690.html

    SOURCE Research and Markets

    read more
    Prescription drugs

    In-depth research on emerging growth trends, regional status of major key players, driving factors, business strategies and industry size forecast to 2026 – Bristol City Supporters Trust

    The Non-prescription Drugs market report covers the whole scenario of the global market including key players, their future promotions, preferred vendors, market shares along with historical data and price analysis. It continues to offer key details on changing dynamics to generate market improving factors. It aims to rationalize the expenses of the company. You can also find the current revenue generation rate and spend score here. The best thing about the Non-Prescription Drugs market report is the provision of guidelines and strategies followed by leading market players. The investment opportunities in the market highlighted here will be of great help in moving the business forward. Knowing the current market status is the most important thing covered here to help big players survive in the compatiator analysis market.

    This Non-Prescription Drugs Market study depicts the economic catastrophe induced by the COVID-19 outbreak, which has affected all sectors of the business. A major global economic loss has occurred due to several industrial closures and loss of income. Here, a high degree of information is offered to assess the market situation.

    Get Full Sample PDF Copy of Report: https://www.worldwidemarketreports.com/sample/720473

    The report helps to identify the major players in the non-prescription drugs market. It helps to analyze the competitive environment of the Non-Prescription Drugs market, including company overview, company total revenue, market opportunities, value, production sites and facilities , SWOT analysis, product details. The study also reveals the sales, revenue and market share of each market player included in this report for the period 2022-2026. It also helps to determine growth drivers and future prospects for the forecast schedule.

    The main key vendors in this market are: Pfizer, Roche, Sanofi, Johnson & Johnson, Merck & Co. (MSD), Novartis, AbbVie, Gilead Sciences, GlaxoSmithKline (GSK), Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly , Teva, Bayer

    To understand how the impact of covid-19 is covered in these reports: https://www.worldwidemarketreports.com/covidimpact/720473

    By Product Type, the market is primarily split into: Branded Drugs, Generic Drugs

    By application, this report covers the following segments: Hospital, Clinic

    Regions Covered in the Non-prescription Drugs Market Report 2022:

    ✤ The Middle East and Africa (GCC countries and Egypt)
    ✤ North America (United States, Mexico and Canada)
    ✤ South America (Brazil etc.)
    ✤ Europe (Turkey, Germany, Russia UK, Italy, France etc.)
    ✤ Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

    Additionally, the report provides an overview of key market drivers, challenges, opportunities, and risks and vendor strategies. Key players are also profiled with their market shares in the discussed Global Non-prescription Drugs Market. Overall, this report covers the historical status, current status and future prospects of the global Non-prescription Drugs Market for 2016-2026.

    This Non-Prescription Drugs report provides a superior market perspective in terms of product trends, marketing strategy, future products, new geographic markets, future events, sales strategies, or actions or behaviors of clients. This market research presents actionable market insights with which sustainable and profitable business strategies can be created.

    For more information or query or customization before buying: https://www.worldwidemarketreports.com/quiry/720473

    Important report features:

    ✤ Detailed analysis of the Non-Prescription Drugs market
    ✤ Fluctuating industry market dynamics
    ✤ Detailed market segmentation
    ✤ Historical, current and projected market size in terms of volume and value
    ✤ Recent industry trends and developments
    ✤ Competitive Landscape of Non-prescription Drugs Market
    ✤ Strategies of key players and product offerings
    ✤ Potential and niche segments/regions showing promising growth
    ✤ A neutral perspective on the performance of the non-prescription drug market.

    Report on reasons to buy:

    ✤ The report analyzes the future growth of the non-prescription drugs market.
    ✤ To analyze various perspectives of the Non-prescription Drugs market using Porter’s Five Forces Analysis.
    ✤ Study on which product type is expected to dominate the market and which regions are expected to grow fastest during the forecast period.
    ✤ To recognize the new developments, Non-Prescription Drugs Market shares, and policies employed by key market players.
    ✤ Competitive landscape, including Non-Prescription Drugs market share of major players along with key policies accepted for development over the past five years.
    ✤ Comprehensive company profiles covering product offerings, key financial information, recent developments, SWOT analysis and strategies employed by the leading player in the non-prescription drugs market.

    Click here for full report: https://www.worldwidemarketreports.com/buy/720473

    Report customization : In any case, please contact our sales team, who will ensure that your requirements are met.

    Contact us:

    Global Market Reports,

    Tel: USA +1-415-871-0703

    UK +44-203-289-4040

    Japan +81-50-5539-1737

    E-mail: [email protected]

    Website: https://www.worldwidemarketreports.com/

    read more
    Prescription drugs

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, – Oxford Spokesperson

    Backed by comprehensive primary and secondary research, the Global report Medicines without a prescription Industry 2021 presents profitable market prospects. This market research report has deployed suggestions from numerous industry experts and also presents valuable recommendations from expert and experienced market analysts. Top decision makers in this industry have added their own thoughts from around the world.

    Some Major actors are listed in the report and we will add more as needed. (This report is customizable).

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, AbbVie, Sanofi, Amgen, Novartis, Merck & Co. (MSD), GlaxoSmithKline (GSK), Bayer, Takeda, AstraZeneca, Takeda, Novo Nordisk, Teva, Bristol-Myers Squibb, Boehringer Ingelheim, Allergan, Eli Lilly

    We have recent OTC Drug Market Updates in sample copy @ https://www.maccuracyreports.com/report-sample/91240

    Non-prescription drugs market

    Hospital, Clinic, Other.

    Application as below

    Brand name drugs, generic drug

    MRA Reports uncovered the report which incorporates restraints, market drivers, opportunities, challenges, investment potential, future roadmap, new innovations, vendor profiles, market trends and strategies . The report also details market size forecast for the global non-prescription drugs market. Additionally, further forecasts have been presented regarding the dominating segments of the Non-prescription Drugs market. The report is deployed with numerous charts, tables, and graphs for a better and vivid understanding of the market data.

    Browse Full Report with Facts and Figures of Non-Prescription Drugs Market Report at @ https://www.maccuracyreports.com/reportdetails/reportview/91240

    To add answers to some key questions to the report, which are:

    What are the drivers impacting the market growth of the Non-prescription Drugs Market?

    What will be the estimated Non-Prescription Drugs market size, and the CAGR at which the market will expand, by the end of the forecast horizon?

    Which geographic segments (regions) as well as sub-areas will grow at the fastest rate over the forecast horizon?

    What are the key strategies adopted by emerging organizations in the Non-prescription Drugs Market?

    How will the market dynamics be shaped by the end of the forecast horizon?

    A detailed assessment of major vendors in the Non-Prescription Drugs market is provided and a description of how these major companies focus in emerging markets around the globe is presented in this report. In addition to this, the recent strategic mergers, partnerships, collaborations, and acquisitions taking place in the global Non-prescription Drugs market have been incorporated into this report.

    Make a request before purchase @ https://www.maccuracyreports.com/checkout/91240

    A section demonstrating the main recommendations for established players and new entrants is also presented in this study. Strategic recommendations from senior analysts provide a clear perspective regarding the key strategies to adopt to make the most of entering the non-prescription drug market. MR Accuracy Reports focused on customer requirements. There was a huge demand to add some chapters, so the experts successfully added.

    read more
    Prescription drugs

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, AbbV – The Oxford Spokesperson

    The Global Prescription drugs The industry report gives a comprehensive report on the global prescription drugs market. Details such as market size, key players, segmentation, SWOT analysis, pestle, carrier 5, most influential trends and business environment are mentioned in this report. Additionally, this report contains tables and figures that give a clear outlook of the prescription drugs market. With the help of this report, an organization can achieve its goals and build its unique strategy. A sample report is available in 20 different formats, so let us know your exact requirements so we can focus on your area.

    These are the few market players in this industry-

    Pfizer, Gilead Sciences, Johnson & Johnson, Roche, AbbVie, Sanofi, Amgen, Novartis, Merck & Co. (MSD), GlaxoSmithKline (GSK), Bayer, Takeda, AstraZeneca, Takeda, Novo Nordisk, Teva, Bristol-Myers Squibb, Boehringer Ingelheim, Allergan, Eli Lilly

    We have recent updates from the Prescription Drugs Market in sample copy @ https://www.maccuracyreports.com/report-sample/91238

    prescription drug market

    Hospital, Clinic, Other.

    Application as below

    Brand drugs, generic drugs.

    Fundamental is well established in the important study. The report features up-to-date data on product details, roadmap, investment strategy, revenue figures and sales of major companies. In addition, the details also give the global prescription drugs market revenue and its forecast. Business model strategies of key companies in the Prescription Drugs market are also included. The key strengths, weaknesses and threats shaping the major market players have also been included in this research report. You can make a plan just by looking at this market research.

    Browse Full Report with Facts and Figures of Prescription Drugs Market Report at @ https://www.maccuracyreports.com/reportdetails/reportview/91238

    MR Accuracy Reports has published the report which gives a detailed overview of the key segments of the market. Both fastest and slowest growing market segments are covered in this report. Key emerging opportunities of the fastest growing global prescription drug market segments are also discussed in this report. The market size, share and forecast of each segment and sub-segment are available in this report. Additionally, the region segmentation and trends driving the major geographic region and emerging region have been presented in this report.

    Regional assessment and diversification of segments.

    North America (United States, Canada, Mexico)
    Europe (UK, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
    Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
    Latin America (Brazil, Rest of LA)
    Middle East and Africa (Turkey, GCC, Rest of Middle East)

    Make a request before purchase @ https://www.maccuracyreports.com/checkout/91238

    The research team has gathered the study on the Global Prescription Drugs Market and also presents a history of the tactical activities of mergers, acquisitions, collaborations and partnerships in the market. Senior analysts’ valuable recommendations on strategic investment in research and development can help new entrants or established players to penetrate emerging sectors of the Prescription Drugs Market. Investors will get a clear insight into the dominating players in this industry and their future predictions. Additionally, readers will get a clear perspective on the high demand and unmet consumer needs that will drive the growth of this market. This material has been very useful for all TOP players.

    read more
    Prescription drugs

    F Hoffmann La Roche Ltd, Alizyme, Arena Pharmaceuticals, Orex – The Oxford Spokesperson

    MRI Accuracy Reports published a new report on Global Anti-obesity prescription drugs Industry. This report is in high demand as TOP as well as emerging players leverage this report. This is the most accurate and qualitative research study collected by a team carrying out primary and secondary research. This report is based on briefings and interviews conducted with product manufacturers and their consumers, along with demand research. The mixture of checks and balances combined with the involvement of industry players provides a clear and accurate picture of the entire global prescription anti-obesity drugs market.

    Some players mentioned below for your reference-

    F Hoffmann La Roche Ltd, Alizyme, Arena Pharmaceuticals, Ordemanden Therapeutics, Boehringer Ingelheim, Novo Nordisk A/s, Vivus, Glaxosmithkline

    We Have Recent Anti-Obesity Prescription Drugs Market Updates In Sample Copy @ https://www.maccuracyreports.com/report-sample/92092

    Prescription Anti-Obesity Drugs Market

    Pediatric, Adult.

    Application as below

    Orlistat, Phentermine and Topiramate, Bupropion and Naltrexone, Lorcaserin, Liraglutide.

    Furthermore, the research data contained in the report after working closely with investment bankers and financial analyst presents a clear idea about the investment scenario in the global Prescription Anti-Obesity Drugs market. The report assesses market prospects for public companies, assesses business cases of several private companies, and discusses investment trends in the global anti-obesity prescription drugs market. The analyst suggested that there would be a turning point in this market, so it needs to draw attention away in order to sustain in the market.

    The global Prescription Anti-Obesity Drugs market report covers current and future trends in consumer preferences that will shape the industry. The report assesses the buying trends along with the buying process, technology preference, expenditure, and end-user manufacturer and service provider preferences in the global Prescription Anti-Obesity Drugs Market.

    Browse Full Report with Facts and Figures of Prescription Anti-Obesity Drugs Market Report at @ https://www.maccuracyreports.com/reportdetails/reportview/92092

    The report digs deeper by providing consumer preferences by region and their impact on market revenue and growth. The report also presents the current regulatory scenario of individual regional sectors in the global Prescription Anti-obesity Drugs market. Furthermore, the current regulatory scenario as well as the upcoming regulations that will come into force in the coming years have also been mentioned in this report.

    Regional assessment and diversification of segments.

    North America (United States, Canada, Mexico)
    Europe (UK, France, Germany, Spain, Italy, Central and Eastern Europe, CIS)
    Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
    Latin America (Brazil, Rest of LA)
    Middle East and Africa (Turkey, GCC, Rest of Middle East)

    Several key players operating in the global Prescription Anti-obesity Drugs market have been profiled in this report. The business overview of key players, product offering, revenue share, business strategies and latest innovations have been included in this report. The in-depth competitive framework of the Global Prescription Anti-Obesity Drugs Market will help clients to formulate the best strategies for a desired business outcome. Therefore, contact us to get the sample basic report.

    Please click here today to purchase the full report @ https://www.maccuracyreports.com/checkout/92092

    We have published over 2 million reports and are recognized as the best market research reporting company in the world. As EDITOR, we are always focused on your needs, advice and growth.

    read more
    Prescription drugs

    Overview, Opportunities, Key Companies and Forecasts to 2028 – Pfizer, Merck, Isis Pharmaceuticals, Immuron Limited, GlaxoSmithKline Pharmaceuticals, Formac Pharmaceuticals, Esperion Therapeutics, Eli Lilly, and more. – Oxford Spokesperson

    The research report, titled “Global Prescription Drugs for Hyperlipidemia Market 2022, presents crucial insights and statistical data on the Prescription Hyperlipidemia Drugs Market with respect to the world. The Market Report provides an all-inclusive analytical study of the Prescription Drugs for Hyperlipidemia Market, considering the growth drivers, restraints, and future prospects. The prevailing trends and opportunities are also discussed in this study.

    The report analyzes the global Prescription Drugs for Hyperlipidemia market on the basis of various key segments on the basis of product types, applications and end users. The regional Prescription Hyperlipidemia Drugs market is also considered for the analysis, the results of which are used to predict the performance of the Prescription Hyperlipidemia Drugs market globally over the period of 2022 to 2028.

    Each of the market verticals of the Prescription Drugs for Hyperlipidemia Market is qualitatively and quantitatively analyzed to present a comparative assessment of the market. Basic information such as definition, industry chain powering the market, and policies are also covered in the report.

    Request a sample copy of Prescription Drugs for Hyperlipidemia Market Report (Use company email id for higher priority) @ https://www.maccuracyreports.com/report-sample/519367

    Summary

    According to GRD survey data, the global Hyperlipidemia Drugs market is estimated to be worth million US$ in 2021 and is expected to reach million US$ by the end of 2028, growing at a CAGR % during the forecast period between 2022 and 2028.

    This report studies the Prescription Drugs for Hyperlipidemia market dynamics from angles such as new entries, mergers and acquisitions, financings, exits, and major technological advancements. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competitive landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Five Forces Analysis. Carry.

    Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth rate of Hyperlipidemia Drugs in these regions, from 2016 to 2027, covering

    North America (United States, Canada and Mexico)

    Europe (Germany, France, UK, Italy, Spain and Russia, etc.)

    Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)

    South America (Brazil, Argentina, Colombia, etc.)

    Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

    Market Overview, By Product Type

    HMG COA reductase inhibitors

    Fibric acid derivatives

    nicotinic acid

    Bile acid sequestering agents

    Cholesterol absorption inhibitors

    Combination drug therapy

    Market Overview, By Application

    Hospital

    Clinical

    Key Market Players Analyzed In This Report Including:

    Pfizer

    Merck

    Isis Pharmaceuticals

    Immuron Limited

    GlaxoSmithKline Pharmaceuticals

    Formac Pharmaceuticals

    Therapeutic Hope

    Eli Lily

    Dr. Reddy’s Laboratories

    Amgen

    The research objectives of this report are:

    To study and analyze the global Prescription Drugs for Hyperlipidemia market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.

    To understand the structure of the Prescription Drugs for Hyperlipidemia market industry by identifying its various subsegments.

    Share detailed information on key factors influencing market growth (growth potential, opportunities, drivers, industry-specific challenges and risks).

    To identify the major global Hyperlipidemia Drugs manufacturers and typical regional players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans over the next few years.

    To analyze the Prescription Drugs for Hyperlipidemia market with respect to individual growth trends, future prospects, and their contribution to the total market.

    To project the value and volume of Hyperlipidemia Drugs submarkets, with respect to key regions (along with their respective key countries).

    Analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.

    Establish a strategic profile of key players and analyze in depth their growth strategies.

    In this study, the years considered to estimate the market size of Hyperlipidemia Prescription Drugs are as follows:

    Historical year: 2016-2020

    Reference year: 2020

    Estimated year: 2021

    Forecast year 2021 to 2027

    This report includes the estimation of market size in terms of value (USD Million) and volume from top-down approach by analyzing major sub-markets and their key driving factors, and verified from bottom-up approaches . Major market players have been identified through secondary research and their market shares have been determined through primary and secondary research. All shares, breakdowns and percentage breakdowns have been determined using secondary sources and verified from primary sources.

    For data information by region, company, type and application, 2020 is taken as the base year. Whenever data information was not available for the reference year, the previous year was taken into account.

    Main stakeholders taken into account in the study:

    commodity sellers

    Distributors/Traders/Wholesalers/Suppliers

    Regulatory authorities, including government agencies and NGOs

    Commercial research and development (R&D) institutions

    Importers and exporters

    Government organizations, research organizations and consulting firms

    Trade/industry associations

    End-use industries

    Get up to 30% off the first purchase of Hyperlipidemia Prescription Drugs Market Rreport @: https://www.maccuracyreports.com/check-discount/519367

    The products available in the market are studied on the basis of their manufacturing chain, the price of the products and the profit they generate. An in-depth analysis is then carried out on the various regional Prescription Hyperlipidemia Drugs markets, examining the production volume and efficiency of the Prescription Hyperlipidemia Drugs market globally. The demand and supply statistics for the Prescription Hyperlipidemia Drugs market along with the growth figures recorded by the Prescription Hyperlipidemia Drugs market are also presented for each regional market in this report.

    Various analytical tools are applied in the analysis of the Prescription Drugs for Hyperlipidemia Market to reach a precise understanding of the market players in the potential development of this market. These tools include feasibility analysis, ROI analyses, as well as SWOT analysis of key market players.

    Key questions answered in the Prescription Hyperlipidemia Drugs market report include:
    • What will be the market size and growth rate by the end of the forecast period?
    • What are the key trends in the Global Prescription Hyperlipidemia Drugs Market impacting the growth of the market?
    • What are the potential growth opportunities and threats faced by the major market competitors?
    • What are the key findings of Porter’s Five Forces analysis and SWOT analysis of key players operating in the global Prescription Hyperlipidemia Drugs market?
    • This report gives all the information regarding the industry overview, analysis and revenue of this market.
    • What are the market opportunities and threats faced by the vendors in the global Prescription Drugs for Hyperlipidemia Market?
    If you have any special requirements, please let us know and we will offer the report as you wish.
    Buy Now @ https://www.maccuracyreports.com/checkout/519367

    About Us:

    MRI Accuracy Reports provides customization of reports according to your needs. This report can be customized to meet your needs. Get in touch with our sales team, who will guarantee you get a report tailored to your needs.

    Contact us:

        Call: +1 804 500 1224 / +44 741841 3666 (International)

    E-mail: [email protected]

    Website: www.maccuracyreports.com

    read more
    Prescription drugs

    Prescription drugs sold on the street are dangerous

    BY PATRICK TOM

    Selling drugs on the street without a license is illegal and puts buyers at risk, said Navin Raju, managing director of City Pharmacy Limited.

    He pointed out that many people know that prescription drugs can come with warnings and known side effects.

    Mr. Raju said that the abuse of these prescription drugs increases the risk of experiencing these problems, with the risk of fatal side effects.

    He said the drugs should only be taken under the supervision of a medical professional.

    “Their advice on whether a drug is right for you, dosage, possible side effects and any harmful interactions with other drugs is crucial. It’s unclear what you’re getting when you make a purchase on the street” , did he declare.

    “All medicines must have a batch number for traceability purposes and an expiry date.”

    Mr Raju said CPL advises the public to always get their medicines from a reputable pharmacy or outlet.

    He said it’s never a good idea to take a prescription drug without a valid prescription.

    The drug may not be right for you and may cause unpleasant side effects or serious health risks.

    “Medicines should not be considered as consumer products. Fake drugs can cause real damage to your health.

    “Don’t be tempted by spam emails advertising cheap drugs. If something sounds too good to be true, it usually is,” he said.

    “You can also check the pharmacist’s registration status by searching for the name and address of the pharmacy.”

    Mr Raju said drugs sold on the street can be shoddy at best and dangerous at worst.

    What you receive in the mail may be a new, counterfeit, substandard or unapproved drug, which may put your health and safety at risk.

    read more
    Prescription drugs

    What’s in a name? When it comes to prescription drugs, many, experts say

    How do prescription drugs get their brand names? It’s a process, experts say. Photo by Sponge/Wikimedia Commons

    January 21 (UPI) — The Food and Drug Administration announced Wednesday that it has approved a drug called Quviviq for the treatment of insomnia, a disorder that causes trouble sleeping.

    The brand name of this drug, which is expected to hit the market in the United States in May if it meets FDA standards for controlled substances, may seem like a mouthful.

    However, there is most likely a lot of thought and money behind Quviviq.

    “The manufacturer says it improves sleep with less drowsiness, so they may think ‘viviq’ connotes vital, lively, or less groggy,” said Arlene Teck, creative director, name development at Ixxeo Healthcare in Rockaway, NJ. , a pharmaceutical brand strategy consulting firm. UPI in a telephone interview.

    “The high pitch of the last syllable can evoke a sense of alertness,” Teck said, adding that neither she nor Ixxeo had worked on the brand.

    Although drug brand names seen in TV commercials, magazine ads and elsewhere may seem bizarre, there’s usually a method behind the apparent madness, experts said.

    “Companies spend a lot of time trying to get the right names to achieve their marketing goals,” Dr. G. Caleb Alexander, an epidemiologist whose research focuses on drug use and safety, told UPI by phone. on prescription.

    “The name shapes product perception, but it’s only part of a broad, thorough and coordinated marketing strategy,” said Alexander, a professor at Johns Hopkins University in Baltimore.

    Here is an overview of the process behind the brand naming of prescription drugs.

    Drug manufacturers develop a chemical name for a new drug based on a set of rules established by the International Union of Pure and Applied Chemistry and the United States Adopted Name Council.

    This latter group is operated under the auspices of the American Medical Association, the American Pharmaceutical Association and the US Pharmacopeial Convention, and any new name must refer to the underlying ingredients and mechanism of action of a drug. , according to the board.

    The chemical or generic name must also receive authorization from the World Health Organization’s International Nonproprietary Name program.

    Bring in the consultants

    Once the chemical name has been cleared for use and the drug has entered clinical trials, manufacturers will engage consultants such as Ixxeo Healthcare, with the goal of developing a brand name that allows the product to be marketed effectively, without violate FDA guidelines.

    New drugs go through three stages of clinical trials, and the process of creating brand names usually begins right at the start of phase 2 trials, Teck said.

    “By then, we’re pretty sure it’ll be a keeper and won’t die along the way” in the research and development process, she said.

    According to Tina Goldstone, director of marketing at Interbrand, a New York-based marketing consultancy, consultants typically work with clients to understand the drug, its category and class, and how it works or how it works.

    From a potential list of hundreds of names, the best options are selected and “pre-selected” against currently available databases of names and legal terms, as well as world languages ​​to avoid possible conflicts, she said.

    A famous example occurred in the 1960s, when Vicks marketed its cough drops in Germany, not realizing that the letter “v” was pronounced like the English letter “f” in German.

    As a result, the name Vicks read like a vulgar slang term for Germans.

    Beware of existing products

    It’s also important for new drug brands to make sure their names aren’t too close to those of existing products, Teck and Goldstone said.

    In addition to causing potential confusion for doctors and consumers, drugs with similar names could increase the risk of medication errors or incorrectly prescribed drugs, according to Teck.

    This has become an even bigger issue in recent years as prescribing has become high-tech, with prescribers and pharmacists often using software systems or devices with drop-down menus, she said.

    About 1.5 million people in the United States suffer health complications or even death each year from improperly prescribed medications, the Institute of Medicine estimates.

    A 2020 analysis published by the journal BMJ Quality and Safety found that 27 brand names of drugs used in the United States were identical to those of 38 products in other countries with different active ingredients.

    “How a drug is named can have big implications for the safe use of a drug,” said Johns Hopkins’ Alexander.

    Doctors and pharmacists are usually trained to learn the chemical names of drugs because brand names differ from country to country and often become unnecessary when generic forms hit the market, he said.

    FDA limits

    The FDA’s 42-page drug naming guidelines are publicly available.

    In addition to ensuring that the brands do not create possible consumer sources for prescribers, pharmacists and the public, the names cannot refer to the drug’s active ingredients or exaggerate their effectiveness or benefits, Teck said. Ixxeo.

    According to the agency, up to a third of all drug names submitted for FDA approval are rejected.

    “The attributes of the compound can influence the name — if it’s a potent, high-potency product, one might want to go for a potent name,” Interbrand’s Goldstone said.

    However, “the actual name of the compound or generic will not influence the name because a [brand] a name too close to the name of the compound would be rejected by regulatory authorities,” she said.

    What a drug is and what it does – its mechanism of action – will most likely appear in the name, particularly if it is a first-class drug or a drug that works differently than those already on the market, Teck mentioned.

    Additionally, names should also be easy to remember and pronounce, Teck said.

    At her agency, potential names are spoken, sung, shouted and even spoken by people “holding their noses”, she said.

    “We try to imagine someone with a cold, or these days wearing a face mask, walking up to the pharmacy counter and saying the name of the medicine,” Teck said.

    At the same time, with direct-to-consumer advertising of prescription drugs — the United States is one of the few countries in the world that allows it, although it is regulated by the FDA — the name brand name of a drug can also affect its “marketability”. “, according to Goldstone.

    An example of a drug brand name that lends itself well to marketing is the erectile dysfunction drug Viagra, a moniker designed to evoke vitality, virility and vigor, experts said.

    More recently, Comirnaty, the brand name for Pfizer-BioNTech’s COVID-19 vaccine, “represents a combination of the terms COVID-19, mRNA, community, and immunity,” according to the makers and the Miami-based Brand Institute, which helped in the naming process.

    Often these names are tested with groups of doctors, pharmacists and consumers to make sure they resonate with all three, Goldstone said.

    However, given FDA restrictions, the extent to which their feedback ultimately influences the final brand choice is often limited, Ixxeo’s Teck said.

    “This is not an area of ​​pharmaceutical product development that most consumers are aware of,” Johns Hopkins’ Alexander said.

    “Yes, there’s an interest in having something that’s easy to remember, fairly easy to pronounce, and sticky, and the stickier the better, but those are just some of the considerations involved” , did he declare.

    read more
    Prescription drugs

    Iran’s Medicine Mafia Behind Shortages and High Cost of Prescription Drugs – OpEd – Eurasia Review

    A short prelude

    Since the birth of the tyrannical regime of the mullahs in Iran, another social and frightening phenomenon has also been born; widespread monopolization. After the 1979 anti-monarchy revolution in Iran and the establishment of the religious dictatorship, the regime’s power vultures began to dominate and take control of the main outlets of the economy. The creation of a multitude of false and non-existent legal and illegal entities, holdings, bank accounts and businesses has been the evil product of this domination and control.

    After the passage of more than four decades, the Iranian economy is recognized by its two distinct fronts. On the one hand, the regime, its repressive forces and its affiliates, and on the other, the Iranian people.

    The first front is dominated by the office of Iran’s Supreme Leader Khamenei, which has around $200 billion in assets, the infamous Islamic Revolutionary Guard Corps (IRGC) and a host of other entities sharing the same ideas.

    The second front is made up of ordinary Iranian citizens who, according to Speaker of Parliament Ghalibaf, make up around 94% of the population.

    The current state of prescription drugs in Iran

    The availability and affordability of prescription drugs in Iran fell sharply more than two years ago, and it has become almost impossible to find foreign drugs after the recent pandemic. According to media reports, ordinary Iranians are experiencing a severe shortage of prescription drugs and drug prices are skyrocketing across the country.

    Many people complain that pharmacies are unable to supply their prescriptions. As expected, government officials are offering conflicting reasons — including US sanctions — for shortages and price hikes; however, pharmacists blame government mismanagement of health care, corruption, the black market and the collapse of Iran’s currency.

    In September 2018, it was reported that the price of drugs prescribed to dialysis and kidney transplant patients had increased by 100-300% since March of the same year. Other prescription drugs have also seen unprecedented price increases. Many senior officials in the governments of former President Hassan Rouhani and current President Ebrahim Raisi have blamed current drug shortages on US-imposed economic sanctions. Yet the US Treasury Department’s list does not include drugs.

    The source of the problem

    The real reason for the shortage of prescription drugs lies in the Iranian regime’s corrupt system and its dominance over the pharmaceutical industry.

    The Iranian medical mafia is not a new phenomenon; with the onset of the COVID-19 pandemic in Iran in 2019, people had to go through a winding path of illegal channels and contacts, called the Iranian medicine mafia, instead of pharmacies, to obtain prescription drugs, often paying much more than the advertised price. Looking back, one might realize that Iran’s medical mafia had been around for many years, but the spread of COVID-19 helped it gain strength and expansion.

    Regarding the shortage of certain items in pharmacies, Ali Fatemi, Vice President of the Iranian Pharmacists Association, said: “Previously, the shortage of medicines was related to foreign medicines and medicines for certain diseases, but now we have problems in supplying certain Iranian medicines and this shortage in our country is unprecedented”.

    Iran’s new budget and prescription drugs

    To raise funds for its budget deficit, the government of Ebrahim Raisi plans to eliminate all pre-existing subsidies for prescription drugs. Facing public anger and widespread criticism from the regime’s own analysts and politicians, government officials say prescription drugs will still be subsidized because they fall under the subsidized exchange rate category.

    However, leaders of drug importing companies insist that the prescription subsidies allocated in the budget are not enough to meet the need. The Director General for Pharmaceutical Affairs confirmed concerns raised by pharmaceutical companies about subsidies and their availability.

    Iranians are angered by reports of drug trafficking and the sale of drugs on the black market, which is owned and controlled by regime elites. This is when the authorities claim to have enough funds to import certain drugs; drugs that cannot be found in pharmacies and that end up on the black market at exorbitant prices.

    In a report published in January, Colonel Davoud Moazami Goudarzi, head of Tehran’s cyberpolice, said an Instagram page with more than 90,000 followers was selling drugs in cyberspace. The report says more than 500,000 rare drugs were confiscated from the site.

    In conclusion

    It is safe to say that in principle there are enough drugs in the country, but the Iranian medical mafia, i.e. the regime elites and the IRGC, are selling the drugs to desperate patients. through the black market to earn more money. Most Iranians cannot afford to buy drugs on the black market, which has led and may lead to more deaths and poverty

    read more
    Prescription drugs

    Mark Cuban’s online pharmacy is now open with low-cost prescription drugs

    Mark Cuban’s online pharmacy promising affordable prices on prescription drugs is up and running.

    The Mark Cuban Cost Plus Drug Company cuts out the middleman and negotiates directly with drug manufacturers and pharmacies to obtain discounts and rebates on behalf of employers, health insurers and government health programs.

    It says it offers the lowest direct-to-consumer prices on more than 100 medications, including those commonly prescribed for high cholesterol and blood pressure.

    The cholesterol drug Atorvastatin typically costs more than $55, according to the Cuba-backed company’s website. Cost Plus charges $3.60. Prescription amlodipine for high blood pressure usually costs around $50. Cost Plus lists it at $3.30.

    Alex Oshmyansky, CEO of the Mark Cuban Cost Plus Drug Company.

    “The Mark Cuban Cost Plus Drug Company is trying to reduce drug costs for patients by any means necessary,” said CEO Alex Oshmyansky. “In our online pharmacy, we basically found a category of drugs that are extremely expensive, not really because of the manufacturer’s price, but because of price markups due to intermediaries in the supply chain, mainly pharmaceutical wholesalers. and pharmacy benefits managers.”

    The company established its own registered pharmaceutical wholesaler and purchased drugs directly from manufacturers. He then sells the drugs at a fixed markup of 15% and a pharmacist fee of $3.

    The pharmacy is cash only at the moment. By next year, Oshmyansky said the company hopes to allow customers to use their insurance.

    Wednesday’s launch comes just weeks after the creation of Cuba’s Pharmacy Benefits Management Operation, which works directly with the online pharmacy. Customers can go to the website and order generic versions of drugs to be shipped to their front door.

    Mark Cuban Cost Plus Drugs was first launched under a different name in 2018 as a generic drug startup. A year ago, the billionaire owner of the Dallas Mavericks went public with his support.

    The company is currently building an $11 million, 22,000 square foot manufacturing facility in Deep Ellum.

    Oshmyansky said thousands of people had created accounts when the website launched on Wednesday.

    “Our goal is not just to get attention today, but to try to help people every day, so hopefully we can keep the excitement going,” Oshmyansky said.

    read more
    Generic drugs

    Mark Cuban’s drug company launches pharmacy, promising huge savings on generic drugs

    Mark Cuban Cost Plus Drug Company (MCCPDC) has launched its online pharmacy as part of an ongoing effort to provide consumers with drugs at low prices.

    The pharmacy claims to offer significant savings, with several prescription drugs costing more than half the price of the next most affordable option. For example, imatinib for the treatment of leukemia has a retail price of $9,657 per month, according to the MCCPDC, compared to $120 with a common voucher. Its price through the new company, however, is only $47 per month.

    The initial launch of the pharmacy inventory consists of 100 generic drugs.

    The MCCDPC aims to circumvent so-called middlemen and markups and boasts of reflecting actual manufacturer prices with a fixed 15% fee. To avoid working with pharmacy benefit managers, the pharmacy will be cash only. The pharmacy is powered by Truepill’s digital health platform and leverages its nationwide pharmaceutical footprint to fill and deliver prescriptions.

    “We will do whatever it takes to bring affordable pharmaceuticals to patients,” Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug, said in an announcement. “The mark-up on potentially life-saving medicines that people depend on is an issue that cannot be ignored. It is imperative that we act and help expand access to these medicines for those who need them most.”

    RELATED: 2 New PBM Launches Aim to Bring Greater Transparency to the Market

    In November, the MCCPDC launched its own Pharmacy Benefits Manager and pledged to be transparent about the costs it pays for drugs with those who work with it. With this venture, he hopes to completely eliminate the traditional PBM model.

    The company plans to integrate its pharmacy and wholesaler with its PBM so that PBM customers have access to wholesale pricing through the pharmacy. Its Dallas pharmaceutical plant is expected to be built by the end of this year.

    “There are many bad actors in the pharmaceutical supply chain that prevent patients from getting affordable medicines,” Oshmyansky said. “The only way to guarantee affordable prices is to integrate vertically.”

    read more
    Prescription drugs

    Some northern Manitobans wait weeks for mail and prescription drugs



    OTTAWA — A remote part of northern Manitoba has gone three weeks without mail delivery, which has left residents waiting for prescription drugs.

    “It’s just the attitude of Canada Post, like they don’t care,” said Cecil Thorne, a resident of Pikwitonei, 630 kilometers north of Winnipeg.

    The town of about 80 people sits along a stretch accessible by snow-covered roads or the Hudson’s Bay Railroad, where mail was last delivered Dec. 22.

    Mail normally arrives on the Via Rail train three times a week, although two recent trips have been cancelled.

    The local postmaster told Thorne he could not get permission from Canada Post to come to Thompson and pick up the mail at the post office.

    The crown corporation said it was because the winter road had been closed, which remained the case Friday evening according to the Manitoba 511 website.

    However, Thorne said the postmaster of nearby Thicket Portage still made the trip along that stretch.

    “It appears our mail has been held hostage in Thompson,” said Thorne, who drove himself to Thompson along the winter road and said post office staff could not allow him to pick up his own mail.

    “It’s two crown corporations: Via Rail and Canada Post, and between them you’d think they could figure out a way to deliver the mail.”

    A Canada Post spokesperson said staff are trying to resume postal service as soon as safely possible.

    “We recognize the hardship and frustration faced by residents of Pikwitonei and surrounding communities who have seen mail delivery interrupted,” wrote Phil Legault.

    He said staff tried to find another arrangement as soon as Via Rail canceled its route on January 10, but were unable to arrange a delivery.

    “When notified of rail service interruptions, Canada Post has a process with contingencies that allows us to deliver mail while maintaining its integrity and security,” Legault wrote.

    “We appreciate that customers depend on us and we take that commitment very seriously.”

    Thorne said his part of the province depends on the mail, as they only have internet access through a shoddy satellite system, and most people get their medication through the mail.

    In March 2021, the Free press reported that residents of The Pas were waiting for Christmas packages 10 weeks after the 2020 holiday.

    The state-owned company said at the time that it was overwhelmed by an online delivery boom from November 2020, when the province implemented COVID-19 restrictions prohibiting stores from selling virtually all non-essential items.

    [email protected]

    Dylan Robertson

    Dylan Robertson
    Head of the Parliamentary Office

    In Ottawa, Dylan likes to snoop through access to information requests and ask politicians, “What about Manitoba?

    read more
    Prescription drugs

    Two people arrested after large supply of prescription drugs seized in raid

    Two people have been arrested after a large quantity of prescription drugs were found during a police search in Bolton.

    On Friday, officers from GMP’s Bolton West Neighborhood team executed a warrant at an address on The Pewfist in Wesoughton.

    Inside the premises, officers discovered a large quantity of prescription drugs believed to have been obtained illegally without a prescription.

    READ MORE: Amorous girl, 19, followed her ex, 42, on a getaway to Benidorm, then scratched ‘NONCE’ on the bonnet of his car when he dumped her

    Officers believe the drug was intended to be sold to others.

    As a result of the search, two people were arrested for possession with intent to supply Class A drugs.



    A large quantity of prescription drugs was seized during a police warrant in Bolton

    Both were questioned and then released under investigation.

    Police say they have not yet been able to establish what the drug is and will carry out tests to find out.

    A GMP spokesperson said: ‘We are now beginning the painstaking work (no pun intended) to find out exactly what the drug is.

    “Although the box may say one thing, the origins of these drugs are not known.

    “They could be counterfeit or completely fake and as such we cannot be sure what is in them.”

    Sign up for MEN’s email newsletters to get the latest on sports, news, current affairs and more by following this link.

    read more
    Prescription drugs

    This is why prescription drugs are so expensive

    Oligopoly: a state of limited competition, in which a market is shared by a small number of producers or sellers.

    SALT LAKE CITY — Why are prescription drugs so expensive? An advocate for open access, transparency and competitive markets in the pharmaceutical industry shares his mind-blowing insights into the prescription drug industry and how insiders, whose job it is to watch over consumers, rake in a fortune.

    Welcome to the show

    Heather Kelly, host of Money Making Sense, talks with Antonio Ciaccia, president of 3 Axis Advisors, about pharmacy benefit managers and their role in controlling prescription drug costs.

    “How do prescription drugs get to our pharmacies? asked Kelly.

    In simple terms, Ciaccia explained the main pillars of the prescription drug supply chain:

    • A drug manufacturer sells to a drug wholesaler, such as McKesson, Cardinal Health, or AmerisourceBergen.
    • The wholesaler then sells the medicine to pharmacies, hospitals and medical practices.
    • And with each step, the price of the drug increases for the end consumer.

    PBMs administer prescription drug benefits on behalf of health insurers, Medicare Part D drug plans, large employers and other payers.

    By negotiating with drug manufacturers and pharmacies to control drug spending, PBMs have a significant behind-the-scenes impact on determining total drug costs for insurers, patient access to drugs, and provider compensation. pharmacies, according to the Commonwealth Fund.

    “Keep these discounts to themselves”

    “They’re not doing a great job, especially for my mom,” Kelly said, explaining that her mom, who is on Medicare, pays $250 out of pocket every month for a drug she needs. “She still has to buy four or five more. So these PBMs don’t do a great job. I’m just telling you now.

    “Unfortunately, the system was supposed to work much better,” Ciaccia said.

    He added that PBMs were designed to counterbalance the drugmaker, wholesalers and pharmacies and negotiate greater discounts for consumers.

    “The problem is that PBMs are really good at negotiating these discounts, but they’re even better at keeping these discounts to themselves, often forcing the patient to pay the full list price when they’ve negotiated a price themselves. far different and better for himself,” he said.

    Ciaccia said PBMs used to be just claims processors, but have since landed on the list of America’s biggest and richest companies.

    The top 10 Fortune 500 companies in the United States include:

    • CVS Health, owner of CVS Pharmacy, a chain of retail pharmacies; CVS Caremark, a pharmaceutical benefits manager;
      UnitedHealthGroup, which offers healthcare products and insurance services;
      McKesson, which distributes pharmaceuticals and provides health information technology, medical supplies and care management tools; and
      AmerisourceBergen, a wholesale drug company.

    Who watches the watchdog?

    “They’re bigger than the pharmaceutical companies and drugmakers they were hired to police in the first place,” Ciaccia said.

    He said PBMs ended up making prescription drug pricing more complicated and expensive.

    “The PBM uses all of us as individuals to negotiate deep discounts that they get at the end of the transaction. But they don’t pass them on to us as a patient,” Ciaccia said.

    Heather said her blood was starting to boil “a little bit right now”.

    No one knows the price of drugs

    Ciaccia said if you walked into a grocery store and it cost $20 for a gallon of milk, you’d know right away you were being ripped off. You would take your money to another grocery store where the price of milk would match market expectations.

    It’s “what ultimately holds quality and price accountable in your grocery store. Nobody knows what the prices of thousands of different drugs are or what they should be,” he said.

    Ciaccia said that due to the “enormous” lack of transparency, the pharmaceutical market is ripe for exploitation.

    “Let’s be clear, PBMs aren’t the only villains in the drug supply chain, but they’re the only ones whose existence is predicated on trying to save us money,” he said. declared.

    Related:

    read more
    Prescription drugs

    Free prescription drug program in Lake County needs more participation and funding

    CONCORD TOWNSHIP, Ohio — Prescription drug costs are already high and unaffordable for many, but with inflation, some of those prices have skyrocketed.

    Fortunately, there is a program in Lake County that provides people with the medications they need for free. It’s called the Prescription Assistance Program, and it’s for Ohioans who need prescription drugs but can’t afford them, like Marge Burnett.

    As a diabetic, Burnett knows a lot about the cost of prescription drugs, especially when insurance doesn’t foot the bill.

    “Sometimes it triples the cost. And of course now with inflation and all. I mean, some of the drugs are just out of sight. And I probably wouldn’t be able to afford all of that,” Burnett said.

    Luckily, she doesn’t have to worry – thanks to PAP.

    Burnett started volunteering with the program several years ago through the Lake County Retired Senior Volunteer Program (RSVP), then quickly learned she could get help too.

    “It was a blessing in disguise because I’m on social security and low income, so it works better for me,” Burnett said.

    PAP President Joel Lucia said all of these drugs come from multiple sources and are sorted by volunteers at the Northeast Ohio Prescription Drug Repository in Concord Township.

    “The State of Ohio passed a law called the Ohio Drug Repository Law that allowed groups like us and non-profit corporations to form and receive drugs that would otherwise be thrown away and provide them to people who can’t afford their medicine,” said Lucie. “We probably have three-quarters of a million dollars worth of drugs.”

    Any Ohio resident who needs help can call, see if their medications are in stock, and register with a prescription from their doctor. Then the repository sends it by mail. Residents only need to pay a $10 shipping fee.

    Per Ohio drug depot law, the pharmacy does not handle any controlled substances.

    “We don’t do background checks. We do not do financial audits. If they call us, we assume they cannot afford their medication. So give us a call,” Lucia said. “We have people all through our program now, people who, if they didn’t get this medicine, would be unable to buy food for their children or are skipping their medicine.”

    But even with the huge amount of drugs in the repository and the huge need in the community, tens of thousands of dollars worth of drugs are wasted each month simply because there aren’t enough people getting there. enroll in the program.

    “We have around 700 people using the program. We can serve three, four times more,” Lucia said. “The only problem we have is that people think it’s too good to be true. And most people think it’s a scam. It’s not a scam.”

    Additionally, Lucia said they faced another problem.

    “If we can’t increase our funding or if someone else doesn’t pick up the slack, we’ll probably close by September or October next year,” Lucia said. “It would be nice if we could link up with the hospital or another organization that would need our services. This could expand our services.

    Lucia said the program needs around $65,000 a year to keep it running. He gets funding from United Ways of Lake and Geauga counties, but needs more.

    “We operate with limited resources. It’s an absolute minimum. There isn’t a program anywhere in Ohio that will give you the edge we can for the dollar. For every dollar we receive, we give back $5 or $6 to the community,” Lucia said.

    And while they’re trying to figure that out, he wants people who are struggling to make ends meet to know that help is out there.

    “Go spend the money on groceries or gifts for your kids. Get the medicine for free from us. We throw it away. So I don’t know how to convince people that we are real. We are alive. We are here. We are here to help you,” Lucia said.

    Anyone interested in enrolling in the Prescription Assistance Program or wanting to donate money to help keep it open can call 440-350-1470 or visit the program’s website.

    Jade Jarvis is a reporter for News 5 Cleveland. Follow her on Facebook, Twitter, and Instagram.

    Download the News 5 Cleveland app now for more stories from us, plus top news alerts, the latest weather forecasts, traffic updates and more. Download now on your Apple device here, and your Android device here.

    You can also watch News 5 Cleveland on Roku, Apple TV, Amazon Fire TV, YouTube TV, DIRECTV NOW, Hulu Live and more. We are also on Amazon-Alexa devices. Learn more about our streaming options here.

    read more
    Prescription drugs

    Prescription Drugs Market and Forecast 2031

    Prescription Drug Market Size, Global Key Leaders Analysis, Segmentation, Demand, Future Trends, Gross Margin, Impact of Covid-19 on Emerging Technologies, and 2031 Forecast

    According to an analysis by Market Research.biz, a detailed scenario of the market environment is accessible, encompassing the current and future state of the market, according to a new study on the Prescription Drug Market . The scale and possibility of profit, as well as the profile of the producer, manufacturing specifics and consumption trends, have all been studied in depth. In terms of drivers, opportunities, and restraints, the report provides insight into upcoming trends and market dynamics. For various market players to assess the possibility of investments in various regional areas, a thorough assessment of these components is essential.

    Reserve your FREE sample report @
    https://marketresearch.biz/report/prescription-drugs-market/request-sample/

    The precise information of the Prescription Drugs market research is displayed in the form of diagrams and pie charts for the convenience of the readers. The overall presentation of the report is interesting, with a basic structure, specific provisions and data based on reinsurance and awareness. The administrators, key players on the lookout, topographic division, product type and representation, and end customer applications in the market were all analyzed by the survey team. For each segment and region, it calculates transaction revenue.

    The aim of the report is to give a more complete view of the current situation, the economic crisis and the impact of COVID-19 on global activity. Our analysts, who are monitoring the situation around the world in the aftermath of the COVID-19 crisis, believe the market will provide producers with interesting prospects.

    Main key players

    • Novartis AG
    • Pfizer, Inc.
    • Hoffmann-La Roche SA
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • GlaxoSmithKline Plc.
    • AstraZeneca Plc
    • Celgene Corporation
    • Other players

    The market research report divides the Prescription Drugs market into applications, type, and market share. This study covers the analysis of cost structure and growth factor of the industry market in detail. This report also throws light on the fastest growing market segments and various factors driving the growth of these segments.

    Prescription Drug Market Segmentation Overview: –

    Prescription Drug Market, By Product Type

    • Generic medicines
    • Brand name drugs
    • Orphan drugs

    Prescription Drug Market, By Indication

    • Oncology
    • Antidiabetic drugs
    • Vaccines
    • Sensory organs
    • Immunosuppressants
    • Anti coagulants
    • Other indications

    Prescription Drug Market, By Distribution Channel

    • Hospital pharmacies
    • Retail pharmacies and pharmacies
    • Online pharmacies

    Because the Covid-19 eruption has had such a broad impact on businesses, it is becoming increasingly important to understand the implications of all collaborations. With that in mind, we have conducted extensive and unique research into the impact of Covid-19 on the market. Here is a link to the Covid-19 study report: https://marketresearch.biz/report/prescription-drugs-market/request-sample/covid-19-impact/

    Highlights of the Market Research Report

    • Each of the major players is presented in the study report along with a SWOT analysis.
    • The research includes regional analysis along with detailed market segmentation by type and application.
    • An in-depth examination of the drivers, opportunities and restraints of the global market.
    • Research report takes an in-depth look at prescription drugs

    You can ask questions about the study or express your concerns about it here:
    https://marketresearch.biz/report/prescription-drugs-market/#inquiry

    Finally, the analysis highlights the performance of key elements and application components of the Prescription Drugs market in each regional industry. Likewise, orientations stratified on the list of important actors operating within each regional economy inform the competitive dynamics of the regional economy. This allows for a deep and in-depth examination of the entire Prescription Drug Market company. Further, the report includes the global Prescription Drug Market industry forecast for each object, geography, and application sector for the years 2022-2031.

    When preparing a report, the following years are taken into account:

    Historic year: 2015-2020

    Baseline year: 2021

    Forecast period: 2022 to 2031

    Click here for the full INDEX, including data, facts, figures, tables and more:
    https://marketresearch.biz/report/prescription-drugs-market/#toc

    Key Questions Answered In The Prescription Drugs Market Report

    • What are the main drivers and constraints of the market today? What impact will future training and constraints have?
    • What are the main drivers and constraints of the current market? What effect will drivers and restraints have in the future?
    • What are the main effects on the global COVID-19 pandemic market?
    • What is the growth rate of the world market? What will the growth trend be in the future?

    Contact us at

    MarketResearch.Biz (Powered by Prudour Pvt. Ltd.)

    420 Lexington Avenue, Suite 300

    New York, NY 10170,

    United States

    Website:
    https://marketresearch.biz

    Email ID: [email protected]

    © Scoop Media

    read more
    Generic drugs

    More NJ seniors are now eligible to buy $5 generic drugs and $7 brand name drugs under PAAD

    More low-income New Jersey seniors qualify for discounted pharmaceutical drugs after the state raised its income threshold in two of its longstanding subsidy programs, the administration said Thursday. of Governor Phil Murphy.

    The change means, in part, that people 65 and older who earn less than $38,769 a year could buy generic drugs for $5 and brand name drugs for $7, officials said.

    “Few issues have a greater financial impact on New Jersey families than the ever-escalating cost of prescription drugs,” Murphy said in a statement. .”

    Discounts are available through two programs: Pharmaceutical Assistance for the Elderly and Disabled, or PAAD, and the Senior Gold Prescription Discount Program.

    The expansion comes as the Build Back Better Act, a federal bill that includes a provision allowing Medicare to negotiate prices with drugmakers, stalled in Congress.

    More on the invoice: NJ Democrats Approve Medicare Price Negotiations, But Will Biggest Bill Pass?

    The Murphy administration said the state was taking steps to provide financial assistance. He included $25 million in his budget this fiscal year to reduce the cost of health insurance and prescription drugs.

    As part of this plan, Murphy raised the income limit by $10,000 on the PAAD and Senior Gold programs. The expansion took effect Jan. 1 and could be available for 20,000 New Jersey residents.

    PAAD is now open to residents 65 and older and people with disabilities earning up to $38,769 if single and $45,270 for couples. It cuts prices to $5 for covered generic drugs and $7 for covered name brands.

    The Senior Gold Prescription Discount program is for seniors and people with disabilities earning up to $48,769 if single and $55,270 if married. It offers drugs at half price after a $15 copayment.

    Medicare-eligible consumers must be enrolled in Medicare Part D, the prescription drug plan, to participate. To complete an application, go to https://www.state.nj.us/humanservices/doas/services/njsave/

    The expansion of the program was unanimously approved last year by the Assembly and the Senate. And it won the endorsement of AARP New Jersey, a consumer group that found Americans pay three times more for prescription drugs than their counterparts in other countries.

    “Residents of all ages depend on their prescriptions, and no one should have to choose between food, medicine, or rent,” Evelyn Liebman, AARP New Jersey’s advocacy director, said last year about Bill. “Prescription drugs don’t work if people can’t afford them. This extension will also expand eligibility for essential public service assistance programs for those who need them most.”

    Michael L. Diamond is a business journalist who has written about New Jersey’s economy and the health care industry for more than 20 years. He can be contacted at [email protected]

    This article originally appeared on Asbury Park Press: NJ PAAD: More Seniors Now Eligible to Buy Discounted Drugs

    read more
    Prescription drugs

    Analysis of 2021 Non-prescription Drugs Market Outlook by Major Key Players

    New Jersey, United States, – The Global Non-Prescription Drugs Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Non-Prescription Drugs market. The market analysts who produced the report have provided in-depth information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Non-Prescription Drugs Market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Non-Prescription Drugs market is carefully analyzed and researched by market analysts. Market analysts and researchers have performed an in-depth analysis of the global non-prescription drug market using research methodologies such as Pestle and Porter’s Five Forces Analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players gain insight into the overall current and future market scenario. The Non-prescription Drugs report includes in-depth research on potential segments including product types, applications, and end-users, along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=215723

    The main players covered by the non-prescription drugs markets:

    • Pfizer
    • rock
    • Sanofi
    • Johnson & johnson
    • Merck & Co. (msd)
    • Novartis
    • Abbvie
    • Gilead Sciences
    • Glaxosmithkline (gsk)
    • Amgen
    • Astrazeneca
    • Bristol-myers Squibb
    • Eli lilly
    • Suits you
    • Bayer
    • Novo Nordisk
    • Allergan
    • Takeda
    • Boehringer Ingelheim
    • Takeda

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to gain in-depth insights into the entire industry.

    Market Breakdown of Non-Prescription Drugs by Type:

    Non-prescription Drugs Market Split By Application:

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=215723

    Scope of Non-Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the non-prescription drug markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the main challenges that the global Non-Prescription Drug markets could face in the future?
    • Who are the leading companies in the global non-prescription drug market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies envisioned by the players to maintain their grip on the global Non-Prescription Drugs market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-non-prescription-drugs-market-size-and-forcast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Non-prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical non-prescription drug breakdown data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Doctors may be able to reduce the number of prescription drugs older patients take

    Dublin, Ireland – Do Seniors Really Need to Take a Plethora of Different Medicines to Stay Healthy? A new study finds that many patients could and probably should throw away some of their prescriptions that are no longer beneficial to their health.

    Researchers at RCSI University of Medicine and Health Sciences have found that medical interventions by a patient’s doctor can eliminate old drugs that can combine with other drugs to cause more harm than good. For many seniors, the number of prescription drugs they take seems to increase with their age. Previous studies show that one in three older Americans is taking prescription drugs that are not suited to their symptoms or that could cause further harm.

    Unfortunately, an increasing number of older people are also living with more than one medical or multimorbidity problem. Healthcare providers often prescribe medications that treat each of these conditions, leaving the patient or their caregivers to juggle all of these prescriptions.

    Real intervention can eliminate bad prescriptions

    To remedy this, the researchers looked at the results of the SPPiRE project (or Supporting prescribing in older people with multimorbidity and significant polypharmacy in primary care). The study included 51 general practitioners and 404 patients in Ireland, inviting older patients taking at least 15 medications to participate in a review of their medications by their doctor.

    The review included a screening of each prescription to determine which ones were inappropriate to take together, which ones patients were able to stop taking, and which medications should be a priority for patients. The results show that doctors were able to remove more than 800 drugs among 208 participants in the intervention.

    After removing the 800+ drugs, the researchers noted only 15 possible side effects of ending these prescriptions. Almost all of the adverse events were a mild reaction to stopping treatment and these symptoms resolved once the doctors put the patients back on that particular drug.

    “It is possible that identifying this risk group for whom at least 15 drugs were prescribed has in itself improved prescribing,” explains Dr Caroline McCarthy, Clinical Lecturer and Research Fellow in the Department of Medicine. General of the RCSI. , in one university outing.

    “It can be intimidating for GPs with limited time and resources to actively manage these prescriptions, and patients can also be wary of change, especially if they have been on a medication for a long time,” adds Dr. McCarthy.

    “The intervention approach to manage this difficult problem is promising and demonstrates that, even in this very complex group, stopping drugs that may no longer be needed or appropriate is both possible and generally safe,” concludes Professor Susan Smith, Associate Director of HRB. Primary Care Clinical Trials Network.

    The results appear in the newspaper PLOS Medicine.

    read more
    Prescription drugs

    Dog Prescription Drug Market Drivers and Restraints for Each Segment

    New Jersey, United States, – The Global Dog Prescription Drugs Market report is one of the most comprehensive and significant additions to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Dog Prescription Drugs market. The market analysts who produced the report have provided detailed information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Prescription Drugs for Dogs market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Prescription Drugs for Dogs market is carefully analyzed and researched by market analysts. Market analysts and researchers have performed an in-depth analysis of the global prescription dog drugs market using research methodologies such as Pestle and Porter’s Five Forces Analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players get an overview of the overall current and future market scenario. The Dog Prescription Drugs report includes in-depth research on potential segments including product types, applications, and end-users along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=228634

    The Major Players Covered By The Prescription Drugs For Dogs Markets:

    • Elanco Animal Health
    • Ceva Animal Health
    • MSD Animal Health
    • Zoetis
    • Virbac
    • Dechra
    • Vetoquinol
    • Animal care group
    • Ourofino Saude Animal
    • Boehringer Ingelheim

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising by product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to acquire in-depth insights into the entire industry.

    Prescription Dog Medication Market Split By Type:

    • Oral type
    • Type of smear
    • Injection type
    • Spray type

    Dog Prescription Drugs Market Split By Application:

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=228634

    Scope of Dog Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the Prescription Drugs for Dogs markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the major challenges that the global Prescription Drugs for Dogs markets could face in the future?
    • Who are the major companies in the global prescription dog medication market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies envisioned by the players to maintain their hold on the global Dog Medicines market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-dog-prescription-drugs-market-size-and-forecast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical dog prescription drug distribution data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Analysis of 2021 Pet Prescription Drugs Market Outlook by Major Key Players

    New Jersey, United States, – The Global Pet Prescription Drugs Market report is one of the most comprehensive and significant addition to the market research archive of Market Research Intellect. Provides detailed research and analysis of the major aspects of the global Animal Prescription Drugs market. The market analysts who produced the report have provided detailed information on key growth drivers, restraints, challenges, trends, and opportunities to provide a comprehensive analysis of the global Animal Drugs market. Market players can use the analysis of market dynamics to plan effective growth strategies and prepare for future challenges in advance.

    Each trend in the global Animal Drugs market is carefully analyzed and studied by market analysts. Market analysts and researchers have performed an in-depth analysis of the global pet prescription drugs market using research methodologies such as pestle and Porter’s five forces analysis.

    They have provided accurate and reliable market data and helpful recommendations with the aim of helping players get an overview of the overall current and future market scenario. The Pet Prescription Drugs report includes in-depth research on potential segments including product types, applications, and end-users along with their contribution to the overall market size.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=228630

    The Major Players Covered By The Pet Prescription Drugs Markets:

    • Elanco Animal Health
    • Ceva Animal Health
    • MSD Animal Health
    • Zoetis
    • Virbac
    • Dechra
    • Vetoquinol
    • Animal care group
    • Ourofino Saude Animal
    • Boehringer Ingelheim

    Market segmentation of automated drug delivery systems:

    The Automated Drug Delivery Systems market report has categorized the market into segments comprising product type and application. Each segment is evaluated based on share and growth rate. Meanwhile, analysts looked at potential areas that could prove rewarding for builders in the years to come. The regional analysis includes reliable forecast on value and volume, thereby helping market players to gain in-depth insights into the entire industry.

    Prescription Medicines for Animals Market Breakdown by Type:

    • Oral type
    • Type of smear
    • Injection type
    • Spray type

    Animal Medicines Market Split By Application:

    • Pet
    • Livestock

    Based on geography: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina and Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa).

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=228630

    Scope of Pet Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Key questions answered in the report:

    • What is the growth potential of the pet prescription drug markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the main challenges that the global pet prescription drug markets may face in the future?
    • Who are the leading companies in the global veterinary drugs market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies envisioned by the players to maintain their grip on the global veterinary drugs market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-animal-prescription-drugs-market-size-and-forecast/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Animal Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical animal prescription drug breakdown data from 2016 to 2020 and forecast to 2021-2029.

    About Us: Market Research Intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-48080
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    An order for the distribution of fake prescription drugs

    MANHATTAN, Kansas (WIBW) – After the RCPD warned residents of the dangers of fake prescription drugs and fentanyl on Thursday, a man was arrested for distributing drugs on Friday.

    the Riley County Police Department said officers arrested Austin Dowling, 28, of Manhattan, for distributing controlled substances that caused an overdose in April. The alleged substances – Oxycodone and Fentanyl.

    RCPD shows the difference between fake and real Oxycodone(RCPD)

    The RCPD said an arrest warrant was issued for Dowling during an April 2021 opioid-related overdose investigation in Manhattan.

    The officer said he arrested Dowling after he was found driving near the intersection of Valleywood Dr. and Barnes Rd. And was taken into custody just before 11 a.m.

    The RCPD said Dowling was arrested on warrant on two counts of distributing possession with intent to distribute a controlled substance, distribution of a controlled substance causing grievous bodily harm and two counts of using a medium. communication for a drug transaction.

    Dowling was also arrested on two additional warrants for breach of probation and failure to appear. He is currently confined to Riley Co. jail with a total bond of $ 116,000.

    Copyright 2021 WIBW. All rights reserved.

    read more
    Prescription drugs

    2021 Prescription Drug Market Size Analysis by Major Companies and Forecast to 2028

    New Jersey, United States, – Market Research Intellect has been analyzing the prescription drug technology and markets since 2018. Since then, through the analysis of company research, we have been very close to the latest research and market developments.

    In addition, Market Research Intellect works closely with many clients to help them better understand technology and the market environment and develop innovation and commercialization strategies.

    Market Research Intellect offers extensive expertise in analyzing the prescription drug market. We have been in this industry for 20 years and have closely followed the rise and / or fall, success and / or disappointment of many emerging technologies during this time.

    This gives us a unique eye of experience when it comes to analyzing emerging technologies in electronic materials. This is very important as it helps to build a realistic market and technology roadmap that reflects the true potential of the technology based on its intrinsic characteristics and the true level of technology and business challenges it faces.

    Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=202717

    Further, the market revenue by region and country is provided in the Prescription Drugs report. The report’s authors also shed light on common business tactics adopted by players. The major players in the global bPrescription Drugs Market and their complete profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Prescription Drug market are mapped by the report. As a result of this report, major players in the global Prescription Drugs Market will be able to make right decisions and plan their strategies accordingly to stay ahead of the game.

    The competitive landscape is an essential aspect that any key player should be aware of. The report highlights the competitive scenario of the Global Prescription Drug Market to know the competition at the national and global level. The market experts also provided an overview of each major player in the global Prescription Drugs Market, taking into account key aspects such as business areas, production, and product portfolio. Further, the companies in the report are studied on the basis of key factors such as company size, market share, market growth, revenue, production volume, and profit.

    The main players covered by the prescription drugs markets:

    • Pfizer
    • rock
    • Sanofi
    • Johnson & johnson
    • Merck & Co. (msd)
    • Novartis
    • Abbvie
    • Gilead Sciences
    • Glaxosmithkline (gsk)
    • Amgen
    • Astrazeneca
    • Bristol-myers Squibb
    • Eli lilly
    • Suits you
    • Bayer
    • Novo Nordisk
    • Allergan
    • Takeda
    • Boehringer Ingelheim
    • Takeda

    Prescription Drugs Market Breakdown by Type:

    Prescription Drugs Market Split By Application:

    The Prescription Drug Market report has been separated into distinct categories such as product type, application, end user, and region. Each segment is rated on the basis of CAGR, share and growth potential. In the regional analysis, the report highlights the potential region, which is expected to generate opportunities in the global Prescription Drug Market in the coming years. This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the global Prescription Drugs Market and its growth potential in the coming years.

    Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202717

    Scope of Prescription Drugs Market Report

    Report attribute Details
    Market size available for years 2021 – 2028
    Reference year considered 2021
    Historical data 2015 – 2019
    Forecast period 2021 – 2028
    Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
    Covered segments Types, applications, end users, etc.
    Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
    Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
    Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
    Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

    Regional Prescription Drugs Market Analysis can be represented as follows:

    Each regional Prescription Drug industry is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and to ensure you stay ahead of the competition.

    Based on geography, the global prescription drug market has segmented as follows:

      • North America includes the United States, Canada and Mexico
      • Europe includes Germany, France, UK, Italy, Spain
      • South America includes Colombia, Argentina, Nigeria and Chile
      • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

    Key questions answered in the report:

    • What is the growth potential of the prescription drug markets?
    • Which product segment will take the lion’s share?
    • Which regional market will emerge as a precursor in the years to come?
    • Which application segment will grow at a sustained rate?
    • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
    • What are the main challenges that the global prescription drug markets could face in the future?
    • Who are the leading companies in the global prescription drug market?
    • What are the main trends that are positively impacting the growth of the market?
    • What are the growth strategies considered by the players to maintain their grip on the global Prescription Drugs market?

    For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/prescription-drugs-market-size-and-forecast/

    Visualize Prescription Drug Market Using Verified Market Intelligence: –

    Verified Market Intelligence is our BI platform for telling the story of this market. VMI provides in-depth predictive trends and accurate insight into over 20,000 emerging and niche markets to help you make key revenue impact decisions for a bright future. VMI provides a comprehensive overview and global competitive landscape by regions, countries and segments, as well as as key players in your market. Present your market reports and findings with built-in presentation capabilities, delivering over 70% of time and resources to investors, sales and marketing, R&D and product development. VMI supports data delivery in interactive Excel and PDF formats and provides over 15 key market indicators for your market.

    Visualize the Prescription Drug Market Using VMI @ https: //www.marketresearchintellect.com/mri-intelligence/

    The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Prescription Drugs market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and. applications. Historical prescription drug distribution data from 2016 to 2020 and forecast to 2021-2029.

    About us: Market research intelligence

    Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

    Contact us:
    Mr. Edwyne Fernandes
    United States: +1 (650) -781-480
    UK: +44 (753) -715-0008
    APAC: +61 (488) -85-9400
    US Toll Free: +1 (800) -782-1768

    Website: –https://www.marketresearchintellect.com/

    read more
    Prescription drugs

    Crackdown on the illegal sale of prescription drugs

    Police have launched a crackdown on the illegal sale of “prescription drugs” by pharmacies across the state.

    Acting on the instructions of the Director General of Police C. Sylendra Babu, special teams from the Narcotics Intelligence Bureau CID as well as officials from the Department of Food Safety and Drug Administration carried out surprise checks in pharmacies in several districts. The aim was to reduce the sale of these drugs without a proper prescription, especially to students and young people.

    According to Mahesh Kumar Aggarwal, ADGP, Crime, action has been taken against some pharmacies in the districts of Chengalpattu, Tiruvannamalai, Thanjavur, Salem, Vellore and Tirupattur. Police and the Department of Food Safety and Drug Administration had warned pharmacy owners not to sell over-the-counter “prescription drugs”. Surprise checks would continue, he said. Mr. Aggarwal called on the public to pass on any information about the illegal sale of controlled drugs by calling the hotline 10581 or sending a message via WhatsApp to 949810581. The public can email this contribution to spnibcid @ gmail. com.

    In a separate operation, the police conducted a special campaign in all neighborhoods against the sale of narcotics and psychotropic substances. During the operation, over 2,000 kg of ganja and 21 kg of heroin worth approximately 23 crore were seized and 838 accused persons arrested. Some of these suspects had sold contraband to drug addicts. The move follows instructions from Chief Minister Deputy Stalin, who briefed the Assembly on the matter and told officials at a recent meeting that strict measures should be taken to curb the sale of drugs such as ganja near educational institutions, the sources said.

    Intervention force

    Earlier this week, the national meeting of the Narco Coordination Center Apex Level Committee (NCORD) described drug abuse as a major national security threat that could be addressed with comprehensive coordination between central agencies. and drug control states. The meeting, which was attended by senior police officers from across the country, was asked to form a dedicated anti-narcotics task force, the sources added.

    read more
    Generic drugs

    Generic drugs provide information to doctors, so why is Health Canada promoting pharmaceutical brand names?

    Generic drug names are often long, but they can tell doctors what type of drug it is and how it works. But it is the brand names that appear first and most prominently in Health Canada documents.

    Brand names are widely used when we want to refer to a specific product – an Apple computer, a Tesla car. Sometimes brand names are used so widely that they take over – we ask for a Kleenex instead of a tissue.

    Drugs have two names. The brand name is the one chosen by the company that manufactures it and that company is the only one authorized to use the name. (The name proposed by the company is being reviewed by Health Canada.) Brand names are almost always short and catchy so that physicians will remember them.

    Generic names are assigned globally by the World Health Organization in collaboration with national naming authorities. These names are often long, but part of the reason for this is that they tell doctors about the pharmacological properties and / or chemical structure of the drug.

    The generic name of the US $ 2 million per patient new drug for spinal muscular atrophy is onasemnogene abeparvovec. The brand name is Zolgensma. Which one will physicians (and patients) retain and use? The answer is obvious.

    One of the associate editors of the Canadian Medical Association Journal notes that “some brand names are created to be reassuring or promising – so-called ‘benefit-oriented’ names such as Paxil, Celebrex, and Gluconorm – while they should in fact be prescribed with great care and taking into account the potential effects of the drug on each patient.

    Is using brand names the right way to talk about prescription drugs? Apparently, Health Canada thinks so. Do you want information on safety issues with a medicine? On the Canadian recall site, you will see the brand name in CAPITALS and the generic name in lower case and in parentheses.

    Want to see if there is a shortage of the drug your doctor just prescribed for you? Go to Drug Shortages Canada and you will find the brand names of the drugs, again in all caps.

    If you want to know why Health Canada approved a particular drug, the Basis of Approval Summary document will help you understand. But again, the brand name is the most important, and again it’s in all caps.

    What’s in a name?

    In medical school, students learn to use generic names. Medical journals require authors to use generic names in the articles they write. Does the name used by doctors matter? The answer is yes.

    When Australian anesthesiologists and doctors trained to be anesthesiologists at two university hospitals were given the brand names of the drugs, they could only correctly identify the therapeutic group from which the drug came in just over half of the cases. Without knowing which therapeutic group the drug was from, doctors could have accidentally used another drug from the same group or they could have used the drug incorrectly.

    The more money doctors received from drug companies in the form of meals, travel arrangements, and property royalties, the less likely they were to prescribe by generic name. Seeing pharmaceutical company sales representatives more frequently is associated with increased prescriptions for brand name products, resulting in more expensive prescriptions. Sales representatives also typically omit important information about the safety of the drugs they are promoting. Therefore, besides more expensive prescriptions, they can also be more likely to harm patients.

    Brand names, drug regulation (the domain of Health Canada) and drug promotion came together particularly blatantly in the case of buprenorphine-naloxone, the brand name Suboxone, an opioid drug used to treat addiction. opioids.

    Even though generic formulations of the drug have been available in Canada since 2013 (and even earlier in the United States), the drug is widely referred to by its brand name, including in the media, by policymakers, and by physicians.

    Brand education

    This happened in particular through the promotion of an “educational” program developed and implemented by Indivior, the company which owns the rights to Suboxone. In some provinces, completing this branded program is a prerequisite for prescribing buprenorphine-naloxone. The same strategy was used for a related injectable form of buprenorphine, also owned by Indivior.

    This use of the branded program is the case even though there are already some very good accredited, non-industry educational programs to teach proper opioid addiction care and prescriptions to doctors, nurses and pharmacists.

    The inclusion of the brand name in the title of this program is against recommended practices and accreditation standards for Canadian medical education programs.

    Yet the brand-name program is fully endorsed by Health Canada through that agency’s review and approval of the Suboxone Product Monograph. This document, which describes the nature of the drug and its approved uses in Canada, includes a description of the requirement to participate in the branded “training program”.

    As has been documented in the United States, Indivior and its parent company Reckitt Benckiser have engaged in various unscrupulous practices to promote their multibillion-dollar line of buprenorphine products – ultimately paying some of the largest fines in the world. pharmaceutical history of the United States. From this perspective, a branded “educational” program appears to be yet another vehicle for brand promotion, and one in which Health Canada is directly involved.

    When doctors use brand names, they may be less knowledgeable about the medications they are prescribing, their prescriptions cost more, and patients may be more likely to suffer from side effects. When Health Canada prioritizes brand names over generic names, it is actively contributing to all of these issues.

    Health Canada should know better and do better.

    In 2018-2021, Joel Lexchin received payments for writing a dissertation in a drug side effects action for Michael F. Smith, lawyer, and a second dissertation on the role of promotion in generating orders for Goodmans LLP and Canadian Institutes of Health Research for a presentation at a workshop on conflicts of interest in clinical practice guidelines. He is currently a member of research groups that receive funding from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is a member of the Foundation Board of Health Action International and the Board of Canadian Doctors for Medicare. It receives royalties from the University of Toronto Press and James Lorimer & Co. Ltd. for the books he wrote.

    Abhimanyu Sud has received funding or has been consulted by the Canadian Institutes of Health Research, Health Canada, the Association of Faculties of Medicine of Canada, the University of Toronto, the Center for Effective Practice and the Mississauga-Halton Local Health Integration Network for research and medical education related to opioid use and drug policy.

    read more
    Generic drugs

    Generic drugs provide information to physicians, so why is Health Canada promoting pharmaceutical brand names?

    Generic drug names are often long, but they can tell doctors what kind of drug it is and how it works. But it’s the brand names that appear first and most prominently in Health Canada documents.

    Brand names are widely used when we want to refer to a specific product – an Apple computer, a Tesla car. Sometimes brand names are so widely used that they take over – we ask for a Kleenex instead of a tissue.

    Medicines have two names. The brand name is the one chosen by the company that manufactures it and this company is the only one authorized to use the name. (The company’s proposed name is reviewed by Health Canada.) Brand names are almost always short and catchy so doctors will remember them.

    Generic names are assigned globally by the World Health Organization in conjunction with national naming authorities. These names are often long, but part of the reason for their length is that they inform doctors about the pharmacological property and/or chemical structure of the drug.

    The generic name of the US$2 million per patient new drug for spinal muscular atrophy is onasemnogene abeparvovec. The brand name is Zolgensma. Which one will doctors (and patients) remember and use? The answer is obvious.

    One of the associate editors of the Canadian Medical Association Journal points out that “some brand names are created to be reassuring or promising — so-called ‘benefit-based’ names like Paxil, Celebrex and Gluconorm — whereas they actually need to be prescribed with great care and taking into account the potential effects of the drug on each patient.

    Is using brand names the right way to talk about prescription drugs? Apparently Health Canada thinks so. Would you like information on the safety issues of a medicine? On the Canada recall site, you will see the brand name in UPPERCASE and the generic name in lowercase and in parentheses.

    Want to see if there’s a shortage of the drug your doctor just wrote you a prescription for? Go to Drug Shortages in Canada and you will find the brand names of the drugs, again in all caps.

    If you want to know why Health Canada approved a particular drug, the Summary of Reasons for Approval document will help you understand. But again, the brand name is the most important, and again it’s in capitals.

    What’s in a name?

    In medical school, students learn to use generic names. Medical journals ask authors to use generic names in the articles they write. Does the name used by doctors matter? The answer is yes.

    When Australian anesthetists and physicians training to become anesthetists at two teaching hospitals were given the brand names of the drugs, they were only able to correctly identify the therapeutic group the drug came from in just over half of the case. Without knowing which therapeutic group the medicine came from, doctors might have accidentally used another medicine from the same group or used the medicine incorrectly.

    The more money physicians received from drug companies in the form of meals, travel, and property royalties, the less likely they were to prescribe by generic name. Seeing pharmaceutical company sales representatives more frequently is associated with more prescriptions for brand name drugs, which translates into more expensive prescriptions. Sales reps also typically leave out important safety information about the drugs they promote, so in addition to prescriptions costing more, they may also be more likely to harm patients.

    Brand names, drug regulation (the domain of Health Canada) and pharmaceutical promotion have come together in a particularly blatant way in the case of buprenorphine-naloxone, brand name Suboxone – an opioid drug used to treat drug addiction. opioids.

    Even though generic formulations of the drug have been available in Canada since 2013 (and even earlier in the United States), the drug is widely referred to by its brand name, including in the media, by policymakers, and by doctors.

    brand education

    Part of this happened through the promotion of an “educational” program developed and delivered by Indivior, the company that owns the rights to Suboxone. In some provinces, following this branded program is a prerequisite for being able to prescribe buprenorphine-naloxone. The same strategy was executed for a related injectable form of buprenorphine, also owned by Indivior.

    This use of the branded program is the case even though there are already very good, accredited, non-industry educational programs to teach proper opioid addiction care and prescribing to physicians, nurses, and pharmacists.

    The inclusion of the brand name in the title of this program is against recommended practices and standards for accreditation of medical education programs in Canada.

    Yet, the branded program is fully sanctioned by Health Canada through that body’s review and approval of the Suboxone product monograph. This document, which describes the nature of the drug and its approved uses in Canada, includes a description of the requirement for participation in the branded “training program”.

    As documented in the United States, Indivior and its parent company Reckitt Benckiser engaged in a variety of unscrupulous practices to promote their multi-billion dollar line of buprenorphine products – ultimately paying some of the largest fines in the industry. American pharmaceutical history. From this perspective, a branded “educational” program seems to be one more vehicle for promoting a brand, in which Health Canada is directly complicit.

    When doctors use brand names, they may be less knowledgeable about the drugs they prescribe, their prescriptions cost more, and patients may be more likely to experience side effects. When Health Canada prioritizes brand names over generic names, it is actively contributing to all of these issues.

    Health Canada should know better and must do better.

    In 2018-2021, Joel Lexchin received payments for writing a memoir in a drug side effects action for attorney Michael F. Smith and a second memoir on the role of promotion in the generation of orders for Goodmans LLP and Canadian Institutes of Health Research for a presentation at a workshop on conflict of interest in clinical practice guidelines. He is currently a member of research groups that receive funding from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is a member of the Foundation Board of Health Action International and of the Council of Canadian Physicians for Medicare. He receives royalties from the University of Toronto Press and James Lorimer & Co. Ltd. for the books he wrote.

    Abhimanyu Sud has received funding from or consulted with the Canadian Institutes of Health Research, Health Canada, the Association of Faculties of Medicine of Canada, the University of Toronto, the Center for Effective Practice, and the Mississauga-Halton Local Health Integration Network for research and medical education regarding opioid use and drug policy.

    read more
    Prescription drugs

    Florida to become the first state to import prescription drugs from Canada

    Plans to import cheaper prescription drugs from Canada have been in the works for years. In Florida, it could finally happen sooner than many realize – perhaps as early as early next year.

    Florida Health Care Administration Secretary Simone Marsiller recently told a state Senate panel, “Hopefully we can start importing in the first quarter of the new year.

    The fact that, while they differ in everything else, President Joe Biden and Governor Ron DeSantis both support her.

    “If you have drugs in Canada, the same drug costs 25 percent of what it costs here. We want Floridians to be able to share those discounts,” DeSantis said.

    A RAND study looked at drug prices in nearly 40 countries and found that the United States pays more than all prescription drugs. Average prices have risen by about 250% in the United States or, as President Biden recently noted, “about two to three times what other countries pay.”

    In the United States, insurance companies cover most of the cost of drugs for those who are insured. But those without coverage and those with insurance that doesn’t cover their particular medications burn themselves or go without.

    In Canada, prescription drugs are much cheaper because the Canadian government regulates and controls the prices. So the idea is to help Americans take advantage of Canada’s price controls.

    As you might expect, the pharmaceutical lobby opposes plans to import prescription drugs from Canada. He ran advertisements questioning the safety of using drugs imported from other countries – an advertisement even stating: “Too many have already died from counterfeit drugs; are you willing to take that risk? “

    PREVIOUS: Advertising campaign claims imported drugs are risky for Floridians

    But Governor Ron DeSantis says we can trust Canada – and Congress agrees. He passed a law allowing commercial imports of drugs from Canada in 2003. Sixteen years later, Florida was one of the first states to begin the process.

    The state has spent the past two years putting the system in place, which the governor says will keep it safe.

    “This program only applies if we show that we are providing drugs that are safe and cheaper than what we already have,” said Governor DeSantis.

    The final step is FDA clearance, and President Biden has already ordered the FDA to get to work. As soon as the FDA gives the green light, Florida plans to take action.

    PREVIOUS: Florida drug import plan moves forward

    Life Science Logistics in Lakeland is ready at this time. Its warehouses would start filling up with boxes and bottles of pills – all prescription drugs from Canada.

    “We’re ready to start importing in 90 days,” a company spokesperson told FOX 13.

    The state has not defined or announced certain details, such as which drugs will come first. State officials have suggested they could start with drugs to treat diabetes, hepatitis, COPD and / or HIV / AIDS.

    They will likely start with a small number of drugs for those with Medicaid, then for others with public insurance. Further expansion would be based on the success of the program as well as demand.

    There are some wrinkles in the plane that need to be addressed. The pharmaceutical industry is challenging it in court. And supplies can also be a problem, as Canada cannot supply its own citizens while having enough for the United States, or even all of Florida, for that matter. Shipments should be considered “surplus” or “surplus” in the Canadian market.

    But after years of planning, Florida could overcome these hurdles in 2022, triggering big changes in where we get our drugs and how much we pay for them.

    read more
    Prescription drugs

    Counterfeit prescription drugs and illicit cigarettes worth hundreds of thousands of pounds seized in Orford raid

    TWO men have been arrested after police seized hundreds of thousands of pounds of counterfeit prescription drugs and illicit cigarettes following a raid in Orford, Warrington.

    Over the past several months, agents from the Warrington Problem-Solving Team have conducted a detailed investigation into the illegal supply of prescription drugs in the town.

    On Tuesday, December 21, the team conducted a warrant at an address in Orford where they recovered thousands of counterfeit prescription drugs, around £ 200,000 of counterfeit cigarettes and tobacco and a large amount of stolen wine and spirits .

    Two local men, aged 67 and 31, were also arrested at the address on suspicion of money laundering and receiving stolen property.

    The couple have since been released under investigation pending further investigation.

    Sergeant Anthony Sullivan of the Warrington Problem Solving Team said: “This warrant is part of our ongoing investigation into the supply of illegal drugs.

    “Illegal drugs have no place in our city; they are ruining the lives of some of the most vulnerable people in our community, while lining the pockets of shameless criminals.

    “I want to reassure the public that we are doing everything we can to crack down on this type of activity.

    “However, we cannot do our job without the help of the public and cannot repeat the message enough that you are essential in helping your community by reporting illegal activity to us.

    “If anyone has any information about illegal drug activity or any other criminal activity taking place in your community, they should report it to Cheshire Police on 101 or www.cheshire.police.uk/tua .

    “Information may also be reported anonymously, via Crimestoppers, on 0800 555 111.”

    read more
    Prescription drugs

    The future of the safe harbor for prescription drugs remains uncertain

    In November 2020, four months after the Trump administration issued a series of executive orders reiterating its policy goals on reducing costs for consumers of prescription drugs and leading the Department of Health and Human Services, Office of the Inspector General (“HHS-OIG”) to implement these policy objectives, the HHS-OIG has issued a Final rule to amend certain provisions of the Safe Harbor regulation under the Federal Anti-Recoil Act (“AKS”). The final rule included three key provisions:

    1. Removal Safe Harbor protection for manufacturer discounts paid directly or indirectly through a Pharmacy Benefits Manager (“PBM”) to Medicare Part D or Medicare Advantage plans (the “Discount Rule”). “);
    2. Creation of a new safe harbor to protect point-of-sale (“POS”) price reductions paid by manufacturers to Medicare Part D plans, Medicare Advantage plans and Medicaid managed care organizations (“MCO”); and
    3. Creation of a new safe harbor to protect the fair market value (FMV) service fees paid to PBMs by manufacturers.

    The final rule imposed an effective date of January 1, 2022 for the discount rule. However, in January 2021, two months after the final rule was issued and in a lawsuit by the Pharmaceutical Care Management Association challenging the surrender rule, the Biden administration agreed to postpone the entry date. in force of the discount rule on January 1, 2023, as reflected in a Order by the United States District Court for the District of Columbia.

    In the meantime, however, Congress passed the Law on investment in infrastructure and employment (the “Infrastructure Act”). This law, signed by President Biden on November 15, 2021, further delayed the implementation of the discount rule until January 2026. Thus, the rule, which many believed would be removed as part of the payment of the cost of the infrastructure bill, was still alive, if only delayed until the middle of the next presidential term.

    Then, on November 19, 2021, the House of Representatives adopted the Rebuild Better Act (“BBBA”), which included the last nail in the coffin of the ruler. Section 139301 of this bill stated that the HHS-OIG “shall not implement, administer or enforce” any of the provisions of the rule. This was the total repeal that had been provided for in the previous law.

    The bill went to the Senate before Thanksgiving and was to go through a reconciliation process that is exempt from Senate filibuster rules and would only have required all 50 Democratic and Independent Senators to vote for, the Deputy Speaker Kamala Harris playing the tiebreaker role. 51st vote in favor of the bill. However, Senator Joe Manchin (D – W. Va.) Recently announced his opposition to the bill, and his vote could prevent the bill from being passed. If the BBBA is not passed by the Senate, its ban on implementing the final rule will fail with it, and unless any further action is taken, the discount rule will take effect in January 2026.

    As a result, it is not clear until the Senate took action in January whether PBMs, MCOs, Part D plans and Medicare Advantage plans will need to worry about these changes to the anti-rollback provisions. . If the Senate does not pass the bill, then all of these entities should begin reviewing their policies and procedures over the next four years in preparation for the rule coming into force.

    Reed Smith will continue to monitor developments related to the discount rule and its impact on the industry.

    read more
    Generic drugs

    Generic Drugs Market in United States, By Type, By Application, By Drug Delivery Method, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast And Opportunity, 2026

    Generic Drugs Market in United States, By Type (Small Molecule Generics Vs Biosimilars), By Application (Cardiovascular Diseases, Diabetes, Neurology, Oncology, Infectious Diseases, Others), By Mode Of Drug Administration (Oral, Topical, parenteral, other), by form (tablet, capsule, injection, other), by source (in-house or contract manufacturing organizations), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, others), by region, competition, forecast and opportunities, 2026

    New York, December 23, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Generic Drugs Market in United States, By Type, By Application, By Drug Administration, By Form, By Source, by distribution Channel, by region, competition, forecast and opportunities, 2026 “- https://www.reportlinker.com/p06192577/?utm_source=GNW

    The US generic drug market was valued at USD 70.78 billion in 2020 and is expected to grow at a CAGR of 9.43% during the forecast period and may reach a market value of USD 126.74 billion by 2026. Factors such as the profitable nature of generic drugs and increasing demand from developing economies are primarily responsible for this estimate of the futuristic growth of the US generic drug market over the next five years. Generic drugs do not require extensive research and development like prescription drugs and patented drugs. Market players and research institutes invest heavily in pharmaceutical patents. In addition, FDA approvals for generic drugs are not required because the generic drugs contain the same composition as the previously patented drug and thus support the growth of the US generic drug market over the next five years. The healthcare industry in the United States, in terms of generic drugs, has gone from an 80% growth in 2020 to a previous growth of 20% in 2015.
    Increasing exports of generic drugs to developing economies like Kenya, India etc. also confirms the growth of the US generic drug market in the next five years.
    The generic drugs market in the United States is segmented on the basis of drug type, mode of administration, form, source of manufacture, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars.

    Small Molecule Generics are expected to achieve the largest market revenue shares and dominate the market segment over the next five years due to their simpler and easier manufacturing processes. Manufacturers of generic drugs when producing generics with small molecules are required to prove that the end product contains chemical compounds identical to those of the patented drug.

    With similar pharmacokinetic functions and properties, the generic small molecule is accepted. In addition, the demand for cost-effective generic drugs is expected to further support the growth of the US generic drug market over the next five years.
    Based on the applications, the market may be fragmented into cardiovascular disease, diabetes, neurology, oncology, infectious disease, and others. Cardiovascular disease is expected to dominate the market segment while recording the largest market revenue shares over the next five years on account of growing cardiovascular disease cases in the United States.

    Additionally, the increased demand for the treatment and extended drug regimens is driving the growth of the cardiovascular disease sub-segment while supporting the growth of the generic drug market in the United States over the next five years. Increased pharmaceutical research and development for the oncologic disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.
    Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sandoz US, Endo Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Abbott Laboratories Inc., Eli Lilly and Company, Sun Pharma Inc., Lupine Pharmaceuticals, Inc. and Zydus Pharmaceutical USA Inc. is among the major market players in United States leading the growth of the generic drug market.

    Years considered for this report:

    Historical years: 2016-2019
    Baseline year: 2020
    Estimated year: 2021
    Forecast period: 2022-2026

    Goal of the study:

    • To analyze the historical growth in the market size of the generic drugs market in the United States from 2016 to 2020.
    • Estimate and forecast the US generic drugs market size from 2021 to 2026 and the growth rate to 2026.
    • To categorize and forecast the United States generic drug market on the basis of drug type, application, drug administration route, form, source, distribution channel, competitive landscape, and regional distribution.
    • Identify the dominant region or segment in the generic drug market in the United States.
    • Identify the drivers and challenges of the US generic drug market.
    • Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the US generic drug market.
    • Identify and analyze the profile of the main players operating in the US generic drug market.
    • Identify the main sustainable strategies adopted by the players in the generic drugs market in the United States.
    The analyst performed both primary and secondary research exhaustive for this study. Initially, the analyst found a list of manufacturers around the world.

    Subsequently, the analyst conducted primary research surveys of the identified companies. During the interviews, respondents were also asked about their competitors.

    Using this technique, the analyst could include manufacturers who could not be identified due to the limitations of secondary research. The analyst looked at manufacturers, distribution channels and the presence of all major players across the globe.
    The analyst calculated the size of the generic drugs market in the United States using a bottom-up approach, in which data from various end-user segments was recorded and forecast for years to come. The analyst obtained these values ​​from industry experts and company representatives and validated them externally by analyzing historical data for these types of products and applications to arrive at an appropriate overall market size.

    Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations, and financial reports were also investigated by the analyst.

    Key target audience:

    • Manufacturers, suppliers, distributors and other stakeholders of generic drugs
    • Government bodies such as regulatory authorities and policy makers
    • Organizations, forums and alliances related to generic drugs
    Market research and consulting firms
    The study is useful in providing answers to several critical questions that are important to industry players such as manufacturers, suppliers, partners, end users, etc., in addition to enabling them to develop investment strategies and capitalize on market opportunities.

    Scope of the report:

    In this report, the United States Generic Drugs Market has been segmented into the following categories in addition to industry trends which have also been detailed below:
    • Generic Drugs Market in United States, by Type:
    o Generic Small Molecule
    o Biosimilars
    • United States Generic Drugs Market, By Application:
    o Cardiovascular diseases
    o Diabetes
    o Neurology
    o Oncology
    o Infectious diseases
    o Others
    • Generic drug market in the United States, by drug administration method:
    o Oral
    o Parenteral
    o Topical
    o Others
    • Generic Drugs Market in United States, by Form:
    Tablet
    o Capsule
    o Injection
    o Others
    • Generic drugs in the United States, by source:
    o In-house manufacturing
    o Contract manufacturing organizations
    • Generic drug market in the United States, by distribution channel:
    o Retail pharmacies
    o Online pharmacies
    o Hospital pharmacies
    o Others
    • Generic drug market in United States, by region:
    o South
    o Midwest
    o West
    o North East

    Competitive landscape

    Company Profiles: Detailed analysis of the major companies present in the global generic drugs market.

    Customizations available:

    With the market data provided, we offer customizations based on the specific needs of a business. The following customization options are available for the report:

    Company Info

    • Detailed analysis and profiling of additional market players (up to five).
    Read the full report: https://www.reportlinker.com/p06192577/?utm_source=GNW

    About Reportlinker
    ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

    __________________________

    CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
    read more
    Generic drugs

    Generic Inhalation and Nasal Spray Market $ 6.87 Billion by Indication, Age Group, Class, Route, Distribution Channel and Region

    Dublin, December 23, 2021 (GLOBE NEWSWIRE) – The ‘Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative impact of COVID- Report 19 “has been added to ResearchAndMarkets.com offer.

    The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

    Market statistics
    The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

    Market segmentation and coverage

    This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

    • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

    • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

    • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

    • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

    • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

    • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

    Companies mentioned

    • Allergan plc

    • Altaire Pharmaceuticals inc.

    • Beximco Pharmaceuticals Ltd.

    • Catalent Pharma Solutions

    • Cipla Limited

    • Hikma Pharmaceuticals PLC

    • Mylan NV

    • Navajo Manufacturing Company Inc.

    • Pharmaceutical company Nephron

    • Perrigo Company plc

    • Preferred Pharmaceuticals Inc.

    • Sandoz International GmbH

    • Sheffield Pharmaceuticals LLC

    • Sun Pharmaceutical Industries Ltd.

    • Teva Pharmaceutical Industries Ltd.

    Cumulative impact of COVID-19
    COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insights on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

    Competitive strategic window
    The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

    FPNV positioning matrix
    The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

    Market share analysis
    The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

    Competitive scenario
    The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of competitors, thus providing information to improve products and services.

    Main topics covered:

    1. Preface
    1.1. Objectives of the study
    1.2. Market segmentation and coverage
    1.3. Years taken into account for the study
    1.4. Currency and price
    1.5. Language
    1.6. Limits
    1.7. Hypotheses
    1.8. Stakeholders

    2. Research methodology

    3. Executive summary

    4. Market overview
    4.1. introduction
    4.2. Cumulative impact of COVID-19

    5. Market dynamics
    5.1. introduction
    5.2. Conductors
    5.2.1. Low cost associated with generic prescription drugs
    5.2.2. Increased prevalence of asthma and COPD disorders
    5.2.3. High cost of health care in developed regions
    5.3. Constraints
    5.3.1. Strict regulations for generic drugs
    5.4. Opportunities
    5.4.1. Successful drug patents expire and FDA approvals increased
    5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care
    5.5. Challenges
    5.5.1. Pressure on prices due to the presence of several players in the segment

    6. Generic Inhalation and Nasal Sprays Market, by Indication
    6.1. introduction
    6.2. Allergic rhinitis
    6.3. Asthma
    6.4. COPD

    7. Generic Inhalation Nasal Spray Drugs Market, By Age Group
    7.1. introduction
    7.2. Adults
    7.3. Children 2 to 5
    7.4. Children 6 to 12

    8. Generic Inhalation and Nasal Spray Drugs Market, By Class
    8.1. introduction
    8.2. Allergy blocker
    8.3. Anticholinergic
    8.4. Antihistamine
    8.5. decongestant
    8.6. Mast cell inhibitor
    8.7. Nasal steroid

    9. Generic inhalation and nasal sprays market, by road
    9.1. introduction
    9.2. Inhalation
    9.3. Nasal spray
    9.4. Tropical Lotion

    10. Generic inhalation and nasal sprays market, by distribution channel
    10.1. introduction
    10.2. Hospital medical store
    10.3. Online pharmacy
    10.4. Retail pharmacy

    11. America Generic Inhalation and Nasal Spray Market

    12. Asia-Pacific Generic Inhalation and Nasal Spray Market

    13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

    14. Competitive landscape
    14.1. FPNV positioning matrix
    14.1.1. Quadrants
    14.1.2. Business strategy
    14.1.3. Product satisfaction
    14.2. Market ranking analysis
    14.3. Market share analysis, by key player
    14.4. Competitive scenario
    14.4.1. Merger & Acquisition
    14.4.2. Agreement, collaboration and partnership
    14.4.3. New product launch and improvement
    14.4.4. Investment and financing
    14.4.5. Awards, recognition and expansion

    15. Company usability profiles

    For more information on this report visit https://www.researchandmarkets.com/r/374c1l

    CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
    read more
    Generic drugs

    U.S. Generic Drugs Market, By Type, By

    New York, 23 Dec. 2021 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of United States Generic Drugs Market, By Type, By Application, By Mode of Drug Delivery, By Form, By Source, By Distribution Channel, By Region, Competition, Forecast and Opportunities, 2026″ – https://www.reportlinker.com/p06192577/?utm_source=GNW

    The generic drugs market in the United States was valued at USD 70.78 billion in 2020 and is expected to grow at a CAGR of 9.43% during the forecast period and may reach a market value of USD 126.74 billion. ‘by 2026. Factors such as the cost-effective nature of generic drugs and growing demand from developing economies are largely responsible for this futuristic growth estimate of the US generic drugs market over the next five years. Generic drugs do not require extensive research and development like prescription drugs and brand name drugs. Market players and research institutes are investing heavily in patented pharmaceuticals. Moreover, FDA approvals for generic drugs are not required since generic drugs contain the same composition as that of the previously patented drug and thus support the growth of the generic drug market in the United States over the next five years. . The healthcare industry in the United States, in terms of generic drugs, has gone from 80% growth in 2020 to a previous growth of 20% in 2015.
    The increase in generic drug exports to developing economies like Kenya, India, etc. also justifies the growth of the US generic drug market in the next five years.
    The US generic drugs market is segmented on the basis of type, drug delivery route, form, manufacturing source, application, company, and regional distribution. Based on type, the market can be divided into generics and small molecule biosimilars.

    Small molecule generics are expected to register the largest market revenue shares and dominate the market segment over the next five years owing to its simpler and easier manufacturing processes. Generic drug manufacturers when producing small molecule generics are required to prove that the final product contains the same chemical compounds as the patented drug.

    With similar functions and pharmacokinetic properties, the generic small molecule is accepted. Additionally, the demand for cost-effective generic drugs is expected to further support the growth of the generic drugs market in the United States over the next five years.
    Based on the applications, the market can be fragmented into cardiovascular diseases, diabetes, neurology, oncology, infectious diseases and others. Cardiovascular diseases are expected to dominate the market segment while recording the highest market revenue shares over the next five years on account of the increasing cases of cardiovascular diseases in the United States.

    Additionally, increased demand for treatment and extended medication protocols is driving the growth of cardiovascular disease sub-segment while sustaining the growth of the generic drug market in the United States over the next five years. Rising pharmaceutical research and development for the oncology disease is expected to drive the growth of the oncology sub-segment and drive the growth of the US generic drug market over the next five years.
    Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sandoz US, Endo Pharmaceuticals Inc., Aurobindo Pharma USA, Inc., Abbott Laboratories Inc., Eli Lilly and Company, Sun Pharma Inc., Lupine Pharmaceuticals, Inc. and Zydus Pharmaceutical USA Inc. is among the major market players in the United States leading the growth of the generic drugs market.

    Years considered for this report:

    Historical years: 2016-2019
    Reference year: 2020
    Estimated year: 2021
    Forecast period: 2022-2026

    Goal of the study:

    • To analyze the historical growth of the market size of the generic drugs market in the United States from 2016 to 2020.
    • Estimate and forecast the market size of Generic Drugs Market in United States from 2021 to 2026 and the growth rate till 2026.
    • To classify and forecast the U.S. Generic Drugs Market based on type, application, mode of drug delivery, form, source, distribution channel, competitive landscape, and regional distribution .
    • Identify the dominant region or segment in the generic drug market in the United States.
    • To identify drivers and challenges for the generic drug market in the United States.
    • Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the generic drug market in the United States.
    • Identify and analyze the profile of the main players operating in the generic drugs market in the United States.
    • Identify the key sustainable strategies adopted by market players in the generic drugs market in the United States.
    The analyst conducted extensive primary and secondary research for this study. Initially, the analyst procured a list of manufacturers across the world.

    Subsequently, the analyst conducted primary research surveys with the identified companies. During the interviews, the respondents were also asked about their competitors.

    Using this technique, the analyst could include manufacturers that could not be identified due to secondary research limitations. The analyst looked at the manufacturers, distribution channels and presence of all major players across the globe.
    The analyst calculated the size of the generic drugs market in the United States using a bottom-up approach, in which data from various end-user segments was recorded and forecasted for the coming years. The analyst obtained these values ​​from industry experts and company representatives and validated them externally by analyzing historical data of these types of products and applications to derive an appropriate overall market size.

    Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by the analyst.

    Key target audience:

    • Manufacturers, suppliers, distributors and other stakeholders of generic medicines
    • Government bodies such as regulators and policy makers
    • Organizations, forums and alliances related to generic medicines
    • Market research and consulting firms
    The study is helpful in providing answers to several critical questions which are important for industry stakeholders such as manufacturers, suppliers, partners, end users etc. besides enabling them to elaborate investment strategies and to capitalize on market opportunities.

    Report Scope:

    In this report, the generic drugs market in the United States has been segmented into the following categories, in addition to industry trends which have also been detailed below:
    • Generic drugs market in the United States, by type:
    o Generic Small Molecule
    o Biosimilars
    • Generic drugs market in the United States, by application:
    o Cardiovascular diseases
    o Diabetes
    o Neurology
    o Oncology
    o Infectious diseases
    o Others
    • Generic drug market in the United States, by mode of drug administration:
    o Oral
    o Parenteral
    o Topical
    o Others
    • Generic drugs market in the United States, by form:
    o Tablet
    o Capsule
    o Injection
    o Others
    • Generic drugs in the United States, by source:
    o In-house manufacturing
    o Contract manufacturing organizations
    • Generic drugs market in the United States, by distribution channel:
    o Retail pharmacies
    o Online pharmacies
    o Hospital pharmacies
    o Others
    • Generic drugs market in the United States, by region:
    o South
    o Midwest
    o West
    o Northeast

    Competitive landscape

    Company Profiles: Detailed analysis of the major companies present in the global generic drugs market.

    Customizations available:

    With the market data provided, we offer customizations based on a company’s specific needs. The following customization options are available for the report:

    Company information

    • Detailed analysis and profiling of other market players (up to five).
    Read the full report: https://www.reportlinker.com/p06192577/?utm_source=GNW

    About Reportlinker
    ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

    __________________________

    
            
    read more
    Generic drugs

    PODIUM | Bennet helps exempt generic drugs through BBB | Opinion






    Maya wheeler


    “About 18 million Americans, or 7% of American adults, say they recently couldn’t afford at least one prescription drug for their household, according to a new poll from Gallup and West Health.”

    Democrats, Republicans and Independents grapple with even insured health care costs as prescription drug prices continue to rise. No one should be forced to choose between filling their prescriptions or their rent, gas, heat or food.

    However, what is not clear is whether our elected officials choose between the people they represent and the Big Pharma lobbyists who write checks to their campaigns.

    President Biden’s Build Back Better Act includes provisions that could go a long way toward implementing these long-promised drug reform policies. The new $ 35 cap on out-of-pocket expenses for insulin for patients on commercial or health insurance plans is a big step forward for vulnerable patients.

    High drug prices disproportionately impact the sickest and poorest Americans. Nearly one in 10 Americans with three or more chronic conditions said they had to skip a drug purchase in the past three months, compared to about one in 25 people without any chronic illness, according to a Gallup poll. Skipping the purchase or rationing of drugs can be fatal. This was illustrated by NPR with the story of Nicole Smith-Holt, who lost her son three days before his next payday because he couldn’t afford to fill his insulin prescription. The price of insulin, which has no generic equivalent, has more than doubled since 2012. Those most in need of prescription drugs are also most likely to be negatively impacted by lack of access affordable drugs.

    For minority communities, access to affordable insulin is an even bigger problem. Almost one in five black adults has diabetes, a rate more than double the white patient population. The high cost of care also contributes to a higher death rate. Black Americans die twice as fast as their counterparts from diabetes.

    We have already seen the ugly health disparities in our system at the forefront of the COVID-19 pandemic, as patients of color have died at much higher rates than whites. Capping out-of-pocket spending will immediately benefit all patients, and especially those in the minority community who need help the most.

    However, the Build Back Better Act is not perfect and some provisions could actually make drugs more expensive and less accessible. The inflation price rebate penalty looks good – drug makers should not be allowed to increase their prices more than the rate of inflation. But it really only works for brand name drugs, which have a government-protected monopoly. This allows companies making the most expensive drugs to set their prices as high as they want.

    Generic drug makers, on the other hand, face much larger price fluctuations and a more competitive market, resulting in lower costs for consumers. And generic drug prices continue to decline on average year over year. The prices of brand-name drugs, meanwhile, continue to be “unsustainable, unjustifiable and unfair,” according to a recent report by Democrats in Congress. So it does not make sense to penalize a generic drug costing $ 1 for raising its price to $ 1.04, but to give a free pass to a large pharmaceutical company raising the price of its brand name drug by 10,000. $ to $ 10,299. As written, this is what the in-house version of the Build Back Better Act would do.

    Fortunately, Senator Michael Bennet and his colleagues on the Senate Finance Committee took note and exempted generic drugs from the penalty. It is the right decision, politically and, more importantly, morally.

    Generics and biosimilars account for 90% of prescriptions filled in the United States, but brand name drugs represent 80% of spending. For example, the osteoporosis drug Fosamax cost $ 2.60 per day or $ 80 per month. Now its generic version costs $ 0.28 per day, less than $ 9 per month.

    These savings and the availability of cheaper drugs could be jeopardized by these new federal government policies if they are not changed. Low-income and working-class families, as well as seniors living on fixed incomes, would be at risk.

    Senator Bennet has repeatedly shown his willingness to learn complex policies, understand its long-term impacts and make the necessary changes. The White House Biden should again heed his leadership and support the Senate version of the Build Back Better Act that makes the bill more patient-friendly.

    Elected officials have been promising drug prices to drop for a long, long time. To come so close, and then fall victim to unintended political consequences thanks to the powerful lobbying of Big Pharma, would be a grave mistake.

    Maya Wheeler is Executive Director of the African Chamber of Commerce, Colorado, and former Chair of the Colorado African American Democrats Initiative (AAICD) with the CO Democratic Party.

    read more
    Prescription drugs

    Marijuana, Many Prescription Drugs Lead to Impaired Driving Chroniclers

    December is National Impaired Driving Prevention Month. You’ve probably heard all about the dangers of drunk driving, but do you know the dangers of drunk driving? Driving under the influence of over-the-counter drugs, prescription drugs, marijuana, or any other mind-altering medication makes it dangerous to drive a vehicle.

    Unfortunately, research indicates that the prevalence of the drug is on the rise among drivers. According to the trauma centers studied from October to December 2020, 56% of drivers involved in serious injuries or fatalities have tested positive for at least one drug.

    How common is drug-impaired driving? After alcohol, marijuana is the most commonly used drug while driving. In 2020, 12.6 million people (aged 16 and over) are believed to have driven after using illicit drugs. Of that total, 11.7 million people were under the influence of marijuana. In another recent survey, 22% of teens admitted that driving with heavy marijuana use is common among their friends. 3.6 million young people between the ages of 16 and 25 admit to having driven under the influence of marijuana in the past year, according to the 2020 National Survey on Drug Use and Health. These statistics are of great concern, given that drugs such as marijuana affect the way people drive, endangering drivers, their passengers and others on the road. Drugs can affect a driver’s perception, attention, balance, coordination, reaction time, and other skills they need to stay alert and safe.

    The National Highway Traffic Safety Administration’s Drug and Alcohol Crash Risk Study found that marijuana users are more likely to be involved in crashes. However, the increased risk may be due in part to the fact that marijuana users are more likely to be young men, who are generally at higher risk for accidents. Either way, research shows that marijuana slows reaction time, impairs driver focus and attention, and reduces hand-eye coordination. The THC in marijuana also interferes with a driver’s ability to multitask, an essential skill necessary for people behind the wheel.

    Impaired driving can also occur after using prescription or over-the-counter medications such as cough suppressants, antihistamines, sleeping pills, and anti-anxiety medications. In some cases, even small amounts of these substances can impair driving skills by impairing perception, mental processes, attention, balance, coordination and other skills required for safe driving. For this reason, many prescription drugs have warning labels that advise against using machines and driving motor vehicles for a period of time after use.

    Car crashes are the leading cause of death for people aged 16 to 19. PARENTS – warn your teenagers not to drive after using marijuana or other drugs, and not to get in a car with a driver who has used marijuana or other drugs! When teens’ driving inexperience is combined with the use of drugs that can affect cognitive and motor skills, the results can be tragic. Help protect your kids and your community this holiday season by helping to keep all impaired drivers off the roads.

    Kelly Sickafoose is Secretary of the Northeast Regional Advisory Council of Community Anti-Drug Coalitions, Executive Director of Drug Free Adams County and Coordinator of Adams County Drug Court. She serves in an advisory capacity in LaGrange and Steuben counties. Contact her at [email protected]

    read more
    Generic drugs

    Global Generic Inhalation and Nasal Spray Market Expected to Reach Over $ 10 Billion by 2026 – ResearchAndMarkets.com

    DUBLIN – (COMMERCIAL THREAD) – The report “Generic Inhalation Drugs and Nasal Sprays Market Research Report by Indication, Age Group, Class, Route, Distribution Channel and Region – Global Forecast to 2026 – Cumulative Impact of COVID -19 “has been added to ResearchAndMarkets.com offer.

    The global generic inhalation and nasal spray market size was estimated to be USD 6,392.52 million in 2020, is expected to reach USD 6,879.55 million in 2021, and is expected to grow at a CAGR of 7.95% to reach 10,119 , 95 million USD by 2026.

    Market statistics

    The report provides market size and forecast in five major currencies: USD, EUR GBP, JPY, and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years 2022 to 2026 are considered as the forecast period.

    Market segmentation and coverage

    This research report categorizes Generic Inhalation Drugs and Nasal Sprays to forecast revenue and analyze trends in each of the following submarkets:

    • Based on the indication, the market has been investigated for allergic rhinitis, asthma and COPD.

    • Based on age group, the market has been researched among adults, children 2-5 years old, and children 6-12 years old.

    • Based on the class, the market has been studied for allergy blockers, anticholinergics, antihistamines, decongestants, mast cell inhibitors, and nasal steroids.

    • Based on Route, the market has been investigated for inhalation, nasal spray, and tropical lotion.

    • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

    • Based on the region, the market has been studied in the Americas, Asia-Pacific and Europe, Middle East and Africa. The Americas are studied in more detail in Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail in California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. Asia-Pacific is further explored in Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates and United Kingdom.

    Companies mentioned

    • Allergan plc

    • Altaire Pharmaceuticals inc.

    • Beximco Pharmaceuticals Ltd.

    • Catalent Pharma Solutions

    • Cipla Limited

    • Hikma Pharmaceuticals PLC

    • Mylan NV

    • Navajo Manufacturing Company Inc.

    • Pharmaceutical company Nephron

    • Perrigo Company plc

    • Preferred Pharmaceuticals Inc.

    • Sandoz International GmbH

    • Sheffield Pharmaceuticals LLC

    • Sun Pharmaceutical Industries Ltd.

    • Teva Pharmaceutical Industries Ltd.

    Cumulative impact of COVID-19

    COVID-19 is an incomparable global public health emergency that has affected nearly all industries, and the long-term effects are expected to impact the growth of the industry during the forecast period. The analyst’s ongoing research is amplifying their research framework to ensure the inclusion of the underlying issues of COVID-19 and potential avenues to follow. The report provides insight on COVID-19 given changes in consumer behavior and demand, purchasing patterns, supply chain diversion, dynamics of current market forces, and significant government interventions. . The updated study provides information, analysis, estimates and forecasts, considering the impact of COVID-19 on the market.

    Competitive strategic window

    The Competitive Strategy Window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for suppliers to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to continue the expansion and growth of the business during a forecast period.

    FPNV positioning matrix

    The FPNV Positioning Matrix assesses and ranks vendors in the Generic Inhalation and Nasal Spray market based on business strategy (company growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features) and customer support) which helps businesses make better decisions and better understand the competitive landscape.

    Market share analysis

    The market share analysis offers the analysis of the suppliers considering their contribution to the overall market. It provides the idea of ​​its revenue generation in the overall market compared to other space providers. It provides insight into the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of the suppliers for the base year. It reveals the characteristics of the market in terms of traits of accumulation, fragmentation, dominance and fusion.

    Competitive scenario

    The competitive scenario provides a outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section delivers valuable insights at different stages while staying up to date with the business and engaging stakeholders in the economic debate. The competitive scenario represents press releases or news from companies categorized as M&A, Agreement, Collaboration and Partnership, New Product Launch and Improvement, Investment and Funding, and Reward, Recognition and Expansion. All the news gathered helps the supplier understand the market gaps and the strengths and weaknesses of the competitors, thus providing information to improve products and services.

    Main topics covered:

    1. Preface

    1.1. Objectives of the study

    1.2. Market segmentation and coverage

    1.3. Years taken into account for the study

    1.4. Currency and price

    1.5. Language

    1.6. Limits

    1.7. Hypotheses

    1.8. Stakeholders

    2. Research methodology

    3. Executive summary

    4. Market overview

    4.1. introduction

    4.2. Cumulative impact of COVID-19

    5. Market dynamics

    5.1. introduction

    5.2. Conductors

    5.2.1. Low cost associated with generic prescription drugs

    5.2.2. Increased prevalence of asthma and COPD disorders

    5.2.3. High cost of health care in developed regions

    5.3. Constraints

    5.3.1. Strict regulations for generic drugs

    5.4. Opportunities

    5.4.1. Successful drug patents expire and FDA approvals increased

    5.4.2. Trend towards generic drugs in developed countries due to rising cost of health care

    5.5. Challenges

    5.5.1. Pressure on prices due to the presence of several players in the segment

    6. Generic Inhalation and Nasal Sprays Market, by Indication

    6.1. introduction

    6.2. Allergic rhinitis

    6.3. Asthma

    6.4. COPD

    7. Generic Inhalation Nasal Spray Drugs Market, By Age Group

    7.1. introduction

    7.2. Adults

    7.3. Children 2 to 5

    7.4. Children 6 to 12

    8. Generic Inhalation and Nasal Spray Drugs Market, By Class

    8.1. introduction

    8.2. Allergy blocker

    8.3. Anticholinergic

    8.4. Antihistamine

    8.5. decongestant

    8.6. Mast cell inhibitor

    8.7. Nasal steroid

    9. Generic inhalation and nasal sprays market, by road

    9.1. introduction

    9.2. Inhalation

    9.3. Nasal spray

    9.4. Tropical Lotion

    10. Generic inhalation and nasal sprays market, by distribution channel

    10.1. introduction

    10.2. Hospital medical store

    10.3. Online pharmacy

    10.4. Retail pharmacy

    11. America Generic Inhalation and Nasal Spray Market

    12. Asia-Pacific Generic Inhalation and Nasal Spray Market

    13. Europe, Middle East & Africa Generic Inhalation Drugs and Nasal Sprays Market

    14. Competitive landscape

    14.1. FPNV positioning matrix

    14.1.1. Quadrants

    14.1.2. Business strategy

    14.1.3. Product satisfaction

    14.2. Market ranking analysis

    14.3. Market share analysis, by key player

    14.4. Competitive scenario

    14.4.1. Merger & Acquisition

    14.4.2. Agreement, collaboration and partnership

    14.4.3. New product launch and improvement

    14.4.4. Investment and financing

    14.4.5. Awards, recognition and expansion

    15. Company usability profiles

    For more information on this report, visit https://www.researchandmarkets.com/r/1lry5e

    read more
    Generic drugs

    The global market for generic inhalants and nasal sprays is expected to reach over $10 billion by 2026

    DUBLIN, December 16, 2021–(BUSINESS WIRE)–The report “Inhalation & Nasal Sprays Generic Drugs Market Research Report by Indication, Age Group, Class, Route, Distribution Channel, and Region – Global Forecast to 2026 – Cumulative Impact of COVID-19” has been added to from ResearchAndMarkets.com offer.

    The global Generic Inhalation Drugs and Nasal Sprays Market size was estimated at USD 6,392.52 million in 2020, is projected to reach USD 6,879.55 million in 2021 and is projected to grow at a CAGR of 7.95% to reach 10 USD 119.95 million by 2026.

    Market statistics

    The report provides market size analysis and forecasts for five major currencies – USD, EUR GBP, JPY and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years from 2022 to 2026 as the forecast period.

    Market segmentation and coverage

    This research report categorizes generic inhalants and nasal sprays to forecast revenues and analyze trends in each of the following submarkets:

    • On the basis of indication, the market has been studied for allergic rhinitis, asthma, and COPD.

    • On the basis of age group, the market has been studied on adults, 2-5 year olds, and 6-12 year olds.

    • Based on class, the market has been studied on Allergy Blockers, Anticholinergics, Antihistamines, Decongestants, Mast Cell Inhibitors, and Nasal Steroids.

    • Based on Route, the market has been studied for Inhalation, Nasal Spray, and Tropical Lotion.

    • Based on the distribution channel, the market has been studied in hospital medical stores, online pharmacies and retail pharmacies.

    • Based on region, the market has been studied in Americas, Asia-Pacific and Europe, Middle East & Africa. The Americas are studied in more detail through Argentina, Brazil, Canada, Mexico and the United States. The United States is studied in more detail through California, Florida, Illinois, New York, Ohio, Pennsylvania and Texas. Asia-Pacific is studied in more detail through Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand. Europe, the Middle East and Africa are studied in more detail in France, Germany, Italy, the Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, the United Arab Emirates and the United Kingdom.

    Companies cited

    • Allergan AG

    • Altaire Pharmaceuticals Inc.

    • Beximco Pharmaceuticals Ltd

    • Catalent Pharmaceutical Solutions

    • Cipla Limited

    • Hikma Pharmaceuticals PLC

    • Mylan AG

    • Navajo Manufacturing Company Inc.

    • Nephron Pharmaceutical Company

    • Perrigo Company plc

    • Favorite Pharmaceuticals Inc.

    • Sandoz International GmbH

    • Sheffield Pharmaceuticals LLC

    • Sun Pharmaceutical Industries Ltd.

    • Teva Pharmaceutical Industries Ltd.

    Cumulative impact of COVID-19

    COVID-19 is an unparalleled global public health emergency that has affected almost every industry, and the long-term effects are expected to impact industry growth over the forecast period. The analyst’s ongoing research amplifies its research framework to ensure inclusion of the underlying issues of COVID-19 and potential pathways forward. The report provides insights into COVID-19 considering shifts in consumer behavior and demand, shopping patterns, supply chain rerouting, current market force dynamics, and significant interventions governments. The updated study provides insights, analysis, estimates, and forecasts considering the impact of COVID-19 on the market.

    Competitive Strategy Window

    The strategic competitive window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period.

    FPNV positioning matrix

    The FPNV Positioning Matrix evaluates and ranks vendors in the Generic Inhalation and Nasal Sprays Market based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (value for money, ease of use, product features, and customer support) that helps businesses make better decisions and better understand the competitive landscape.

    Market share analysis

    The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

    Competitive scenario

    The competitive scenario provides an analysis of the prospects of the various business growth strategies adopted by the vendors. The news covered in this section provides valuable insights at various stages while keeping abreast of activity and engaging stakeholders in the economic debate. The competitive scenario represents press releases or company news categorized into merger and acquisition, agreement, collaboration and partnership, new product launch and improvement, investment and funding, and awards, recognition and expansion. All the news gathered helps the vendor to understand the gaps in the market and the strength and weakness of the competitors, thus providing insights to improve the product and service.

    Main topics covered:

    1. Preface

    1.1. Study objectives

    1.2. Market segmentation and coverage

    1.3. Years Considered for Study

    1.4. Currency and price

    1.5. Language

    1.6. Limits

    1.7. Hypotheses

    1.8. Stakeholders

    2. Research methodology

    3. Executive Summary

    4. Market Overview

    4.1. introduction

    4.2. Cumulative impact of COVID-19

    5. Market dynamics

    5.1. introduction

    5.2. Drivers

    5.2.1. Low cost associated with generic prescription drugs

    5.2.2. Increased prevalence of asthma and COPD disorders

    5.2.3. High cost of health care in developed regions

    5.3. Constraints

    5.3.1. Strict regulations for generic drugs

    5.4. Opportunities

    5.4.1. Blockbuster drug patents expiring and FDA approvals rising

    5.4.2. Inclination towards generic drugs in developed countries due to rising cost of healthcare

    5.5. Challenges

    5.5.1. Pressure on prices due to the presence of several players in the segment

    6. Generic Inhalation and Nasal Spray Market, By Indication

    6.1. introduction

    6.2. Allergic rhinitis

    6.3. Asthma

    6.4. COPD

    7. Generic Inhalation and Nasal Spray Market, By Age Group

    7.1. introduction

    7.2. Adults

    7.3. Children 2 to 5

    7.4. Children from 6 to 12 years old

    8. Generic Drugs for Inhalation and Nasal Sprays Market, By Class

    8.1. introduction

    8.2. allergy blocker

    8.3. Anticholinergic

    8.4. Antihistamine

    8.5. Decongestant

    8.6. mast cell inhibitor

    8.7. nasal steroid

    9. Generic Inhalation and Nasal Spray Drugs Market, By Way

    9.1. introduction

    9.2. Inhalation

    9.3. nasal spray

    9.4. Tropical Lotion

    10. Generic Drugs for Inhalation and Nasal Sprays Market, By Distribution Channel

    10.1. introduction

    10.2. Hospital medical store

    10.3. Online pharmacy

    10.4. Pharmacy retail

    11. Americas Generic Inhalation and Nasal Sprays Market

    12. Asia-Pacific Generic Inhalation and Nasal Spray Market

    13. Europe, Middle East and Africa Generic Inhalation and Nasal Spray Drugs Market

    14. Competitive landscape

    14.1. FPNV positioning matrix

    14.1.1. Quadrants

    14.1.2. Business strategy

    14.1.3. Product Satisfaction

    14.2. Market Ranking Analysis

    14.3. Market share analysis, by key player

    14.4. Competitive scenario

    14.4.1. Merger & Acquisition

    14.4.2. Agreement, collaboration and partnership

    14.4.3. Launching and improving new products

    14.4.4. Investment & Financing

    14.4.5. Reward, recognition and expansion

    15. Enterprise Usability Profiles

    For more information about this report visit https://www.researchandmarkets.com/r/1lry5e

    See the source version on businesswire.com: https://www.businesswire.com/news/home/20211216005562/en/

    contacts

    ResearchAndMarkets.com
    Laura Wood, Senior Press Officer
    [email protected]
    For EST business hours, call 1-917-300-0470
    For US/CAN call toll free 1-800-526-8630
    For GMT office hours call +353-1-416-8900

    read more
    Prescription drugs

    Study: Consumption of Cannabis with Prescription Drugs Could Raise “Significant Risk of Harmful Drug Interactions”

    Metabolites in the blood of users appear to interfere with the metabolism of a wide range of prescribed drugs and could lead to toxicity or accidental overdose.

    Content of the article

    Researchers at Washington State University report that cannabis users who have also used other drugs to treat various conditions may reduce the effectiveness of those drugs.

    Advertising

    Content of the article

    Investigators looking to determine possible drug interactions have found that the positive effects of the treatment drugs taken may decrease or that their negative effects may increase, explains a statement from the university.

    If too much medicine builds up in the body, it could cause “unintended side effects such as toxicity or accidental overdose,” the researchers say.

    1. These are the first exemptions from the Controlled Drugs and Substances Act granted for mental health reasons by the new Minister of Health, Jean-Yves Duclos.  PHOTO BY REUTERS / BLAIR GABLE

      Exclusive: Three Canadians With Mental Disorders Have Legal Access To Psilocybin Mushrooms

    2. FILE: Military march organized in Canada after the body of a fallen soldier was repatriated in September 2009.

      Canadian poll: Anxiety or stress are the top reasons Canadian veterans report turning to medical cannabis

    3. A comparison of the exposed and control groups revealed that the former, immediately after the exposure period, had a decrease in sperm motility.  /

      Study: Exposure to cannabis vapors negatively affects mouse semen for two generations

    To arrive at this point of view, investigators looked at cannabinoids – including THC, CBD, and CBN – and their major metabolites found in the blood of cannabis users. They used manipulated human kidney cells, allowing them to “examine one enzyme at a time.”

    Advertising

    Content of the article

    According to the university’s statement, the researchers suggest that these cannabinoids and metabolites “interfere with two families of enzymes that help metabolize a wide range of drugs prescribed for various conditions.”

    Possible toxicity is a real concern and something doctors should have on their radar, notes lead author Philip Lazarus.

    This is especially the case when cannabis is used medicinally, suggests Lazarus. “It’s one thing if you’re young and healthy and smoke cannabis every now and then, but for older people who are on medication, taking CBD or medicinal marijuana can have a negative impact on their health. treatment, ”he warns.

    The results are based on two studies published in Metabolism and elimination of drugs: one focused on the cytochrome P450 (CYP) family of enzymes, and the other on the UDP-glucuronosyltransferases (UGT) family of enzymes.

    Advertising

    Content of the article

    “Together, these two families of enzymes help metabolize and eliminate from the body more than 70% of the most commonly used drugs,” the statement said.

    Specifically, the researchers found that “cannabinoids and the major metabolites of THC strongly inhibited several CYP enzymes” and that “THC-COO-Gluc appears to play a major role in inhibiting several key enzymes in the liver.”

    Regarding UGTs, the three aforementioned cannabinoids – but especially CBD – “inhibited two of the main UGT enzymes found in the liver. CBD was also found to block three enzymes that make up about 95% of UGT’s renal metabolism, which helps flush toxins and certain drugs from the body, ”the release notes.

    “If you have kidney disease or if you take one or more drugs that are mainly metabolized by the kidneys and you also smoke marijuana, you may be inhibiting normal kidney function and this may have long term effects on your kidneys. you ”Lazarus warns.

    Advertising

    Content of the article

    Possible toxicity is a real concern and something doctors should have on their radar.  /
    Possible toxicity is a real concern and something doctors should have on their radar. / Photo by Getty Images

    Calling the results the first to show the inhibitory potential of THC-COO-Gluc – the most abundant cannabinoid metabolite in plasma – researchers write in one of the studies that “the main cannabinoids and their metabolites present in the plasma of cannabis users inhibit several P450 enzymes”.

    These enzymes “are involved in the synthesis and metabolism of a range of internal and external cellular components”, according to the medical life sciences.

    Shamema Nasrin, the study’s first author, claims that the resulting metabolites created when cannabinoids break down in the body can last for up to 14 days and are in higher concentrations than cannabinoids. These are points, argues Nasrin, that “have been overlooked in previous studies, so we thought we should focus on these as well.”

    Advertising

    Content of the article

    The study authors cite the legalization of cannabis in many parts of the United States and other countries as stressing the “need for a more complete understanding of the constituents of cannabis and their potential for drug interactions.”

    As such, the university statement emphasizes that “it is important to be careful when using cannabis with other prescription drugs.”

    “Taking CBD or marijuana may relieve your pain, but could make the other medicine you are taking more toxic, and this increase in toxicity may mean that you cannot continue taking this medicine,” says Nasrin.

    “So there could be serious ramifications for anticancer drugs, and this is just one example of the many drugs that could potentially be affected by the cannabinoid-enzyme interactions that we are seeing,” she adds.

    Authors of an Australian study exploring potential drug interactions with medicinal marijuana would likely agree. “Care should be taken to closely monitor the reactions of cannabis users to certain drugs to ensure their safety, especially for the elderly and those with chronic diseases or kidney and liver disease.” write the authors of the study published in 2019.

    A see again in the Journal of the Canadian Medical Association last year there was an increase in the clearance of certain drugs among regular cannabis users. However, “no effects from occasional use have been reported.”

    Advertising

    Content of the article

    We apologize, but this video failed to load.

    To subscribe to Weekend dispensary , a new weekly newsletter from The GrowthOp.

    Advertising

    comments

    Postmedia is committed to maintaining a vibrant but civil discussion forum and encourages all readers to share their views on our articles. Comments may take up to an hour of moderation before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread that you follow, or if a user that you follow comments. Visit our Community rules for more information and details on how to adjust your E-mail settings.

    read more
    Prescription drugs

    Hyperlipidemia Prescription Drug Market Outlook to 2026 by Application, End User and Geography

    The latest research report on Prescription Drug Market for Hyperlipidemia Informs the reader of all the important aspects that influence the behavior of the industry, such as the main growth drivers and challenges, to enable stakeholders to make informed decisions for the future. It also includes a comparison of past and current business scenarios to support the study’s forecast. In addition, the document offers a detailed account of the various market segments and recognizes the key areas that promise solid revenues in the years to come.

    According to industry experts, the hyperlipidemia prescription drug market size is expected to yield high profits over the period 2021-2026, registering a XX% CAGR throughout.

    Research literature uncovers the impact of the COVID-19 pandemic on this area, with a focus on barriers such as changes in customer behavior, supply chain flows, and imbalances in business operations . It also recommends various approaches that will ensure an upward growth trajectory in the years to come.

    Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/100872

    ImportantPointers of the Hyperlipidemia Prescription Drugs Market report:

    • COVID-19 Status and Its Impact on Industry Compensation
    • Market and submarkets growth rate approximations
    • Predominant trends in the vertical
    • Business expansion opportunities
    • Advantages and disadvantages of the indirect and direct sales channel
    • Main traders, suppliers and resellers

    Hyperlipidemia Drugs Market Segments Covered in Report:

    Geographic bifurcation: North America, Europe, Asia-Pacific, South America and Middle East & Africa

    • Review of the business landscape for each regional market at country level
    • Aggregate sales and revenue data for each area
    • Share of industry captured by major regional contributors
    • Estimates of the growth rate of each regional market over the evaluation period

    Product Types: HMG COA Reductase Inhibitors, Fibric Acid Derivatives, Nicotinic Acid, Bile Acid Sequestering Agents, Cholesterol Absorption Inhibitors, and Combination Drug Therapy

    • Sales, revenue and market share of each product segment
    • The pricing model for each product category

    Application spectrum: Hospital and Clinic

    • Global turnover and sales secured by each application segment
    • Product pricing according to scope

    Competitive dashboard:

    • Amgen
    • Eli lilly
    • GlaxoSmithKline Pharmaceuticals
    • Isis Pharma
    • Merck
    • Dr Reddy’s laboratories
    • Immuron Limited
    • Esperion Therapeutics
    • Pfizer and Formac Pharma

    • Products and services offered by the best companies
    • Leading organizations manufacturing facilities in the geographies served
    • Annals of price models, gross margins, sales, market share and cumulative revenue of major players
    • SWOT analysis of the main organizations
    • New emerging competitors in the market
    • Review of well-known trading tactics
    • Conclusive overview of market concentration rate and commercialization rate

    Purpose of Prescription Drugs for Hyperlipidemia: –

    To assess the value, market share, sales margin, hyperlipidemia drugs industry status (2016-2020) and forecast scenario (2021-2026).

    To study the main players of the drug Hyperlipidemia and their company profiles, their statistics of production, consumption and import-export

    To analyze the growth, opportunity, development, and risk of the Hyperlipidemia Drugs industry in various regions.

    To understand the competitive view of the market, SWOT and gross margin statistics.

    To present, describe, analyze, and define the Hyperlipidemia Drugs industry on the basis of product type, applications, and regions.

    To examine development plans, industry policies, market size, value, and sales of major players in Hyperlipidemia Prescription Drugs.

    Investigate crucial factors such as market risks, drivers, maturity analysis of prescription hyperlipidemia drugs.

    Table of contents overview:

    1. Hyperlipidemia Prescription Drug Market Overview
    2. Hyperlipidemia Prescription Drug Market Company Profiles
    3. Competition in the market, by players
    4. Market Size Segment by Type
    5. Market Size Segment by Application
    6. North America by Country, Type and Application
    7. Europe by country, type and application
    8. Asia-Pacific by Region, Type and Application
    9. South America by Country, Type and Application
    10. Middle East & Africa by Country, Type and Application
    11. Research results and conclusion.

    Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/100872

    read more
    Prescription drugs

    Florida man admits selling mislabeled prescription drugs to infiltrate Lubbock DEA agent | KLBK | KAMC

    LUBBOCK, Texas – A Florida man admitted on Monday to selling mislabeled prescription drugs to an undercover Lubbock Drug Enforcement Administration agent, court records showed. The admission was part of a plea agreement.

    Albert Richard Boozer, of Palm Beach, Florida, was first contacted by an undercover DEA agent in Lubbock in late 2019, court documents show.

    Court documents say the officer contacted a suspected drug dealer and attempted to purchase 200 Adderall pills for $ 800. The trafficker agreed and the agent wired the money and provided a PO box where the trafficker could send the drugs.

    In February 2020, an envelope arrived with a bottle of the “Super Flex-6” dietary supplement, according to court documents. Inside the bottle were 192 pink circular tablets, which contained tramadol, a controlled narcotic.

    Court documents said later in the month that another envelope arrived at the secret post office box. It contained a smaller bubble envelope containing 101 pink tablets. A lab report said the package contained 97 tramadol tablets.

    While the packages were sent by “Ryan Smith,” Boozer was identified through a Stamps.com account he was using to ship the drugs, according to court documents.

    When investigators obtained a warrant to search his emails, they found several messages regarding the reshipment of prescription drugs for a company in India. Investigators also found several food supplement pill bottles containing pills when they collected garbage from her home. The pills were found to be controlled substances, according to court documents.

    On Monday, the guilty plea had not been accepted by a judge.

    read more
    Prescription drugs

    Is mixing cannabis and prescription drugs a good idea?

    It is well known that cannabis has many medicinal benefits, including the management of chronic pain, epilepsy, anxiety, and the treatment of symptoms of PTSD.

    However, in the case of cannabinoids, a group of substances found in the cannabis plant, there is a risk that its combination with other prescription drugs could lead to harmful drug interactions, new research from scientists at Washington State University (WSU) has suggested. .

    Researchers looked at cannabinoids and their main metabolites found in the blood of cannabis users and found that they interfere with two families of enzymes that help metabolize a wide range of drugs prescribed for various conditions. As a result, either the positive effects of the drugs might decrease, or their negative effects might increase with too much accumulation in the body, causing unintended side effects such as toxicity or accidental overdose.

    The results examined the interaction between three of the most abundant cannabinoids – tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN).

    While more research is essential, the authors suggested using caution when using cannabis with prescription drugs.

    “Physicians should be aware of the possibility of toxicity or a lack of response when patients use cannabinoids,” said Philippe Lazare, lead author of the article and Boeing Distinguished Professor of Pharmaceutical Sciences. “It’s one thing if you’re young and healthy and smoke cannabis every now and then, but for older people who are on medication, taking CBD or medicinal marijuana can have a negative impact on their health. processing. “

    Lazarus added, “It’s one thing if you’re young and healthy and smoke cannabis every now and then, but for older people who are on medication, taking CBD or medicinal marijuana can have a negative impact. negative impact on their treatment. “

    The results

    The researchers used manipulated human kidney cells and confirmed their results in human liver and kidney samples in which enzymes were present.

    Shamema nasrin, a graduate student from WSU College of Pharmacy and Pharmaceutical Sciences, pointed out that even though cannabinoids remain in the consumer’s body for about 30 minutes before being quickly broken down, the metabolites resulting from this process could remain in the system for up to 14 days.

    What’s more, the metabolites are also found “in higher concentrations than cannabinoids,” she explained, adding that they had been “overlooked in previous studies.”

    Potential negative drug interactions include a decrease in the positive effects of the drugs, as well as an increase in its negative effects resulting in excessive build-up in the body which could cause unintended side effects such as toxicity or accidental overdose.

    “Taking CBD or marijuana might ease your pain, but could make the other drug you’re taking more toxic, and this increase in toxicity may mean you can’t keep taking this drug,” Nasrin said. “So there could be serious ramifications for anticancer drugs, and this is just one example of the many drugs that could potentially be affected by the cannabinoid-enzyme interactions that we are seeing.”

    Authorities in Virginia Highlight Potential of Psychedelics in Treating Depression and PTSD

    What happens if you smoke weed every day?

    Photo: Courtesy of Talha Hassan to Unsplash

    read more
    Prescription drugs

    Does Medicare Cover Prescription Drugs?

    TThe good news is that when you are eligible for Medicare, you will also be able to purchase insurance that pays a portion of the costs of your prescription drugs – in many cases, most of the costs. But there are many caveats about Medicare drug coverage and significant variations in coverage and costs between plans.

    Original health insurance (parts A and B) does not cover prescription drugs except in special cases (drugs administered during surgery for example). Original Medicare beneficiaries are eligible to purchase prescription drug coverage, called Medicare, Part D, which is sold and administered by private insurers.

    More Advantage of Medicare plans, on the other hand, include coverage for prescription drugs.

    In both cases, Medicare Part D and Medicare Advantage, it is important to remember that the specific drugs covered vary from plan to plan. The same goes for monthly premiums and other fees. It is therefore beneficial to educate yourself, shop carefully and re-evaluate your choice of package each year.

    What Medicare Part D plans cover

    Medicare drug plans cover both generic and brand name drugs. All plans cover certain categories of drugs to treat specific conditions. Each plan decides which specific drugs to insure by category.

    Each Medicare Part D plan lists the drugs it covers on a formulary, which typically includes both brand name drugs and generic drugs. Forms change, so it is very important to regularly check that your medications are included.

    You should also check each plan for restrictions on drug coverage, such as requirements that certain drugs must be approved in advance by the insurer.

    If you or your provider thinks that none of the covered medications will adequately treat your condition, you can request a exception.

    What you will pay for prescriptions

    In addition to Part D premiums, you may be responsible for cost sharing, which may include deductibles, copayments, or coinsurance. Medicare Part D plans set their own premiums.

    Part D plan deductibles vary from $ 0 to the maximum allowed, which in 2021 is $ 445 (rising to $ 480 in 2022). Those with higher incomes will pay an additional monthly fee of $ 12.30 to $ 77.10 for Part D in 2021.

    Co-payments or coinsurance

    Almost all Medicare Part D and Medicare Advantage plans with prescription drug coverage charge a copayment or coinsurance. Buy with care; your costs will vary from plan to plan.

    Part D coverage requires you to pay varying prices for different categories of drugs. In general, your cost share will be higher for brand name drugs.

    Note that if you delay your Part D registration for too long, you will have to pay a late registration penalty.

    How To Compare Medicare Part D Plans

    Medicare.gov can help you find a Part D plan that covers your prescriptions and can help you compare your costs under various Medicare Part D and Medicare Advantage plans.

    More from NerdWallet

    John Rossheim writes for NerdWallet. Email: [email protected]

    Does the Medicare article cover prescription drugs? originally appeared on NerdWallet.

    The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

    read more
    Prescription drugs

    Pet Prescription Drug Market size, increasing diversity of trends, analysis, future scope analysis with major key industry players by 2026

    The primary objective of the Animal Drugs market report is to determine the performance of the industry over the anticipated time frame to help stakeholders to make informed decisions and action plans that will ensure long term success . The document highlights all the factors that favor the growth of this vertical, followed by counter-approaches to the major challenges facing companies. In addition, it includes the changes in this vertical due to the Covid-19 pandemic and highlights the best opportunities for the future.

    Key points of the impact assessment of Covid-19:

    • Impact of Covid-19 on the economic scenario on a global scale.
    • Changes in the share of supply and demand.
    • Predictions of the long-term effects of the Covid-19 pandemic on the growth matrix.

    An overview of the regional landscape:

    • Geographically, the pet prescription drug market is divided into North America, Europe, Asia-Pacific, South America, Middle East & Africa, Southeast Asia.
    • The contribution of each region to the overall growth of the industry is measured in the study.
    • An analysis of the revenue, sales and growth rate for key regions during the forecast period is also provided.

    Request a copy of this report @ https://www.nwdiamondnotes.com/request-sample/96766

    Other important takeaways from the Pet Prescription Drugs Market report:

    • The report categorizes the pet prescription drug market product landscape into oral type, smear type, injection type and spray type.
    • Sales and volume share estimates for each product category are provided.
    • The study also highlights the market share, growth rate and production pattern of each type of product over the forecast period.
    • In terms of the scope, the Animal Prescription Drugs market is fragmented into Pets, Livestock, geographically, the detailed production and trade analysis of the following countries is covered in Chapter 4.2, 5: United States, Europe, China, Japan and India.
    • The market share guaranteed by each application segment along with their growth rate forecast is discussed in detail in the report.
    • The main companies that are setting trends in the pet prescription drug market are Ceva Sante Animale, MSD Animal Health, Ourofino Saude Animal, Dechra, Virbac, Boehringer Ingelheim, Vetoquinol, Zoetis, Animalcare Group and Elanco Animal Health.
    • Listed companies are analyzed on the basis of their gross margins, production models, product and service portfolio, pricing model, market compensation and market share.
    • Major competitive trends and their implications for businesses are comprehensively elaborated.
    • Granular industry supply chain analysis, with details of key manufacturers, suppliers and consumers is included.
    • The feasibility study of a new project using several methodologies such as SWOT analysis and Porter’s five forces analysis is provided in the document.

    Reasons to access this report:

    • Know the opportunities and plan strategies by having a solid understanding of the investment opportunities in the Animal Prescription Drugs market
    • Identification of key parameters driving investment opportunities in the prescription animal drugs market
    • Facilitate decision making based on solid historical and forecast data
    • Position yourself to make the most of the industry’s growth potential
    • Develop strategies based on the latest reports.
    • Identify key partners and avenues for commercial development
    • Respond to your competitor’s business structure, strategy and outlook
    • Identify the main strengths and weaknesses of important market players

    The key questions answered by this report:

    • What will the market size and growth rate be during the forecast year?
    • What are the key factors driving the global pet prescription drugs market?
    • What are the risks and challenges facing the market?
    • Who are the major vendors in the global pet prescription drugs market?
    • What are the trend factors influencing market shares?
    • What are the main results of Porter’s five forces model?
    • What are the global opportunities for expanding the global pet prescription drugs market?

    Important point mentioned in the Research report:

    • Market overview, market dynamics, market growth etc. are cited in the report.
    • The power and commercial output of major manufacturers have been mentioned along with the technical data.
    • The study provides historical market data with revenue forecast and forecast from 2020 to 2025.
    • This report is a valuable asset for existing players, new entrants and future investors.

    Table of Contents for Market Share by Application, Research Objectives, Market Sections by Type, and Forecast Years Considered:

    Pet Prescription Drugs Market Share by Major Players: Here, the analysis of capital, revenues and prices by the company is included along with other sections such as development plans, areas served, products offered by major players, alliance and acquisition. and seat distribution.

    Global growth trends: Industry trends, growth rate of major producers, and production analysis are the segments included in this chapter.

    Market Size By Application: This segment comprises an analysis of the Animal Prescription Drugs market consumption by Application.

    Pet Prescription Drugs Market Size By Type: It includes analysis of product value, utility, market percentage and production market share by type.

    Manufacturer profiles: Here, the major players of the global Animal Prescription Drugs Market are studied on the basis of sales area, key products, gross margin, revenue, price, and production.

    Animal Medicines Market Value Chain Analysis and Sales Channels: It includes analysis of customers, distributors, market value chain and sales channels.

    Market Forecast: This section focuses on production and production value forecast, forecast of key producers by type, application and regions

    Request customization on this report @ https://www.nwdiamondnotes.com/request-for-customization/96766

    read more
    Prescription drugs

    The Incredibly High Price of Prescription Drugs national news


    Insulin is a medical wonder, saving the lives of millions of people who would otherwise die of diabetes. It can also be prohibitively expensive, going up to $ 300 a vial for newer versions of the treatment, which patients with diabetes need two to three times per month.

    For patients with less common ailments, the sticker shock can be much worse. Do you have a small child with spinal muscular atrophy, a rare genetic condition that weakens muscles, causes movement problems over time and can be fatal? The good news is that the Food and Drug Administration in 2019 approved a drug, Zolgensma, a one-off curative therapy. The bad news is that it costs over $ 2.1 million – and may not be covered by insurance – making it the most expensive drug in the world.

    The prices of prescription drugs in America are a constant source of frustration, anger and bewilderment among patient-consumers. Why are some drugs so expensive – and why are some pills significantly more expensive than the same drug sold overseas? Who decides the price of prescription drugs – and how do you make them affordable without stifling the innovation and research that has produced the miracle cures patients enjoy today?

    Political cartoons about Congress

    Congress is grappling with this problem now, examining provisions of the “Build Better” bill that seek to reduce the burden on consumers by capping the co-payments patients are supposed to cover and annual out-of-pocket expenses in some cases. circumstances. As is is currently written, the measure would allow Medicare to negotiate drug prices – something the government was specifically prohibited from doing when Medicare Part D, the prescription drug benefit for the elderly, was created in 2003.

    The new measure would also impose a tax penalty if drug companies raised prices more than inflation, capped insulin co-payments to $ 35 per month, and capped out-of-pocket expenses for the elderly at $ 2,000 for the elderly. drugs covered by Medicare.

    Many Democrats have portrayed the battle as a battle between helpless patients and drugmakers chasing dollars. Republicans say efforts to set prices, even in a roundabout way, will discourage the development of the very treatments that save lives.

    “The public truly have a love-hate relationship with the pharmaceutical industry. They appreciate and appreciate the role of the pharmaceutical industry” in developing treatments that change and save lives, Mollyann Brodie, Executive Vice President of health research group Kaiser Family Foundation said in a webinar this week. “On the other hand, they also think the industry is too profit-oriented and the profits are too high.”

    The industry, represented by the powerful Pharmaceutical Research and Manufacturers of America (PhRMA), certainly has its bogeymen. Chief among them is Martin Shkreli, the so-called “pharmaceutical brother” who sparked anger in 2015 when his company, Turing Pharmaceuticals, increased the price of a life-saving drug, Daraprim, from $ 13.50 to $ 750 per tablet. (Shkreli is in prison for security fraud. Turing and his parent company agreed wednesday to pay $ 40 million to settle a case alleging stealing from patients).

    But pharmaceutical companies have also developed critical therapies and groundbreaking research in diseases ranging from cancer to Alzheimer’s disease. They may have saved humanity through the rapid development of vaccines (and a possible new treatment) against the COVID-19 virus.

    But why are some drugs so expensive? And what can be done to make therapy more affordable?

    The answer is much more complicated than it looks, experts say. And the solutions aren’t as straightforward as viewing the manufacturers as the sole source of the problem.

    “Everyone likes to find the bad guys,” says Wayne Winegarden, director of the Center for Medical Economics and Innovation at the Pacific Research Institute. Aside from some known bad actors (like Shkreli), “there is no bad guy here. We have a really bad health care system that incites all kinds of crazy behavior,” Winegarden says.

    Drug prices, experts explain, are determined by various players. A manufacturer sets an “introductory price” – which will usually be higher if it is a new treatment or a breakthrough treatment. An intermediary, called the Pharmacy Benefit Manager, then negotiates discounts and rebates with manufacturers for the drug, which they then provide to pharmacies, doctors and hospitals.

    But Pharmacy Benefit Managers don’t necessarily pass the discount on to patients, says Leslie Dach, president of the healthcare reform group Protect Our Care. They also don’t reveal how much of the rebate they got, so patients don’t know what the true cost is.

    Insurance may very well cover a particular drug, explains Dach. But since the co-payment is based on the original manufacturer’s price – not the lower negotiated cost paid by the Pharmacy Benefit Manager – the patient ends up paying more.

    “Everything here is a black box,” he says.

    Pharmacies are also at an impasse, says Douglas Hoey, CEO of the National Community Pharmacists Association. Pharmacy Benefit Managers – three of whom, he says, control 80% of the market – are “incredibly powerful with health care providers.” Intermediary companies can, for example, refer patients to pharmacies in the network and say to pharmacies: “If you do not take our prices, we will refer this patient elsewhere”.

    This means that even when the initial cost of a drug goes down, a patient may not see the benefit. A report by Milliman, commissioned and released this week by PhRMA, found that the net price of insulin in 2021 was, on average, 84% lower than the list price due to discounts, rebates and other payments. But experts note that a decrease in the net and reduced price does not necessarily mean that the patient’s co-payment will be lower. The study singled out Pharmacy Benefit Managers, saying that companies “have been found to favor products with high list prices and large discounts over lower list price equivalents,” with “unintended consequences” for them. patients whose co-payment is based on the original list prices.

    The Pharmaceutical Care Management Association, which represents Pharmacy Benefit Managers, blamed the manufacturers, noting that the high prices start there.

    “Ironically, the industry that controls the list price of prescription drugs has tried to point the finger at those who focus on reducing the cost of prescription drugs to patients and payers,” the group said in a statement.

    It’s true that manufacturers set original prices, says Rena Conti, professor at Boston University, associate research director of biopharmacy and public policy at the university’s Institute for Health System Innovation and Policy. . But she says the answer isn’t simply to penalize the profitable industry.

    “There are a lot of very misaligned incentives that create a lot of headaches for real people at the pharmacy counter,” said Conti, who is due to testify on the matter before a House committee on Friday. “We are also the beneficiaries of a very robust pharmaceutical industry that is actually bringing new products to market, some of which are really transforming our lives. “

    “The point here is not to punish but rather to really think about how we might have the opportunity to realign the incentives,” she adds. For patients paying thousands of dollars or more for essential medicines, this change cannot come soon enough.

    read more
    Prescription drugs

    ASHP wants to stop white bags on prescription drugs

    The American Society of Health-System Pharmacists (ASHP) is working to end a practice known as “white bagging,” officials said.

    White bagging is when a payer demands that providers can only source drugs from a limited selection of specialty pharmacies affiliated with the payer. In white sachets, pharmacies in the health system receive these drugs from specialized pharmacies which they must then dispense to patients. Typically, as part of the purchasing and billing system, pharmacies in the health system maintain their own inventories and prepare medications based on physicians’ electronic health records.

    “We believe ASHP is compromising patient care,” said Kyle Robb, PharmD, state policy and advocacy associate at ASHP, during a presentation at the company’s virtual meeting in mid-year. White bags blind clinicians and hospitals to drug supply chains, can lead to delays in care and compromise electronic medical records, he added.

    “White bagging has really emerged and gained momentum over the past couple of years,” noted Tom Kraus, MHS, vice president of government relations at ASHP.

    In March, the ASHP and the American Hospital Association co-signed a letter to the FDA asking the agency to enforce the Drug Supply Chain Security Act (DSCSA) – which required that electronic chain histories supplies are maintained for all prescription drugs. until this drug is delivered to the patient – with the aim of ending the white bags.

    “Our main argument with the FDA is that white bagging fundamentally bypasses the DSCSA,” Robb said. The DSCSA was adopted in 2013 in response to a meningitis outbreak in several states caused by contaminated steroids made at a compounding pharmacy in Massachusetts.

    As part of white bagging, specialty pharmacies do not share transaction information with vendors, which means hospitals do not know the supply chain history of white bagged drugs. he explained.

    However, the FDA has yet to take regulatory action regarding the white bags, Robb said.

    The ASHP saw more state-level action for the first time this year, he noted. Prior to 2021, no state had white bag legislation, and only one state had introduced a bill in 2020. So far this year, 11 states have introduced white bag bills. Three states – Louisiana, Arkansas, and Virginia – have passed laws.

    Louisiana’s law was passed in June and ensures that plans cannot refuse to pay a provider for the provision of clinician-administered drugs and cannot punish patients with additional fees, according to Robb. The law also requires that drugs in white sachets from specialized pharmacies be accompanied by a history of transactions.

    In Arkansas, the new legislation takes a different approach to preventing white bags: it only applies to hematology and oncology patients, although the Arkansas Insurance Commissioner may extend the covered conditions. This law states that payers must cover both medical and pharmaceutical benefit channels, and that patients and providers can choose the billing channel that works best for them.

    In Virginia, plans must allow unprivileged pharmacies to dispense drugs covered at network rates and cannot increase costs for patients who use unprivileged pharmacies. The Virginia Board of Pharmacy has also passed regulations on the storage and tracking of white bagged medications.

    • Lei Lei Wu is a news intern for Medpage Today. She is based in New Jersey. To follow

    Disclosures

    Robb and Kraus did not report any financial disclosures.

    read more
    Generic drugs

    Generic Drugs Market Size To Exceed US $ 574.63 Billion

    Ottawa, November 09, 2021 (GLOBE NEWSWIRE) – According to the new study report released by Precedence Research, titled “Generic drugs market by drug type, brand, drug route of administration, therapeutic application and distribution channel: analysis of global opportunities and industry forecast, 2021-2030 ”, the increasing prevalence of chronic diseases, especially cardiovascular disorders, has propelled the market demand for generic drugs.

    Generic drugs are crushing the pharmaceutical industry market with record growth and a sustainable market trend, making it a lucrative area in which to operate.

    The report is ready | To have Sample copy of the report OR any customization requirements @ https://www.precedenceresearch.com/customization/1205

    A generic drug contains the same chemical substance as a drug that was previously protected by a chemical patent. After the patents on the original pharmaceuticals expire, generic drugs can be sold. The medical profile of generics is considered to be equal in terms of performance because the active chemical ingredient is the same. The generic drug contains the same active pharmaceutical ingredient (API) as the brand name drug, but it can change in terms of manufacturing technique, formulation, excipients, color, taste and packaging. The profitability of generic drugs has contributed to a competitive advantage over brand name drugs is the main factor adding to the growth of the market.

    The crucial factors responsible for the growth of the market are:

    • The low cost of generics as an alternative to brand name drugs
    • Large number of brand name drug patents expired
    • Initiatives from governments and other regulatory bodies around the world

    The expiration of brand name drug patents to open up new avenues for generic drug players to enter on the market

    The expiration of brand name drug patents continues to increase, offering huge potential opportunities in the drug market. Generic drug manufacturers have constantly focused on developing and launching various innovative drugs as well as formulations such as biosimilars which are helping in the growth of the market. In addition, government initiatives to promote the manufacture of generic drugs for deadly chronic diseases have further stimulated the market growth in emerging economies in particular. In addition, the growing aging populations across the world who are more prone to various diseases have fueled the growth of the market.

    Global Generic Drugs Market Size and Estimates, by Brand, 2021-2027 (USD Billion)

    Brand segment 2021 2023 2025 2027 TCCA (2021-27)
    Brand generics 200.60 234.66 272.41 313.86 7.75 %
    Pure generics 213.96 230.32 246.06 260.77 3.35 %
    Total 414.56 464.98 518.45 574.63 5.59 %

    Oral generics seeking an advantage due to their most popular route of drug administration

    Major advantages associated with oral generics such as convenience of oral drug administration, patient preference, cost-effectiveness, and ease of large-scale manufacture of oral dosage forms, oral medication is the most common route of administration. more widespread. About 65 percent of commercially available generic drugs are taken orally. Oral formulations account for approximately 90% of the global market share of all pharmaceutical formulations intended for human use, according to current estimates. Orally administered pharmaceuticals make up about 84 percent of the top-selling pharmaceuticals. They are the main contributor to the growth of the market due to the preferred and cheap option. Additionally, they are patient friendly, especially in geriatric and pediatric populations, and are relatively easy to create compared to their large molecule rivals.

    HIGHLIGHTS OF THE STUDY

    • The oral segment of the administration route is estimated to grow at a remarkable rate and represent the largest share throughout the study period.
    • Brand-name generics dominate the generic drug market in 2020, but pure generics are expected to overtake brand-name generics by 2027.
    • The Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period owing to the rapid penetration of local players in the market.
    • North America dominated the generic drug market and is expected to maintain its trend throughout the forecast period.
    • The Cardiovascular segment of Therapeutic Applications segment posted significant revenue share in the year 2020, while the Oncology segment was poised to grow at the fastest rate for the foreseeable future.
    • The retail pharmacy holds the leading position in the distribution channel segment; however, online distribution grows at a significant rate during the forecast period.

    Asia Pacific region to gain ground in the global generic drug market due to lower manufacturing cost and highly skilled labor

    Asia-Pacific is expected to show significant traction in the market during the forecast period. This is attributed to lower manufacturing costs and highly skilled labor in Asian countries. According to the India Brand Equity Foundation, India has the second largest number of US FDA manufacturing plants outside of the United States that are involved in the manufacture of generic drugs. In addition, the manufacturing cost is 33% lower in India than in the United States, which increases the accessibility of generics in these countries.

    Global Generic Drugs Market Size And Estimates, By Region, 2021-2027 (Billions USD)

    Region 2021 2024 2027 TCCA (2021-27)
    North America 149.46 165.00 178.77 3.03 %
    Europe 121.34 136.67 151.47 3.77 %
    Asia Pacific 98.08 130.01 168.14 9.40 %
    Latin America 29.99 38.88 49.36 8.66 %
    Middle East and Africa 15.69 20.79 26.89 9.40 %
    Total 414.56 491.35 574.63 5.59 %

    Asia-Pacific has placed a strong emphasis on increasing the supply of drugs at lower prices, even if this requires purchasing from non-traditional sources, with a historically low rate of drug use. generics. Hence, emerging countries such as India and China are complementing the growth of the generics market.

    In 2019, generic and biosimilar pharmaceuticals saved the U.S. healthcare system $ 313 billion, including $ 96 billion in Medicare savings and $ 48.5 billion in Medicaid savings. Generics fill 90% of prescriptions in the United States for just 20% of the cost, at a time when access to reliable, cheap, high-quality prescription drugs is more critical than ever. In 2019, the average primary co-pay for generics was $ 6.97 compared to the average primary co-pay for brand-name drugs of $ 56.32. These supporting factors are expected to drive generic drug sales over the next few years.

    Browse more health industry research reports @ https://www.precedenceresearch.com/industry/healthcare

    Market competitiveness and business prospects

    The global generic drug market is fragmented due to the presence of several large and small companies spread across the world. The main market players are adopting new strategies to gain attractiveness on the market. The report provides in-depth competitive analysis and profiles of major market players such as Mylan NV, Abbott Laboratories, ALLERGAN, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, STADA Arzneimittel AG, GlaxoSmithKline Plc., Baxter International Inc., Pfizer Inc., Sandoz International GmbH and others. Other players operating in the value chain are AurbindoPharma, Sun Pharmaceutical Industries Ltd., Aspen Pharmacare, Fresenius Kabi Ag, Lupine, Novartis, Glenmark, Sawai, PiramalPharma Solutions, Hikma, Cipla, Dr. Reddy’s, Endo, Stada and Mallinckrod between others.

    Main market segments covered:

    By type of drug

    By brand

    By drug administration

    By therapeutic application

    • Central nervous system (CNS)
    • Cardiovascular
    • Dermatology
    • Oncology
    • Respiratory
    • Others

    Key distribution channel

    • Hospitals Pharmacies
    • Retail pharmacies
    • Others

    By geography

    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa (MEA)

    Click here for See the table of contents of the full report

    The study of the full report is ready | Purchase this Premium Research Report @ https://www.precedenceresearch.com/checkout/1205

    You can place an order or ask any question, please feel free to contact us at [email protected] | +1 9197 992 333

    About Us

    Precedence Research is a global market research and consulting organization. We provide an unmatched nature of offering to our customers around the world, in all industry verticals. Precedence Research has expertise in providing in-depth market intelligence as well as market intelligence to our clients across various companies. We are obliged to serve our various clienteles present in companies of medical services, health, innovation, new generation technologies, semiconductors, chemicals, automotive, aerospace and of defense, among various companies present in the world.

    For the latest update, follow us:

    https://www.linkedin.com/company/precedence-research/

    https://www.facebook.com/precedenceresearch/

    https://twitter.com/Precedence_R

    read more
    Generic drugs

    Increasing the use of generic drugs is an anti-inflationary tactic

    We hear these days of alarming growth in inflation, especially in housing and gasoline. That dreaded “I” word permeates discussions as affordability becomes a dominant issue.

    One area that could actually see prices drop, however, is our prescription drug coverage.

    We are used to assuming that our health care system is better than that of our southern friends, but in reality Americans have over 90% of their prescription drugs filled with generics, whereas in Canada we we only have about 73%.

    Generic drugs have the same ingredients, undergo the same rigorous testing and are just as safe and effective, the only difference is that they are more affordable than branded options. For example, if we increased our prescription drug coverage through generic drugs by just 1%, we could save more than $703 million.

    This is a critical public policy area where governments could realize significant savings.

    But it is also an area where consumers themselves, and employers, can make significant savings in this time of rising prices. Indeed, this is an area where HR personnel and others making decisions about employee drug plans have the opportunity to save money for everyone involved.

    As one insurance broker recently noted, “I’ve never been able to convince a client to include the mandatory generic clause. Given the right information, my clients take this for granted. It is simply a question of education.

    We need to make this “evidence” a reality by ensuring that all employers have generic drug substitution policies to encourage patients and prescribers to choose the most cost-effective drugs. This means that the drug plan would reimburse at cost a generic drug rather than a more expensive brand name option, which would result in savings for the employer and for the employee, who would obtain the same medical ingredients at a lower price. cost.

    This change means that insurance coverage is further extended to reduce the employee’s out-of-pocket expenses. Such a change would maximize their shared dollars so everyone involved would have more money to redirect to other priorities.

    Provinces in Canada deal with designating generic drugs as “interchangeable” with branded versions, and many insurers rely on public formulary listings for mandatory generic substitution policies. Provinces should do a better job of making generic substitution more readily available so that patients and employers can realize this savings potential.

    Specifically, in Saskatchewan and Manitoba, interchangeability is limited to publicly funded drugs, which limits access to low-cost generic versions of prescription drugs not covered by government drug plans. Meanwhile, British Columbia, Alberta, Quebec and New Brunswick, for example, leave this decision to the discretion of pharmacists, and only drugs listed on formularies are automatically included.

    Instead, we need all provinces to allow generic substitution to be readily available so employees and employers can save money on their drug plans.

    As Manulife said, “When it comes to your prescription drugs, why pay more than you have to?

    Jim Keon is president of the Canadian Generic Pharmaceutical Association.

    read more
    Prescription drugs

    DEA investigation into Ryan Vermillion linked to prescription drug cashout

    Vermillion, who worked with Washington coach Ron Rivera for nine seasons as the Carolina Panthers’ head athletic coach before joining him in Washington in January 2020, has been placed on administrative leave by the team at the middle of the criminal investigation.

    Vermillion’s attorney, Barry Coburn of the Washington law firm Coburn & Greenbaum, declined to comment on Thursday. NBC Sports Washington was the first to report that the federal investigation is related to prescription drugs.

    Around 3 p.m. Friday, about two dozen DEA agents and Loudoun County law enforcement officers executed search warrants at the team’s training facility in Ashburn, Va., along with at Vermillion’s nearby home, according to several people familiar with the situation. Some team and player staff were at the facility when officers arrived in unmarked cars and searched an area of ​​the training facility that related to Vermillion and the drug disbursement.

    NFL teams typically employ multiple physicians who often specialize in orthopedic surgery and have their own practices separate from their football work. These physicians travel with the teams and work in conjunction with full-time club athletic trainers and strength and conditioning coaches. They are supposed to manage the dispensing of prescription drugs.

    The DEA’s investigation is not the first involving an NFL team or its medical staff and the unauthorized distribution of prescription drugs.

    In 2014, the DEA, in conjunction with the Transportation Security Administration, conducted surprise inspections of several NFL medical teams, including those of the San Francisco 49ers, Seattle Seahawks, and Tampa Bay Buccaneers. The investigations focused on the possible disbursements of medicines without a prescription or label as well as on the dispensing of medicines by the trainers.

    These investigations were prompted by a class action lawsuit brought by more than 1,300 former NFL players who claimed team medical staff liberally dispensed narcotics and the nonsteroidal anti-inflammatory drug Toradol to help keep players in the field. Players at the time described instances in which they were given dangerous concoctions of drugs and recalled coaches handing out pills in hotels, locker rooms and on team planes, among other violations.

    In 2010, the DEA investigated the then San Diego-based Chargers after safety Kevin Ellison was caught with 100 Vicodin pills during a traffic stop. In 2013, the New Orleans Saints were fined after security footage showed a flying Vicodin coach in 2010.

    On Wednesday, Washington safety Landon Collins, who serves as the team’s player representative for the NFL Players Association, was asked by reporters about his experience with Vermillion.

    “It was great. it was beautiful,” said Collins, who suffered a season-ending Achilles tendon injury last year. “A great guy, a humble guy, very respectful. It helped me a lot in this situation, especially with the return of my injury. Just a great guy overall.

    The NFLPA released a statement on Wednesday saying it had requested more information from the NFL about the search of Washington facilities because the matter “directly affects the health and safety of players.” On Thursday, the players’ union sent a letter to all certified players’ agents saying it had informed the NFL that it was investigating the DEA searches. In the letter, the NFLPA noted that a player had been contacted by the DEA.

    The Washington Football Team said in a statement Monday that the investigation was “not team related.” Rivera referred to the team’s statement when speaking to local reporters on a video conference call this afternoon, but told NBC Sports Washington that “I know who Ryan is, and last year I trusted Ryan with my health and would do it again.” Rivera was diagnosed with cancer in 2020 and underwent treatment throughout last season.

    In April, healthcare provider Inova and Robin West, an orthopedic and sports medicine surgeon who served as the Washington team’s chief medical officer, announced the end of their medical partnerships with the team. Anthony Casolaro is Washington’s chief medical officer/internal medicine, and Chris Annunziata is the team’s chief medical officer/orthopedics. Washington has eight other doctors on its medical team.

    Rivera said the team will operate “pretty much by committee” in Vermillion’s absence. Bubba Tyer, who retired as Washington’s director of sports medicine in 2009, attended practices this week to help assistant sports coaches.

    read more
    Generic drugs

    Schuyler County joins others in suing generic drug makers for alleged price fixing

    WATKINS GLEN, NY (WETM) – Schuyler County has joined more than two dozen city governments, and others, in suing generic drug makers for alleged price-fixing.

    The county, along with local governments in New York and elsewhere, filed a 1,000-plus-page subpoena and lawsuit on June 30 against more than 50 businesses, seeking injunctive relief, damages and damages. which, according to the complaint, resulted from an illegal agreement. between the defendants to allocate customers, rig bids and fix, increase, maintain and/or stabilize the prices of all of their generic pharmaceutical products,

    The lawsuit follows a vote by the County Legislature in 2020 allowing County Attorney Steven Getman to partner with Napoli Shkolnik PLLC, a New York City law firm “in the investigation and/or the pursuit of any legal claims against generic pharmaceutical manufacturers and/or their officers based on their actions in price fixing, market allocation and participation in other violations of antitrust laws or other wrongdoing regarding generic pharmaceuticals.

    According to Getman, the lawsuit pursues claims in several areas. These include increased health insurance premiums for county employees, additional workers’ compensation costs, and higher costs for pharmaceuticals purchased for use by the county jail, all based on artificially inflated generic drug prices.

    Various government agencies have already filed a lawsuit, Getman said, alleging violations of state and federal antitrust and consumer protection laws.

    “In 2014, the Department of Justice launched an investigation into the prices of various generic drugs,” Getman explained. “As a result of the federal investigation, in 2017, state attorneys general from 48 states filed a civil lawsuit alleging price fixing, market splitting and other antitrust violations by 16 pharmaceutical defendant companies regarding fifteen (15) generic prescription drugs. ”

    “As alleged, the defendants’ anti-competitive conduct falls primarily into two categories. First, the defendants communicated with each other to determine and agree on the market share that each would control and the customers to which each competitor was entitled. Second, competitors would have communicated – either in person, over the phone or via text – and agreed to collectively raise and/or maintain prices for a particular generic drug.

    The lawsuits, Getman said, now involve more than 100 generic drugs and more than fifty pharmaceutical defendants, including Teva, Sandoz, Mylan, Pfizer, Actavis, Amneal, Apotex, Aurobindo, Breckenridge, Dr. Reddy’s Laboratories, Glenmark, Greenstone, Lannett, Lupin, Par, Taro USA, Upsher-Smith, Wockhardt USA and Zydus.

    “As noted, hundreds of generic drugs have been implicated across the country. Each affected county or municipality can file a lawsuit asserting overpayments for each applicable generic drug,” Getman explained. “The key issue in formulating a lawsuit was to determine for which generic drug(s) each county had overpaid, and whether each was the direct or indirect purchaser.”

    According to County Administrator Tim O’Hearn, the lawsuit was filed without risk to the county, as Napoli Shkolnik is working on an emergency basis which covers all costs associated with the lawsuit.

    “By moving forward with litigation, the County Legislature hopes to ease the burden on taxpayers and seeks to hold manufacturers accountable for any illegal role in the high cost of generic drugs,” O’Hearn said.

    Locally, along with Schuyler County, Chemung, Yates and Livingston counties are acting as plaintiffs in the lawsuit. Other municipalities in New York and elsewhere are also part of the deal. The case is currently set to be heard in federal district court for eastern Pennsylvania.

    In addition to the generics case, Schuyler County worked with Napoli Shkolnik to pursue an ongoing lawsuit against manufacturers and distributors of prescription opiates for damages to the county resulting from the fraudulent marketing and distribution and negligent opiates in and to the county. . This case remains pending in state court.

    A related lawsuit, involving Nassau and Suffolk counties, and the New York State Attorney General’s office, is currently underway on Long Island against several companies accused of fueling the opioid crisis. The lawsuit in Long Island will serve as a test for the claims of Schuyler County and other New York municipalities, as well as an indicator of what could happen to drugmakers, distributors and pharmacies in other states.

    read more
    Generic drugs

    Does Medicare Exceed Expenses? Costco costs much less for generic drugs | Health info

    By Robert Preidt, health day reporter

    (Health Day)

    WEDNESDAY, July 7, 2021 (HealthDay News) — Can Costco beat Medicare Part D when it comes to prescription drug prices?

    Apparently, that’s what a new study claims that found about half of generic drugs were cheaper when purchased from the discount retailer than through the government program.

    Researchers compared the prices paid by Medicare Part D plans (including direct patient payments) for 184 generic prescription drugs to the cash prices paid by Costco members for the same prescriptions in 2017 and 2018. More than 45 million Americans are enrolled in Medicare Part D, which covers outpatient prescriptions.

    Compared to Costco member prices, Medicare plans topped 13% in 2017 and nearly 21% in 2018, the results showed. Medicare plan participants paid more than Costco members on nearly 53% of 90-day fills in 2018. Of all 30- and 90-day prescription fills, Medicare plans overpaid 43% of the time, researchers found. from the University of Southern California (USC). .

    “Our analysis shows that in systems like Costco’s, where incentives are put in place to deliver value directly to the consumer at the pharmacy counter, this is what happens,” the author said. Erin Trish study. She is associate director of the USC Schaeffer Center and assistant professor of pharmaceutical and health economics at USC’s School of Pharmacy.

    “It’s time to fix these incentives in the Medicare Part D system to put the patient first,” Trish said in a USC press release.

    His team published their findings online July 6 as a research letter in JAMA internal medicine.

    Pharmacy benefit managers and other intermediaries negotiate drug prices on behalf of Medicare, but they do not appear to pass all of the savings on negotiated prices to plans and patients, the researchers said.

    Generic drugs account for 22% of Part D spending, so policymakers should take a closer look at the practices of these intermediaries, the team suggested.

    Study author Geoffrey Joyce is director of health policy at the Schaeffer Center and chair of the department of pharmaceutical and health economics at the USC School of Pharmacy. He said: “Efforts to reduce prescription drug prices tend to focus on brand name drugs, but the opaque pharmaceutical supply system can also lead health plans and taxpayers to overpay for generics.”

    And Karen Van Nuys, executive director of the Schaeffer Center’s Life Sciences Value Innovation Program and assistant professor at USC’s School of Public Policy, added, “There’s a lot of price competition among manufacturers of these drugs, but this competition does not benefit the These are not small market drugs where there may be only one supplier who can quote their price. »

    SOURCE: University of Southern California, press release, July 6, 2021

    Copyright © 2021 Health Day. All rights reserved.

    read more